US006340583B1

(12) **United States Patent**

Yan et al.

(10) Patent No.: **US 6,340,583 B1**

(45) Date of Patent: **Jan. 22, 2002**

(54) **ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF**

(75) Inventors: **Chunhua Yan**, Boyds; **Karen A. Ketchum**, Germantown; **Valentina Di Francesco**, Rockville; **Ellen M. Beasley**, Darnestown, all of MD (US)

(73) Assignee: **PE Corporation (NY)**, Norwalk, CT (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/813,817**

(22) Filed: **Mar. 22, 2001**

(51) Int. Cl.^{7} C12N 9/12; C12N 1/20; C12N 15/00; C12N 5/00; C07H 21/04

(52) U.S. Cl. **435/194**; 435/320.1; 435/252.3; 435/325; 536/23.2

(58) Field of Search 435/194, 252.3, 435/325, 320.1; 536/23.2

(56) **References Cited**

PUBLICATIONS

GenEmbl Database, Accession No. D45906, Feb. 1999.*

Sambrook et al., Molecular Cloning Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989.*

* cited by examiner

Primary Examiner—Rebecca E. Prouty
Assistant Examiner—M. Monshipouri
(74) *Attorney, Agent, or Firm*—Celera Genomics; Robert A. Millman; Justin D. Karjala

(57) **ABSTRACT**

The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

9 Claims, 41 Drawing Sheets

```
   1 CCCAGGGCGC CGTAGGCGGT GCATCCCGTT CGCGCCTGGG GCTGTGGTCT
  51 TCCCGCGCCT GAGGCGGCGG CGGCAGGAGC TGAGGGGAGT TGTAGGGAAC
 101 TGAGGGGAGC TGCTGTGTCC CCCGCCTCCT CCTCCCCATT TCCGCGCTCC
 151 CGGGACCATG TCCGCGCTGG CGGGTGAAGA TGTCTGGAGG TGTCCAGGCT
 201 GTGGGGACCA CATTGCTCCA AGCCAGATAT GGTACAGGAC TGTCAACGAA
 251 ACCTGGCACG GCTCTTGCTT CCGGTGAAAG TGATGCGCAG CCTGGACCAC
 301 CCCAATGTGC TCAAGTTCAT TGGTGTGCTG TACAAGGATA AGAAGCTGAA
 351 CCTGCTGACA GAGTACATTG AGGGGGGCAC ACTGAAGGAC TTTCTGCGCA
 401 GTATGGATCC GTTCCCCTGG CAGCAGAAGG TCAGGTTTGC CAAAGGAATC
 451 GCCTCCGGAA TGGACAAGAC TGTGGTGGTG GCAGACTTTG GGCTGTCACG
 501 GCTCATAGTG GAAGAGAGGA AAAGGGCCCC CATGGAGAAG GCCACCACCA
 551 AGAAACGCAC CTTGCGCAAG AACGACCGCA AGAAGCGCTA CACGGTGGTG
 601 GGAAACCCCT ACTGGATGGC CCCTGAGATG CTGAACGGAA AGAGCTATGA
 651 TGAGACGGTG GATATCTTCT CCTTTGGGAT CGTTCTCTGT GAGATCATTG
 701 GGCAGGTGTA TGCAGATCCT GACTGCCTTC CCGAACACT GGACTTTGGC
 751 CTCAACGTGA AGCTTTTCTG GGAGAAGTTT GTTCCCACAG ATTGTCCCCC
 801 GGCCTTCTTC CCGCTGGCCG CCATCTGCTG CAGACTGGAG CCTGAGAGCA
 851 GACCAGCATT CTCGAAATTG GAGGACTCCT TTGAGGCCCT CTCCCTGTAC
 901 CTGGGGGAGC TGGGCATCCC GCTGCCTGCA GAGCTGGAGG AGTTGGACCA
 951 CACTGTGAGC ATGCAGTACG GCCTGACCCG GGACTCACCT CCCTAGCCCT
1001 GGCCCAGCCC CCTGCAGGGG GGTGTTCTAC AGCCAGCATT GCCCCTCTGT
1051 GCCCCATTCC TGCTGTGAGC AGGGCCGTCC GGGCTTCCTG TGGATTGGCG
1101 GAATGTTTAG AAGCAGAACA AACCATTCCT ATTACCTCCC CAGGAGGCAA
1151 GTGGGCGCAG CACCAGGGAA ATGTATCTCC ACAGGTTCTG GGGCCTAGTT
1201 ACTGTCTGTA AATCCAATAC TTGCCTGAAA GCTGTGAAGA AGAAAAAAAC
1251 CCCTGGCCTT TGGGCCAGGA GGAATCTGTT ACTCGAATCC ACCCAGGAAC
1301 TCCCTGGCAG TGGATTGTGG GAGGCTCTTG CTTACACTAA TCAGCGTGAC
1351 CTGGACCTGC TGGGCAGGAT CCCAGGGTGA ACCTGCCTGT GAACTCTGAA
1401 GTCACTAGTC CAGCTGGGTG CAGGAGGACT TCAAGTGTGT GGACGAAAGA
1451 AAGACTGATG GCTCAAAGGG TGTGAAAAAG TCAGTGATGC TCCCCCTTTC
1501 TACTCCAGAT CCTGTCCTTC CTGGAGCAAG GTTGAGGGAG TAGGTTTTGA
1551 AGAGTCCCTT AATATGTGGT GGAACAGGCC AGGAGTTAGA GAAAGGGCTG
1601 GCTTCTGTTT ACCTGCTCAC TGGCTCTAGC CAGCCCAGGG ACCACATCAA
1651 TGTGAGAGGA AGCCTCCACC TCATGTTTTC AAACTTAATA CTGGAGACTG
1701 GCTGAGAACT TACGGACAAC ATCCTTTCTG TCTGAAACAA ACAGTCACAA
1751 GCACAGGAAG AGGCTGGGGG ACTAGAAAGA GGCCCTGCCC TCTAGAAAGC
1801 TCAGATCTTG GCTTCTGTTA CTCATACTCG GGTGGGCTCC TTAGTCAGAT
1851 GCCTAAAACA TTTTGCCTAA AGCTCGATGG GTTCTGGAGG ACAGTGTGGC
1901 TTGTCACAGG CCTAGAGTCT GAGGGAGGGG AGTGGGAGTC TCAGCAATCT
1951 CTTGGTCTTG GCTTCATGGC AACCACTGCT CACCCTTCAA CATGCCTGGT
2001 TTAGGCAGCA GCTTGGGCTG GGAAGAGGTG GTGGCAGAGT CTCAAAGCTG
2051 AGATGCTGAG AGAGATAGCT CCCTGAGCTG GGCCATCTGA CTTCTACCTC
2101 CCATGTTTGC TCTCCCAACT CATTAGCTCC TGGGCAGCAT CCTCCTGAGC
2151 CACATGTGCA GGTACTGGAA AACCTCCATC TTGGCTCCCA GAGCTCTAGG
2201 AACTCTTCAT CACAACTAGA TTTGCCTCTT CTAAGTGTCT ATGAGCTTGC
2251 ACCATATTTA ATAAATTGGG AATGGGTTTG GGGTATTAAA AAAAAAAAAA
2301 AAAAAAAAAA AAAAAAAAAA  (SEQ ID NO:1)
```

FIG.1A

FEATURES:
5'UTR: 1-228
Start Codon: 229
Stop Codon: 994
3'UTR: 997

Homologous proteins:
Top 10 BLAST Hits

	Score	E
CRA|1000682328847 /altid=gi|8051618 /def=ref|NP_057952.1| LIM d...	485	e-136
CRA|18000005015874 /altid=gi|5031869 /def=ref|NP_005560.1| LIM ...	485	e-136
CRA|88000001156379 /altid=gi|7434382 /def=pir||JC5814 LIM motif...	469	e-131
CRA|88000001156378 /altid=gi|7434381 /def=pir||JC5813 LIM motif...	469	e-131
CRA|18000005154371 /altid=gi|7428032 /def=pir||JE0240 LIM kinas...	469	e-131
CRA|18000005126937 /altid=gi|6754550 /def=ref|NP_034848.1| LIM ...	469	e-131
CRA|18000005127186 /altid=gi|2804562 /def=dbj|BAA24491.1| (AB00...	469	e-131
CRA|18000005127185 /altid=gi|2804553 /def=dbj|BAA24489.1| (AB00...	469	e-131
CRA|18000005004416 /altid=gi|2143830 /def=pir||I78847 LIM motif...	468	e-131
CRA|18000005004415 /altid=gi|1708825 /def=sp|P53670|LIK2_RAT LI...	468	e-131

BLAST dbEST hits:

	Score	E
gi|10950740 /dataset=dbest /taxon=96...	1049	0.0
gi|10156485 /dataset=dbest /taxon=96...	975	0.0
gi|5421647 /dataset=dbest /taxon=9606 ...	952	0.0
gi|10895718 /dataset=dbest /taxon=96...	757	0.0
gi|13043102 /dataset=dbest /taxon=960...	714	0.0
gi|519615 /dataset=dbest /taxon=9606 /...	531	e-149
gi|11002869 /dataset=dbest /taxon=96...	511	e-143

EXPRESSION INFORMATION FOR MODULATORY USE:
library source:
From BLAST dbEST hits:
gi|10950740   teratocarcinoma
gi|10156485   ovary
gi|5421647   testis
gi|10895718   nervous_normal
gi|13043102   bladder
gi|519615   infant brain
gi|11002869   thyroid gland

From tissue screening panels:
Fetal whole brain

FIG.1B

```
  1 MVQDCQRNLA RLLLPVKVMR SLDHPNVLKF IGVLYKDKKL NLLTEYIEGG
 51 TLKDFLRSMD PFPWQQKVRF AKGIASGMDK TVVVADFGLS RLIVEERKRA
101 PMEKATTKKR TLRKNDRKKR YTVVGNPYWM APEMLNGKSY DETVDIFSFG
151 IVLCEIIGQV YADPDCLPRT LDFGLNVKLF WEKFVPTDCP PAFFPLAAIC
201 CRLEPESRPA FSKLEDSFEA LSLYLGELGI PLPAELEELD HTVSMQYGLT
251 RDSPP  (SEQ ID NO:2)
```

FEATURES:
Functional domains and key regions:
[1] PDOC00004 PS00004 CAMP_PHOSPHO_SITE
cAMP- and cGMP-dependent protein kinase phosphorylation site

Number of matches: 2
        1   108-111 KKRT

        2   119-122 KRYT

    [2] PDOC00005 PS00005 PKC_PHOSPHO_SITE
Protein kinase C phosphorylation site

Number of matches: 4
        1   51-53 TLK

        2   106-108 TTK

        3   107-109 TKK

        4   111-113 TLR

    [3] PDOC00006 PS00006 CK2_PHOSPHO_SITE
Casein kinase II phosphorylation site

Number of matches: 4
        1   51-54 TLKD

        2   76-79 SGMD

        3   139-142 SYDE

        4   212-215 SKLE

    [4] PDOC00008 PS00008 MYRISTYL
N-myristoylation site

Number of matches: 4
        1   73-78 GIASGM

FIG.2A

2   77-82 GMDKTV

3   150-155 GIVLCE

4   158-163 GQVYAD

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	142	162	0.872	Putative
2	184	204	0.652	Putative

BLAST Alignment to Top Hit:
>CRA|1000682328847 /altid=gi|8051618 /def=ref|NP_057952.1| LIM
      domain kinase 2 isoform 2b [Homo sapiens] /org=Homo
      sapiens /taxon=9606 /dataset=nraa /length=617
         Length = 617

Score = 485 bits (1235), Expect = e-136
 Identities = 241/265 (90%), Positives = 241/265 (90%), Gaps = 22/265 (8%)

```
Query: 13  LLPVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDPFPWQQKVRFAK 72
            L  VKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDPFPWQQKVRFAK
Sbjct: 353 LTEVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDPFPWQQKVRFAK 412

Query: 73  GIASGM-------------------DKTVVVADFGLSRLIVEERKRAPMEKATTKKR 110
            GIASGM                   DKTVVVADFGLSRLIVEERKRAPMEKATTKKR
Sbjct: 413 GIASGMAYLHSMCIIHRDLNSHNCLIKLDKTVVVADFGLSRLIVEERKRAPMEKATTKKR 472

Query: 111 TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT 170
            TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT
Sbjct: 473 TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT 532

Query: 171 LDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSLYLGELGI 230
            LDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSLYLGELGI
Sbjct: 533 LDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSLYLGELGI 592

Query: 231 PLPAELEELDHTVSMQYGLTRDSPP 255
            PLPAELEELDHTVSMQYGLTRDSPP
Sbjct: 593 PLPAELEELDHTVSMQYGLTRDSPP 617  (SEQ ID NO:4)
```

Hmmer search results (Pfam):

Model	Description	Score	E-value	N
PF00069	Eukaryotic protein kinase domain	100.1	1.1e-26	2
CE00031	CE00031 VEGFR	4.9	0.14	1
CE00204	CE00204 FIBROBLAST_GROWTH_RECEPTOR	4.7	1	1
CE00359	E00359 bone_morphogenetic_protein_receptor	1.8	7.9	1
CE00022	CE00022 MAGUK_subfamily_d	1.5	2.5	1
CE00287	CE00287 PTK_Eph_orphan_receptor	-48.4	3.8e-05	1
CE00292	CE00292 PTK_membrane_span	-61.8	2.1e-05	1

FIG.2B

```
CE00291  CE00291 PTK_fgf_receptor                 -113.0     0.027   1
CE00286  E00286 PTK_EGF_receptor                  -125.1     0.0021  1
CE00290  CE00290 PTK_Trk_family                   -151.3     6.5e-05 1
CE00288  CE00288  PTK_Insulin_receptor            -210.4     0.014   1
```

Parsed for domains:

Model	Domain	seq-f	seq-t		hmm-f	hmm-t		score	E-value
PF00069	1/2	16	79	..	41	105	..	52.1	2.3e-13
CE00022	1/1	124	153	..	187	216	..	1.5	2.5
PF00069	2/2	81	156	..	129	182	..	48.0	3.1e-12
CE00031	1/1	129	156	..	1114	1141	..	4.9	0.14
CE00204	1/1	129	156	..	705	732	..	4.7	1
CE00359	1/1	79	157	..	287	356	..	1.8	7.9
CE00290	1/1	9	218	..	1	282	[]	-151.3	6.5e-05
CE00287	1/1	1	218	[.	1	260	[]	-48.4	3.8e-05
CE00291	1/1	1	218	[.	1	285	[]	-113.0	0.027
CE00292	1/1	1	218	[.	1	288	[]	-61.8	2.1e-05
CE00288	1/1	1	218	[.	1	269	[]	-210.4	0.014
CE00286	1/1	6	218	..	1	263	[]	-125.1	0.0021

FIG.2C

```
   1 TCATCCTTGC GCAGGGGCCA TGCTAACCTT CTGTGTCTCA GTCCAATTTT
  51 AATGTATGTG CTGCTGAAGC GAGAGTACCA GAGGTTTTTT TGATGGCAGT
 101 GACTTGAACT TATTTAAAAG ATAAGGAGGA GCCAGTGAGG GAGAGGGGTG
 151 CTGTAAAGAT AACTAAAAGT GCACTTCTTC TAAGAAGTAA GATGGAATGG
 201 GATCCAGAAC AGGGGTGTCA TACCGAGTAG CCCAGCCTTT GTTCCGTGGA
 251 CACTGGGGAG TCTAACCCAG AGCTGAGATA GCTTGCAGTG TGGATGAGCC
 301 AGCTGAGTAC AGCAGATAGG GAAAAGAAGC CAAAAATCTG AAGTAGGGCT
 351 GGGGTGAAGG ACAGGGAAGG GCTAGAGAGA CATTTGGAAA GTGAAACCAG
 401 GTGGATATGA GAGGAGAGAG TAGAGGGTCT TGATTTCGGG TCTTTCATGC
 451 TTAACCCAAA GCAGGTACTA AAGTATGTGT TGATTGAATG TCTTTGGGTT
 501 TCTCAAGACT GGAGAAAGCA GGGCAAGCTC TGGAGGGTAT GGCAATAACA
 551 AGTTATCTTG AATATCCTCA TGGTGGAAAG TCCTGATCCT GTTTGAATTT
 601 TGGAAATAGA AATCATTCAG AGCCAAGAGA TTGAATTGTT GAGTAAGTGG
 651 GTGGTCAGGT TACAGACTTA ATTTTGGGTT AAAAAGTAAA AACAAGAAAC
 701 AAGGTGTGGC TCTAAAATAA TGAGATGTGC TGGGGGTGGG GCATGGCAGC
 751 TCATAAACTG ACCCTGAAAG CTCTTACATG TAAGAGTTCC AAAAATATTT
 801 CCAAAACTTG GAAGATTCAT TTGGATGTTT GTGTTCATTA AAATCTCTCA
 851 CTAATTCATT GTCTTGTCCA CTGTCCGTAA CCCAACCTGG GATTGGTTTG
 901 AGTGAGTCTC TCAGACTTTC TGCCTTGGAG TTTGTGAGAG AGATGGCATA
 951 CTCTGTGACC ACTGTCACCC TAAAACCAAA AAGGCCCCTC TTGACAAGGA
1001 GTCTGAGGAT TTTAGACCCA GGAAGAATGA GTGATGGGCA TATATATATC
1051 CTATTACTGA GGCATGAGAA GAGTGGAATG GGTGGGTTGA GGTGGTGTTT
1101 TAAGGCCTCT TGCCAGCTTG TTTAACTCTT CTCTGGGGAA CGAGGGGGAC
1151 AACTGTGTAC ATTGGCTGCT CCAGAATGAT GTTGAGCAAT CTTGAAGTGC
1201 CAGGAGCTGT GCTTTGTCTA TTCATGGCCC CTGTGCCTGT GAAACAGGGT
1251 TCGGTGACTG TCACTGTGCC TGTGGCAGTC TGTAGTTACC CAGAGAGAAC
1301 AAAGCTGCAT ACACAGAGCG CACAAGGGAG TCTTGTAACA ACCTTGTCCT
1351 GCTTTCTAGG GCTGAGTCAG GTACCACAGC TTGATCTCAG CTGTCCTCTT
1401 TATTTCAAGA AGTTGACATC TGAGCCATAC CAGGAGTATT GTATTTTGTT
1451 TGAGGCCTCT CTTTTTGGAG GAACATGGAC CGACTCTGTG CTTTTGTCTA
1501 TGCTGGTCTC TGAGCTCACA CAACCCTTCA CCCTCCTTTC TCAGCCAGTG
1551 ATAGGTAAGT CTTCCCTATC TTGCAAGGCT CAGCTCAAGT GTCAGCTTCC
1601 TCTACAAAGA CTTTCCTGGT TCCCCTCATT GGAGTGAACA AGAGTTGACA
1651 TGGTAGAATG GAAAGAGCAG AAGCTTTAGA ATGAGCCAGA CCTGAGTATG
1701 AATGCTAGAT CCACCACTTA GCTAGTCAAC CCTGCCCCCT GCCTCAAGTT
1751 TTAATTTTCC TATCCATTAA GTGAATATAA TAATACCTGT GTCACAGGAT
1801 TATTTTGAGA ATTAAATGAG ATTAGGTCTA TGAAAGCACC TAGCAGAGTT
1851 CTTGGCATAT AGGAGGCATT CATTAAATAT TTGTTCTTCC CCTTTTATAC
1901 CCATTACTTT TCTTTTTCTG AACTAAAATA ATACTTGGTT CTATCTCTGA
1951 AATAACATCC AAGTGAAAAA TCAACAACAT GAAAGAGCAG TTCTTTTCCA
2001 GTGGATTTGC TTCTTAAGGA GCAGAGATTA TGTAATCTAA CAGCCTCCAA
2051 CATACAAAGA GCTTTGTATC TAGAACAGGG GTCCCCAGCC CCTGGACCGC
2101 CAACTGGTAC GGGTCTGTAG CCTGTTAGGA ACCAGGCTGC ACAGCAGGAG
2151 GTGAGCGGCG GGCCAGTGAG CATTGCTGCC TGAGCTCTGC CTCCTGTCAG
2201 ATCAGTGGTG GCATTAGATT CTCATAGGAG TGTGAACCCT ATTGTGAACT
2251 GCACATGCAA GGGATCTGGG TTGCATGCTC CTTATGAGAA TCTCACTAAT
2301 GGCTGATGAT CTGAGTTGGA ACAGTTTGAT ACCAAAACCA TCCCCCCGCC
2351 CCCCAACCCC CAGCCTAGGG TCCGTGGAAA AATTGGCCCC TGGTGCCAAA
2401 AAGGTTGAGG ACTGCTGATC TAGAGGACCA ATTTATTCAA TGTTGGTTGA
2451 GTAAATGAGC TCTTGGATTA GGTGATGGAA AAATCTGAAA AAACAGGGCT
```

<div align="center">

FIG.3-1

</div>

```
2501  TTTGAGGAAT  AGGAAAAGGC  AGTAACATGT  TTAACCCAGA  GAGAAGTTTC
2551  TGGCTGTTGG  CTGGGAATAG  TCATAGGAAG  GGCTGACACT  GAAAAGAAGG
2601  AGATTGTGTT  CGTTTCTTCT  TCTCAGAGCT  ATAAGCAAAG  GCTGAAAGTT
2651  CTAGAAAAAG  GCAAGTTTTG  TTTCAGTAGA  AAAAAGGATA  ATCAGAACCA
2701  TTTTTAGAAA  ATGGAATGAG  ACTACTTTTG  AGGCCATGAG  TTCCTTGTCC
2751  CTGGAGAGAT  GAGCAGAGGT  TGGACAAGTG  CTTACCAGAG  ATCTTGTGGA
2801  GGCAGAAACT  GTGCATCTAG  CAGAGCATTG  GCCTAACCCT  TTCAAATGAG
2851  ATGCTGTTAA  CTCAGTCTTA  TTCTACATGG  TAGGAATCCT  GTCCCTTTGC
2901  CTCCTGCTAC  TTTGGGCCTC  TCAACCTCTT  GGTTTTGTGT  GCAGGTGAAG
2951  ATGTCTGGAG  GTGTCCAGGC  TGTGGGGACC  ACATTGCTCC  AAGCCAGATA
3001  TGGTACAGGA  CTGTCAACGA  AACCTGGCAC  GGCTCTTGCT  TCCGGTAGGT
3051  GGGCCTATCC  TCCCATCTTT  ACCAGTGTAC  TATGGGCCAA  GCACTATTTC
3101  ATGTTCTGAT  GGAAAACACA  GAAACAAGCT  TCTGAGTTGA  GAATTTCAAT
3151  CTTAGGGTGG  GGAAAGGAAT  GTACCAAGGA  AGAGCTCATG  ACCAAACCTC
3201  AAGTGTGGCC  CCCCTGAACC  CAGGTTAAAT  TGGAAGAGCC  ATAAATGGGC
3251  CAGCTGGAGG  CAGGGTGGGG  GGATGAGAGG  AGCCCTTTCC  AGGGTTGTCC
3301  CATATCCCTC  ACTTTATGGG  TGAGGAAACT  GAGGCCCAGG  AAGAGTGACT
3351  TTCCTGTGGC  TGCACTACAG  ATTATGCAGG  TACTTCAAGA  GTTGTTTGTA
3401  TTCTTATTTT  ATTTTATTTT  ATTTTATTTT  ATTTTATTTT  ATTTTATGAG
3451  AGGGATTCTT  GCTGTTGCCC  AGGCTGGAGT  GCAGTGGTGC  AATCTCGGCT
3501  CACTGCAATC  TCTGCCTGCT  GGGTTCAAGT  GATTTTTCTG  CCTTAGCTTC
3551  CTGAGTAGCT  GAGATGACAG  GCACCTGCCA  CCATGCGCAG  CTAATTTTTG
3601  TATTTTAGTG  GAGACGGGGG  TTTCAACATG  TTGGTCAGGC  TGGTCTTGAA
3651  CTCCTGACCT  CAAATGATGC  ACCCACCTCG  ACCTCCCAAA  GTGCTGGAAT
3701  TACAGGCGTG  AACCACTGTG  CCCAGCCAAG  AGTTGTTTTT  AGTGTGGTTG
3751  GCAGAGCCAG  CTCTTCCTTC  ACCACAGGAT  GCCTCCCTAG  GTTCCTACTT
3801  TTTGTTACTA  GCTTTTATTA  TAGCTATATT  ATTATTATTA  TTATTATTAT
3851  TATTATTATT  ATTATTGAGA  CAGAGTCTCG  CTCTGTCGCC  CAGGCTGGTG
3901  TACAGTGGTG  CGATCCCGGG  CTCACTGCAA  CCTCTGCCTC  CCGAGTTCAA
3951  GCAGTTCTCC  TGCCTCAGCC  CCCCGAGTAG  GTGGGACTAC  AGGCGCCTGC
4001  CACCACACCC  GGCTAATTTT  TGTATTTTTA  GTAGAGACGG  GGTTTCACCT
4051  TGTTGACCAG  GCTGGTCTGG  AGCTCCTGAC  CTCAGGTAAG  TGCTAGAATC
4101  ACAGGCGTGA  ACCACTGCGC  CCAGCCAAGA  GTTGTTTTTA  GTGTGGTTGG
4151  CAGAGCCAGC  TCTTCCTCAC  CACAGGTTGC  CTCCCTAGGT  TCCTACTTTT
4201  TGTTACTAGC  TTTATTATAG  CTACATTATT  ATTATTATTG  TTATTATTAT
4251  TGAGACAGAG  TCTCGCTCTG  TCGCCCAGGC  TGGTGTACAG  TGATGTGATC
4301  TTGGCTCACT  GCAACCTCTG  CCCCCCGAGT  TCAAGCAATT  CTCCTGCTTC
4351  AGCCCCCCTA  GTAGGTGGGA  CTCCAGGCAC  CTGCCACCAC  GCCCAGCTAA
4401  TTTTTGTATT  TTTAGTAGAG  GCGGGGTTTC  ACCTTGTTGG  CCAGGCTGGT
4451  CTCAAACTCC  TGACCTCAGG  TGATCCGCCT  GCCTCGGCCT  CCCAAAATGT
4501  TGGGATTACA  GGCATGAGCC  ACCGCGCCCT  GCCTATAGCT  ACATTATTTT
4551  TGTAGGCAGC  TCAGTTTCTT  AAAAATTATA  CAGACTTCAA  ATCAGATTTG
4601  TTCCTGCTGT  CTGAGGCTCA  GTTTCTTCAT  CTGGAAAATG  GATGGTAATA
4651  ATCTTGTTGA  GATTGAATGA  AATAATATAT  GCAGTGTATC  CAGTACATGG
4701  TAGACACCCA  GTGAATGGTT  ATTCCTTCCT  CCCATCGGAT  TGGAATTCTC
4751  AAGGGTGGGA  ACTTGTCTTT  ATATTCTTCA  CAACGTAAAA  TAGTTGAAAT
4801  TTGTTGGTGG  AAAGAAGAGC  AGTCCACTCC  AGAGGCTGGA  TGGGCATGCC
4851  TGGCCCCCAA  GGTCTGAAGT  GGTAGGGCTG  TGCCTATATC  CTGAGAATGA
4901  GATAGACTAG  GCAGGCACCT  TGTGCTGTAG  ATTCCAGCTC  CTGCACATAG
4951  CTCTTGTTGT  AAAACATCCC  TGTGCTTATA  CCAAGTAATT  GAGTTGACCT
```

<div align="center">

FIG.3-2

</div>

```
5001 TTAAACACTT GCCTCTTCCC TGGGAACCAT ATAGGGGATT GGCCTGGAGA
5051 CGTCTGGCCT CTGGAAGAGT TGGAAAGCAG CCATCATTAT TATCCTTTCC
5101 TTTCAGCTAT AACTCAGAGC TCTCAAGTCT TTTCTGTGGA TCTTATTGCC
5151 TTGGTTCTTG CCCCTTTTAC TCCCAGGGAA GTTGATTCTG TCTTTTCTGT
5201 TCCATTTAGT ATGACAGGAG CAGAGAATGT CAGAGCTGTA AGGGACCTTA
5251 TAGTTAAAGC CTTTGGCTGG TCCTTTCATT TTATAGCTGG GACTAATAAG
5301 TAACGTCAAA ACCCAATGAG TTCACAGATT GGGTCTCGCC TTGGCATGTA
5351 ACCCATATGT TCATATTCTT GCTGTTTTCC TATGTGTATG AATATTTTCT
5401 ATCCAAAATA AGCAGGACAG GGTAGAGCAA GTTAATCTTT GGAATTTCTG
5451 GATTCTCTTA GAGCTAAAAA ACTTCAGAAC TAGAAGAAAC CACCCACTAT
5501 ATGGTATAAC CCATTCATAT CACAGATGAG GCCTGAAACC AAAAAGACTT
5551 GCTCAGGCCA TGGATGACAA GAGCTGGCCC TAGCACTGAA CTCTTGGGTC
5601 ATTTGTAGGT CTAGTCAGAT GCTAGCTTGT TAGCTCTGTG CGTGCGTGTG
5651 TGTGTGTGTG TGTGTGTGTG TGTGTGAGAT AGAGACAGAA AGATAACATA
5701 TGTACACAAA TACATAAAGA GGAAGTAGAC ACGTTAGCAT GGTAGATAAG
5751 AGTACAGGCA GGCCAGGCGT GGTGGCTCAC GCCTGTAATC CCAGCACTTT
5801 GGGAGGCCAA GGCAGGTGGA TCACCTGAGG TCAGGAATTC GAGACCAGCC
5851 TGACCAACAT GGTGAAACCC CATCTCTACT AAATACAGAA AAAAATTAGC
5901 TTGGCATGGT GGCACATGCC TGTAATCCCA GCTACTTGGG AAGCTGAAGC
5951 AGGAGAATCG CTTGAATCCG GGAAGCAGAA GTTGCAGTGA GCCGAGATTG
6001 TGCCATTACA GTCTAGCCTG GGCAACAAGA GGGAAACTCC ATCGCAAAAA
6051 AACAACCACC ACCAAGAGTA CAGGCTATGG AATGAGACTA TGGTTTTAAA
6101 TCCTGGCTTT GCAATTTATT AACTAGCCTT AAGTGACTTC CCTGAGCTTC
6151 AGGCACCAAT CTGTAAAATG AGGATAAGAA TATTACTCAT GCCACATGGT
6201 TGTTAGGGAG GATTAAATGT GATAACCTAT ATAAAGTGGC TAGCATAGCA
6251 TCTGACATAT AGAAAACTCT TAATAGGGCC GGACGTGGTG GCTTATGCCT
6301 GTAATCCTAG CACTCTGGGA GGCCGAGGCA GAAGGATCGC TTGAGCCCAT
6351 GAGCCCAGGA GTTTGAGACC AGCCTGGCCA ACATGGCAAA ACTCCACCTC
6401 TACAAAAAAT ACAAAAATAT TAGCCAGGCG TGATGGCACA CACCTGTAGT
6451 CCCAGCTACT TGGGAAGCTG AGGAGCGATG ATTACCTGAG CCCAGGGATA
6501 TCAAGGCTGT AGTGAGCTGT GATCATGCCA CTGTACTCCA TCCAGCTGGG
6551 GGACAGAGTG AAACCCCTGT CTCAAAACAA AACAAATGAA AAAAAAAACC
6601 CTTAATAATC AGTAACTGTC ACTTTATATT ATGTTGTGAG TGTGTGTCTA
6651 TATACACCTA TATGTATACA TTTCTCTTAT TACACATTCA TTGGTGATCT
6701 GATGTGGAGC CCCAGGGATT AAGGGCAACT TTGAACTACC CTGACACAAT
6751 CAAGCCAAAT ATCATTCCCG TGGAGGAAGT AGAGTATCTA GGTTCTGTCT
6801 CCTAGTTGCA GCTTTACCTT GAGGACAGAG ACTCTAATCC AGCTGTGCTG
6851 AAGGAGCACA TCTCCTGACT TCTGAGCTTT CCCCTGGTAA ATTCAAACTG
6901 GATGTCACGG CGCCCTCAGA TAGAGCCTGG TAATTTGCCC TGGGGAGAGT
6951 GACTGTCTTT TGGATCTAAT TTGACTTTTG CCCCAGTTGG AGGAAAATCT
7001 TCAGGGCTAG GAAGGATTGT ATTTGTCTGA CCCCAGAGAT AACCTGGGTT
7051 TTGAGGAACA TGGGGCATCA ACCTGAATGG TCTTGTAAGA TCTCTCCCAC
7101 GCCAGCTTGC CAGTGTTTCT CTGATGAATT TAGAGTACCT GAGTAGTGCA
7151 GGCCTGCTGG GAGGAGGACT CTCCCTCTGT GCTACTCAGA GAAATTCATT
7201 CTTCAAGGCC CCCTTCCAGC CTTGCTCTTA CCCAGCTGGG CTACAGTTAC
7251 AATAAAGGAA ATGACTTTTC TTCTCCCCTT CCCCCAGTAC CTTTGTTTTC
7301 CTAGTCACAG GGTGGGGCTG GATATTGAAT GGAGAAATTG CTGGGGTCCA
7351 TCCTAAACTC CTCCCCTCAT CTCTCCCTTA CATTACCCCA TTCTTCTGTC
7401 TGCAGCCACA TCCATAATCC TGCCTCTGTT AGCCTTCCGA CAGACCCTCA
7451 GGTGCCCAGG ACAACAGGAA GCTACTTAAA GCTGGAACCT CAGACTGTGC
```

<p style="text-align:center">FIG.3-3</p>

```
7501 AATGGAGGCC AGTGACAAAA CTGAAAGTAG CTCTGTCAGT AATTGTGCTG
7551 GTGCGATTAG GCAGCTGGCC AGAATCTTTT GGATCTCCTG GACATATGGC
7601 TGACTAGTCC TCCCAAGCCT TCCCAACAGG CCTCTTTTTT TTCCTTTTTT
7651 TCTTTTCTTT TTTTTCTTTC TTTCTTTCTT TCTTTTTTTT TTTTTTTTAG
7701 GCTAGTGAAG TGAAATTGTG GGAGTGGAAA AGGAACAAAG AAATCGGTAA
7751 CTGGTAGTGA TCAATTACTT GTAAACACTA TTGTACTTGG ACCAGCCCAG
7801 TAGGCCTTTT TTAAAACTCT GAGTTACCTC TCTTTCCTTT CCTTGAGCAG
7851 TGCCATTAAT TCTGTATCTG GGGCAATCCT TTCTGATGTT CTCTGGACCT
7901 GGCTCTCTCT CCTTAGGAGA GGCCAGGAGA GTAGCCAGAG AGCATGTCAT
7951 TTGTAGCTGA GGTTAAAGTG TGGAGCTATC AATGGTGACC TGGCCTCTTG
8001 GCATGTTAGC AAGCCAGAGG ACCTTGACAA CTTTTTTTGAT GATTGTCCGT
8051 TCACCCTGAT CAAAGGTGTT TGGCTTAGGA GGAGGGAAGA AAAGCTACCC
8101 CTATTAGTCT TGATGGCCCC AGCGTGGGTC TCTATTGCTT GACCTGGTTC
8151 CTAGCAGCAT TATCAGAAGG AAAATCCACC GCTCTTAAGG CTCCTGGGAA
8201 CTTTCAGGAC TTCCTTTCTC AGGATTGCAA ACATAAGACT ATTTGAGCTT
8251 TCACTTTTGA AAAGCGGTTA CTAATACCTA TACTCTGGGA AAGGGCTAAT
8301 GCAGATAGAA GACTGTGGTC ACTGCATCAG GCAACAGACC ATTTCCGCTA
8351 AATTTAGTGA CTCCAGGAAG GCCAGTGAAG AAATAACACA CGTAGCAACC
8401 AGAGACTGTG TTGTAATATG TTGGCTGACA GCAGGGTACT TTCTGTGATG
8451 CTGAAAGCCA CATTCATTTT CTCTCCCCTC ATCCCCATCT AAGCAAGCCT
8501 GGTAGAATCA TAATTACAGT AATAGGTACC ACTTATTGAG TACTCTGTGC
8551 CAGACACCCT CCTGAGCATA CGACATGCAT AGCACATTTA ATCCTTACAA
8601 TGACTTAATA AAATGTAGTA CTAGTCTTAC CTACTTCGAG AATAGGGAAA
8651 TGGAGGTTAC TTGTTTAAAG TCACAGAGCT AATAGGTAGC ATAGCTGAGA
8701 TTTGAACTCA GGCATTCTTA CTCCTTGCCT GCAAGAGTCT CTTGGCATTC
8751 TTGAATGCAA GCATATTTCT TAACCTCACT GAGGCTCAGT TTCCTCTTAT
8801 ATAATATGGG GTAAAGAGCC CTCACCCTGC CTGCCACACA CTGGTAGTGT
8851 CAGATAACAT TGAAGGGTGT TAGTTTAAAG GCTTCATGGA CTCTATAATG
8901 TCAACAAAAG TGCTGTTAAC TTTCTTCTGG GTCTCAGGCT CCTGATGTAG
8951 AGTCAGTGGA GCAACCCTGC CATCTGCTGT TATGCTGTTG ATGTTGCTGC
9001 CACACTTACT AACCTAAACC TTTGATTCTG GCTGTGGCCT TCTCCAGAAG
9051 GTGTTTACTC ATTTGTCCAG TTTATCTTTT AGGAAACAGC CAGCCCGTAG
9101 ATCATTAAGG CTGGCTATTG GACAGGGGGC TGGGGCCTGC CTGACAGAGG
9151 AAGGAAGGGC AGACATCTGG TTCTTCCTCT GCCCCTACAA GAGACTCCAG
9201 CCTGACCACA GAGTGGTACT CCTAGGATGT AGCAGCAGCA TATGAGCTTG
9251 AATGTGCCTT AATCCTGCTC TTTACTTTGA GAAGAGAGAA CTAAGGACCC
9301 ACAGATGTTT CACAGCTTCT ATAGGAGGCA GAGGTAGAAA AATGGAGAGA
9351 GATGAGGCCA GAGATAGATA ACTGATATTA ATTAAACGTT GTATTAAGAA
9401 CCTCACTTAG ATTATCTGAT TCAATCTTCA TAATAACCCT GCAACCCCCA
9451 CCTTTTTTTG AGAACAGGGT CTTGCTCTGT TGTCCAGGCT ACAGTGCACT
9501 GGTACAATCA TAGTTCACTG CAGTGTCAAC CTCCTGAGCT CAAGCAATCC
9551 TCCCACCTCA GCCTTGCAAG CAGCTTGGAC TACAGGCGTG CCACCACACC
9601 TTGCCATTTT TTTTTATTTT AAGTAGAAAC AAGGTCTTAT TAATACTATG
9651 TTGCCCAGGC TGGTCTTGAA CTCCAGCGAT CCTCCTGCCC CAGCCTCCCA
9701 AAGTGCTTGG GATTACGGAA GTAAGCCACT GTGCCTGGCC AGTGCAACCC
9751 CCATTTTATA CTAAAACAGG AAGGCCCAGA AAGGTTTGGA GTAACTTGTC
9801 CAGGGTCACA CAGATGATAT TTGAACTCAG GTCTCCCTGG CTCCCAAGAG
9851 AGTCTGCTTT CCACTAGGAC TCCCAGGAGA AAAAAAAAAA AAAAAACAGT
9901 AGACTTGGAG ACAGAAAATC TGATTTGAGT CTTAGTTGAG CTAGGCTAAC
9951 TGTGTAACTG TGGGCAAGTT CCTTAGCCCC TGTGAGCCTC AGTTTCTTAT
```

<div align="center">FIG.3-4</div>

```
10001 CTGTAAAATG TCATAAAAGA AATCCATCTC ATGGAGTAGT TGTGATGATC
10051 AAGGACTCTG AAAACATTAG AATGGTTTAA TGTGAAGGAT TAGCAGCAGC
10101 ACATGGCAAC ATTGTGCATC TTATATTAAC TATCCAAATA TATCAAGCGT
10151 CATTTGCTAT ATATAAAAGT CATCAAATTA GGCACTGTGG GGGATACGGA
10201 GTTGGCATAC TAGCCTGGCC TCTTAATTAA TTCATTAATT AGCTTATTTA
10251 TTTTTGAGAT AGGTCTTGCT CTATTGCCCA GGCTGGAGTG CAGTGGCATG
10301 ATGATAGCTT ACTATAGCCT CAATCTCCCA GGCTTAAACA ATCCTCCTGA
10351 GTAGCTGGGA CTACAGGCAC ACACTACCAT GCCCAGCTAA TTTTTTTTTA
10401 ATTTTTTGTA GAGACAGGGT CTTGCTCTGT TGCCCAGGCT GGTCTCAAAC
10451 TCCTGGGCTC GAGATCCTCC CACCTGGGCC TCACAAAGTG TTGGGATTAC
10501 AGGTATGAGC CACGGCACCT GGCCTGGTCT CTTAACTGGT TCCCTAAGAC
10551 AGCTGGAAAT AGAGAATGTC ATGGAGCATT CCTAACCATG GGCTCCAGCC
10601 TGGCTTTCAT TCTGTTTCTC CCCTGAAACA ACATTCCTTT AGTAATATTC
10651 CGAATAACAG CTTCATCAGT CTGTCTACCG ACCACTCTTC AGGCTTCATC
10701 TTATATGACC TCCCAAACTG CACTAAGGGT TGTATTAGAG AAAAGTGGAT
10751 AAAGTTCGGA GTCAGGCTGC TTGAGCTTAA ATGCCAGCTT CACTTACCAG
10801 CCACCTGACC ATGAGTCAGC TGCTTAACCA TTCTTTGCCA CAGTTTCCTT
10851 GTCTATGAAA AGGGAAATGG CTCCCACCTC AAAAAGTTGT TAACATTAAA
10901 TTCAATCATG TATTCAAAGT CCTGAGCAGA ATGTCTGGCC ATGACTGGGA
10951 CTTAACAGAT GTTAGCATTT ATTATTAGTA TCTGTCAGTC TTGAAATGTT
11001 CTCTTCCCTT GGCTTTCATG ACATTCCACA CTCTCCTGGT TTTCTCTTAC
11051 CTCTCTGGTA ATACCTGTTT GCTTATCCTT CTTTGTCCAG CTCTGGGATG
11101 TTACCATTCC TTCAGGCGTG CTGTTTTCTC CTTAGGCAGT CTTACACACA
11151 CTCATGACTT CCTTCCATTG TCCTCCACAC ACTGATGACC CTAAAATCAG
11201 TATCTCCAGC CTAAACCTTT CCACTGAGTT CTAGACCCAT ATGTTGTACT
11251 ATCAACCTGG CTTGTCCATT TGAATGTCTT CCAGGCACTT CAGACTCTCT
11301 TCTCTAGACT TTGCTGGACT TTCACTCTTC CCCCTAAAAC TGGCTCCTCT
11351 TCCACTGAAA CATGTATGTC ATTGAGAGGC ACCACCATCC ACCCAGTGCC
11401 TAAGCCAGAA ACCTAGGAAT CCTTGATACC TGTTCTCTCT CATCCTGCAT
11451 ATCCAAGCCT ATCAGTTTTA TCTCTAAATT ATATTTTGGT AGGTTTACTT
11501 CTTTCCTTTT CTCCCACCAC CACCCTGCTC CAAGCTACCA TCATCTCACC
11551 TGGATGTCTG CAATAGCCTC ATCTCCCACA GCCACTCTGC ACCCCCTAAT
11601 CTGTTCTCTA TAGAGCAGTT GGAAGGAGTG ATTTTTGTTG TTTGTTTTGT
11651 TTTGTTTTAG ACAGAGTCTC ACTCTGTTCC CCAAGGCTGG AGTGCAGTGG
11701 CACAATTTCG GCTCACTGCA ACTTCTGCCT CCCGGGTTTA AGCAATTCTC
11751 CTGCCTCAGC CTCCCAAGTA GCTGGGATTA AGGCACCGGC CCCCATACCC
11801 AGCTAATTTT TATATTTTTA GTAGAGATGG GGTTTTGCCA TGTTGGCCAA
11851 GCTAGTCTCG AACTCCTGAC CTCAAGTGAT CCACCTGCCT CGGCCTCCCA
11901 AAGTGCTGGG ATTACAGGTG TGAGCCACTG CACCTGGCTG GAAGGAGTGA
11951 TCTTAAAAAA AAAAAAAACA AAAAAAAACT TGACTGTGTC ACTCTGTGTT
12001 GTCTCTCCTA CCTTGTATAC TTCCACAACT TCCCAGTGTT CTTGGATAAA
12051 GACCAAAATC CTTAACTTGG CCAGGCGCGG TGGCTCACAC CTATCATCTC
12101 AGCACTTTGG GAGGCCGAGG CAGGCAGATC ATGAAGTCAA GAGATTGAGA
12151 CCATCCTGGC CAACATGGTG AAACCCCATC TCTACTAAAA ATACAAAAAT
12201 TAGCTGGTCG TGGTGGCGTG TGCCTGTAGT CCCAGCTACT GGGAGGCTG
12251 AGGCAGGAGA ATCACTTGAA CCTGGGAGGC AGAGGTTGCA GTGAGCCCAG
12301 ATCACGCCAC TGCACTCCAG CCTGGTGACA GAGTAAGACT CCATCTCAAA
12351 AAAAAAAAAA AAAAAAAAA TTCCTTAATT TGGCCTACAG TAGAGCCCTC
12401 CGTAATGTGG CCTCTCTCCA CATCTCCACA ACCTCCTGCT CCCTGCACTT
12451 CAGCCTCACC TCTCTTCTGG ACAGGCCCTC CTTCTGACAA GGGCTTTGTT
```

FIG.3-5

```
12501 CATTCTGCTC CCTCTGCCTA GAATGCCCCC TTACTCTGTT CACTTAACTC
12551 CTGCTTATCG TTTAGATCTT TACCTGGATG GCTCAGAGAA ATATAGAAGT
12601 AATTCCTCAC CCTGAAAAAT AGGTTAGGTC CCTGTTTTAT GTTTTCATAG
12651 ACCTTTCCTT TGAGGCTTTT TTTAAAAAAG TAGTTTTAAT CTCACATTTA
12701 TTCATGTGAT CATCTCCTTA ATGATATCTT AAGACCTCTA ATAGAACAAT
12751 TTGGTCATGG ACTGTGGGGT TTTTGCCCCT CATTGTGTCA GCACTGAGCA
12801 TATTGTTGGC ATAGGAGGGA TATTTGTTGA ATGAATTGCT AGAGGTGGCC
12851 AAGAGATATG ATGTAAGTCA GGCTTTTCCC TGCCCTTCCC CTTCCCCTTC
12901 CCCACATCCT TCCTATAGCA GCCACCGTGG CTGCAGTTAC TGTAAATGGC
12951 AAGACGGAAT CAGTTCCGGA CATTGGGTTG TTTTAGAAAA TTGCCTGCAA
13001 GTGTCAGGGT GATAAGTTAA AGCTTTGTCT TTTGCCCTCA GAGGAGCTAT
13051 CCCATAGTGA GTAGAAGCCA GAGAAGCTGA CCCCAGGAGT CCTTCTTTCC
13101 AGCAGCAGGT CTTGAGCTGC ACTTCTCTGT AGCTACAATC CAGGCAGGAA
13151 CAAGCCCTAG GTACCTCCGG AGAGGAGGGC AAGAGAGGAA GAATGAGTTC
13201 AGCTACTCTA GCCACCAAAC TGATTATGAA TTGCCCTGAA ATCTGAAAAA
13251 TTTCAATTCC AATCGTAAGT TTGTTTTGTT TCATTTTGTT TTCTTAAATT
13301 GTATATTTGA AAGATGGCAT TAACTAAAGA TATATATTCA ATATAGAGTG
13351 GAAAAAATGG AATACTTGCA TAGTATCTTT TACTTATAGG TGATTTATGA
13401 TGGGGAGTGG GGTGGATAGG TTGGCAGTTC CCCCAAGAAG TTGGAAATGA
13451 AGTTTGTCCT CTGTGAGTTG AACTAATTAG ATCCACAAGT AATGAAAGCA
13501 GTATTGTGTT GTAGTTAAGA GCACACTCTA GAACCAGATT GCTTAGTTTC
13551 AAATCCTGGT TCTGCCTTTT ATTATCTGTG TACTTTGGGC AAGTTACTTG
13601 CCCTTTGTGT GCTTCATTTT TCTCATCTAG AAAATGGAGA GGCCAGGCGT
13651 AGTGGCTCAT GCCTATAATC CCAGCACTTT GGGAGGCCGA GGCGGGCAGA
13701 TCACCTGAGG TGAGAAGTTC AAGACCAGCC TGGCCAACAT GGTGAAACCC
13751 TGTCTCTACA AAAATACAAA AATTAGCCAG GCATGATGGC GGGTGCCTGT
13801 AATCCCAGCT ACCCAGGAGC CTGAGGCGGG AGAAACACTT GAACCTGGAA
13851 GGCAGAGGTT GTAGTGAGCC AGGATTGCAC CACTGCACTC CAGCCTGGGT
13901 GACAAGAGCT AGACTCAGTC TAAAAAAAAA AAAAAAAAAC AAACTGGAGA
13951 TACAGGCTGG GTGCAGGGCT TACACTTATA ATATCAGCAC TTTGGGAGGC
14001 CTAGGCGGGA GGATTGCTTG AACTCAGGAG TTTCAAGATC AGTCTGGGTA
14051 ACAGAGCAAG ACCTCATCCC CACAAAAAAT CAAAAATTTA GCCAGGCATG
14101 GTGGCTCATG CCTGTGGTCC CAGCTACTCA GGAGGCTGAG GCGAGAGGAT
14151 TGCTTGAGCC CAGGAGGTTG AGGCTGCAGT GAACCATGAC TGCACCACTA
14201 CATGCCAGCC TGGATGACAG AGCAAGACCC TATCTCAAAA AAAAAAAAAA
14251 AAAGAAACGA GCCAGGCGCG TTTGCTCACG CCAGTAATCC CAGCACTTTG
14301 GGAGGCCAAG GCAGGTGGAT CACTTGAGGT CAGGAGATCG AGACTAGCCT
14351 GGCCAACATG GTGAAACCCC ATCTCAACTG AAAATACAAA AATTAGCCAG
14401 GCATGGTGGC ATGCTCCTGT AGTCCCAGCT ACTCACTTGG AGGCTGAGGC
14451 ACGAGAATCG CTTGAACCCA GGAGGCGGAG GTTGCAGTGG GCCAACATCA
14501 TGTCACTGCA CTCCAGCCTG GGAGACAGAG CGAGACTCTG TCTCAATAAA
14551 TAAATAAACA TAAAATAAAA TAAAATAAAA TAAAATAAAA TAAAAAAATA
14601 TGGAGGCCAG CAGGCACGGT GGCTCACGCA TGTAATCCCA GCACTTTGGG
14651 AGGCCGAGGG GGGCGGATCA CAAGGTCAGG AGATCGAGAC CATCCTGGCT
14701 AACACAGTGA AACCGCGTCT CTACTAAAAA TACACAAAAT TAGCCAGGCA
14751 TGGTGGCAGG CACCTGTAGT CCCTGCTACT CAGGAGGCTG AGGCAGGAGA
14801 ATGGCGTGAA CCCGGGAGGC GGAGCTTGCA GTGAGCTGAG ATCGCGCCAC
14851 TGCAGTCCAG CCTGGGCGAC AGAGCAAGAC TCTGTCTCAA AAAAAAAAAA
14901 AAAAATGGAG GTTGGGCGCG GTGGCTCGCG CCTGTAATCC CAGCACTTTG
14951 GGAGGTCGAG GCGGGCGGAT CACCTGAGGT CAGGAGTTCC AGACCAGCCT
```

FIG.3-6

```
15001 GGCCAACATG GTGAAACCTT GTCTCTACTA AAATTACAAA AATTAGCCAG
15051 GCACGATGGC AGGCACCTGT AATCCCAGCT ACTTAGGAGA CTAAGGCAGG
15101 AGAATAGCTT GAACCTGGGA GATGGAGGTT GCAGTGTGCT GAGATCGCGC
15151 CACTGCCCTC CAGTAGAGTG AGATTCCGTC TCAAAAAAAA AAAAAAAGAA
15201 GAAATGGAGA TACAAACTTA CTACCTACCT CCTTACAACC TACCCTCACA
15251 GTATTACTGT GAATAAAAGT GTGTGTAGCA CTGGGAACAC TATTCACAGA
15301 GCACTCATGA ATGTTTGTTC TTTGTTATTA GTTACTAGAG AGGCAAATGT
15351 CTGCCAGGGC TGAATAATAT GTGTGAATTG GTGATTGTCG CACATATCTA
15401 AAGAAGTAGT TATTTTTTTC AATTAAAACT TAGTTTAAAA ACCAATATAA
15451 GGCCGAGCGC AGTGGCTCAC ACCTGTAATC CCAGCACTTT GGGAGGCCGA
15501 GGTGGGCAGA TCATTTGAGG TCAGGAGTTC GAGACTAGCC TGGCCAACAT
15551 GGTGAAACCC TGTCTCTGCT AAAAAAAAAA AAAAAGTACA AAAATTAGCC
15601 AGGCATGATG GCAGGTCCCT GTAATCCCAG CTACTTGGGA GGCCGAGGCA
15651 GGAGAATTGC TTGAACCCAG GAGGTGGAGG TTGTAGTGAG CCGAGTTTGT
15701 GCCACTGCAC TTCAGCCTGG GTGACAGAGG GAGACACTGT CTCAAAAAAA
15751 AAAAAAAAAA ACCAAAACCA ATATAATAAA TAAGTGGCCA GCAATGAAAC
15801 AGAAAGTGAA AAGTTAGTGA AGCAAAACTA GTACTGTATT CAGATAAAGA
15851 TGCTGAATCT AGATTTGGTC ACCAGAATAG GGTCCTTTGT GGCAACCTGG
15901 GCTAGTTTGG CTGACTCACC ACTGCCAGGA TGAAATTTCT TTCAGTGGCT
15951 ACTCATTTCC CTTTATTTTA AGTCCATGCT CACAGAGCAA CCTTCTGATG
16001 CCTAATTCAG CTTCCTGGGA TACTTAATAA CAGGAAGGGT CTGGAAGTAG
16051 TACCTGTATA GGGGATATGA GTGTTCTGAT TTTAATAGTC AATTCATAAG
16101 TGTACAGAGG GTTTGATAAA TGGTTAGGTC AGAACCATCA CAGAATGTCT
16151 ACACCTCTTT GGACATTAGG AAGGTCAAAA ACCTGAAAGG CCAAAAGCTA
16201 GGCCTAGATT AGGGTCATTC ACCAAGAAAA CATCAGCCTT GAAGAGTTCT
16251 CTGGGTGGTC CACCAGTCAA CCTTCCTTTG ATCACACCTC CTTCCTCGTT
16301 GCTTCTTTAA GCATTGACCT GTAATGGGTA TGGAATTTTT TGCTCACCTA
16351 ACTCCTTCCT TTTACAGAGG AAGAAGTTGA AGCCCAGAGA GATTTAATGG
16401 CTTGCCTAAG ATCACACGCA GATTTTCTGT TAACCAGGGT GATTTTTTCAG
16451 GTGTTCCCTG CCAGACGAGG GCTTTTTTCC TTGAATTGCC TAGAGATTTC
16501 TTGAGATATC CGAAGCATTT TTCCCAGTGC AGCCTGGAGA AGGATGTCCC
16551 TGTCAACACA GCATTTGTTA CTCAATGTTA GACATTCAAT TTTCTAATTA
16601 GTATCATGGA GCAACAGTGG ATGATTATCT ATAAGGGGTT GCAATTCCAT
16651 GCTTATGTGC TTACAGCCCA TATAGACAAA TATCAGCTGT TAAAATGACA
16701 AGGCAGTAGA GATGTGGCCC CAGGACAAAG GCATACTCTG CTGTTAGTGA
16751 ACACTAGTTG GCCAGCAAAT TTCACATGGG CATATACACG GCCAACTGTA
16801 GACTTTAGGC ATTTATACCC ATTCAGAGAG CCAAACTGGC AACTAAAGAT
16851 CAGCATTCTC TTTGGCATTT CAGCTTTGCG TTCTGTTAAA AATCACTGCT
16901 TGCTTAAATA CCTCTGATAG CTCTTCACTG CCTGTAGGCA ACTCTTTAGC
16951 CTAGCAGACT TGGTCTTTAG TGCTCTGCCC CTACTCTCTT CCACCATTCT
17001 GGCCTCCTGT CTAATTGCTG CCCATATGTG CCATGCACTA GAGCTTACAG
17051 ACCTGCTCAG CGTTATATGA GCATACCATA CTCTTTATGC CTCAGTGCAT
17101 TTGCACATGT TGTTCCTTCA GGCCAGAATG CCTGTTACTG CCTGGCAATC
17151 AGCCTATTAG AGTCTGCCAA TACCATCCCA TCTTCTGTGG AGGAGCCCCC
17201 CGCCAAATCC ACCCATACCT CTCCCCACCA ATCAGAGACT TCTTCTCTCT
17251 TTGTTATTCT CTTCGTTATT CTCTTCATAC CTCAGTTATA TCCATTTCAG
17301 TATTTGTTTA CACATCTAGC ATCACTCTTA GAGTGTGAAA TTCTCCAAGT
17351 GTGGAGCCGT ATCTAGTTTG TCTTTGTATC CCAGAGCTTA GCAAAGTGCC
17401 TAGAATGTAG TGGGTGCTCA GAGTGTTTGC TGGGTGAATG ATGTATTTGT
17451 TGAACGACTC TTTGGACACT TGAATAAAGT CCATCCAGTA TGCACCATTA
```

FIG.3-7

```
17501 CCATCTCTTC GCTCTACAAT ATTCTTTTAG GCAAGAGCTT ATCTTTTGAG
17551 GTGATAAGAT AAGCTCAAAC TTATGTAGAC TAAGACCTCA GTCTGTAAAT
17601 GTCATCCCTA AGTCTTAAAC CATCAAAACC AGGGCCTCAA GGAATGGCAT
17651 GCCTTCTGCA ACTGTAGCAA CCTGCTGTGC TTATTTTGCC GTGTTTTTCA
17701 TTTTTCCCCC AAAAGCTAGA GTCCCTTCTC CCATGGGCAG TGCTGGAAGT
17751 GTGCTAACAA ATTCTTTCTC CATACTGCTT ACGATTACAA AAAAAACCCT
17801 CAGCATCTCA TGCCAGACTT GAGTTAAGGT TGTTTTCTTT TGTGTGTCAG
17851 CTGTATTCTG GTCATGACTT CCTGATGATG CCCTATAGAG ATTTTGCTGA
17901 GATCAGAGGG TGCTCCACTG CCATCAGTAG CACTGACTCT TGCAGAAGCA
17951 CCGTTTCTGA AGTTGGCTAA TGTCATCCCT CACGTTTGTT TGTTTGAAAT
18001 TTGTTTTAGT TCCAGAGATA GCACTTTCAT GGAATGACGC TATCTTCTAG
18051 AATCACTTTT TTTTTTTTTT TGAGTTGGAG TCTCGCTGTG TCGCCAGGCT
18101 GGAGTGCAGT GGCACAATCT CAGCTCACTG CAATCTCCAC CTTCCGGGTT
18151 CAAGTGATTC CCCTGCCTCA GCCTCCCGAG GAGCTGTTAC TACAGGCGCA
18201 CACCCCCACT CCTGGCTAAT TTTATGTGTT TTAGTAGAGA CGGGGTTTCA
18251 CCGTGTTGGC CAGGATGGTC TCGATCTCCT GACTTTGTGA TCTGCCTGCT
18301 TCAGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGTCACC GCGCCTGGCC
18351 TAGAATCACC TTTTTATACC ATAACGTGAG CACCACTGCC GCGTCACCAA
18401 GGAAAGAGAG AGGCAGCTAC TGTGGGGTTA CAAATGGGTA AGAGTGGCAC
18451 CAGGAAGGTG AAAGTCTCTA CTTAGCCAAG GCTTAACAAA ATGTCAATCA
18501 CCAAACATTT ATTTATTAAG CTACGTTCAG GATAAGAAGA TGAACAAGCT
18551 ATCTGTACAT TCATTTTCTC GTTTGTAACA AGGTAATGAT AGTGATCTAT
18601 CCTGCCTGCC TCTGAGGGTT ATTGTGAGAA TAAAATGAAA TCAAGTGGAA
18651 AAGCACTTAG GAAAAAGAAA AGCATTGGTT TTCAATTGTT AGTGTGGATC
18701 AGAAACACTG GGGCTTGTTT AAAATGCAGA TTCTTAGCCC CAGTCTCAGC
18751 GATTCTGATT CTGTATATCT GAAGTGGGAC TCAGGAATCT TGATTTTCAA
18801 CAAGCTGACC AGAGGGTCCA ATGCTGCTAT TCCTTTAGTT ACACTTTCAG
18851 AAATATTACT GTAAATCAAA TGGCAAGAAT AAAATAGTTA TTTGAGGCAG
18901 TTTTAGTATG TTGGACCTGG AGTCCAAAGA CTTGGGTCAA ACTCCAGCTT
18951 TGTCAGTTCC TAGACCTGTG ACCTTAAACA GCAACCTTCT CTGTGAACCT
19001 TAGTTCCCTC AGGAACGGCT CTGGTCACCT CCTGCTGTAC TCCATTGATG
19051 ACTCACCACA TAAGGCTCCC TGGGAGTCCC CCAAACCTTT GCTCTCTTAA
19101 CTCCTTTTAC AGCCTCCTAC ATCTCCTGCA GGTGCTGTCT TCTCCTCCTT
19151 TTTCCAGGCC CTGCTCTGAC ACAGCATTCA TTCTCCTCTG GGAAGGGTTC
19201 CTTCAATGTG TCTCCAAGCA CATCACACCC AGGAAGGACC CTGTGGCCAT
19251 ATCTGTCTAT CACCAGATCA AACTACGTGA AGGCAGGCAC TAGGTACTGT
19301 CAGTGCCCAG CATAGGCCTG GCCCATACCA GGTGTCCACA GATGCCTAGT
19351 AAAGAAACCT ATGATTCAGG ACCCCCATGA TGAGCAACTA TAGCACTAGA
19401 ACAGTGATAA TAACTAATGT TTATAATGCA TCTTCAGTTT ACAGAGGGCT
19451 TTTGTACTCA TCATCTAGTT TAGTTCCTGC AACAACCTCT TGAGGAATAT
19501 AGCACAAGCA GGACAAGGGA AGCCCAGAGA TGTTAAATAA TTTATCCAAG
19551 TTTATGCTGC TGGGAAGGGC AGCACTGAAA TTAAAAGAAA AGTTTTCTGA
19601 GCTCAAATCC CATGCCCTTT CCTCAATGTG AGCTCTAGCA AGGTATTCAG
19651 GAATCCTGCC TCTACAGTTC AGAGCCTCAA ATTGCTGGGT ATGTTGAGTT
19701 CTTGTATCTG ATTTTTCTAG ATTTCCTGCC CACATTCTTA CTGTCTGGAT
19751 ATCAGGAAAG AGTTTATCAA ATGCCTGTGG AAATCCAAGA TAAGGTCTCA
19801 TGATGAGTAA CCCAGTGAAA ACATGAAGTC AAGTCTAACT AGTCACTACT
19851 ATTTCACTAC TGCTGACTCC TGATGATCAG CTCCTTTTCT AAGTGCTTAC
19901 TGTCCACTTA TTCCATCATC TGCCTAGAAT TTATGTGAAG GAATCAAAGC
19951 AAAAGGATCA TAAGGCTTCC TTTTTCCAGT ATGTTTTTCC TCCTTTTTGA
```

FIG.3-8

```
20001 AAACTGGGCC AGTTAGCTAT CTCCATTTTT ATTTCATGAA TACATCCCCA
20051 GCGCCTGGTA TATAGTAGAT ATGGAACATT ACACTTTGGA GATATTGCAC
20101 CCATTCTCCA GTTTCTCCAA AGTTACTAAC AATGGTTCCA TCACTGTGCC
20151 AACATATTTT CTTTTTTCAA TATATTGGGA AATAATTCTC CCAGTCTGAA
20201 AATCTGAACA CATTTCATGT GACTTGGTAT CCTCATATGT CTTGGGCTTC
20251 CAATTCTCCA TTCCTAGTTT CAAGTTCATG AACTGTAAAA CAAAGGATTA
20301 GACTAAATCT CTAAAGTTCT ATCCAGATGC CAAATTCTTT TCTCTTTCCA
20351 TGATACCTAA GATAGATGCC AAATATTGTC TTTTACCTGG TGTTTGTGAA
20401 CATGACATCA CATTACAGGA GTAGCAGATA CTAAACTCTC ACTCTGTAAA
20451 ACACTGACTG AGTTCCATGA GCCAGATACT GAAGTGAGCT TGTTCACATA
20501 TGTTCTCATT TAATGCTCAT AACCCTGTGA AGCTGGGAAT TGCTGGGACA
20551 TTTTATTTAT TTATTTATTG AGACGGAGTC TGGCTCTGTC ACCTAGGCTG
20601 GTGTGCAATG GCATGATCTT GGCTCACCGC AACCTCCGCC TCCCGGGTTC
20651 AAGCGATTCT CTTGCCTCAG CCTCCGCAGT AGCTGGGATT ACGGGGCACA
20701 CACCACCACA TCCAGCTAAT TTTGTATTTT TAGCAGAGAT GGAGTTTCTC
20751 CATGTTGGCC AGGTTGGTCA CGAACACTTG ACCTCAAGTG ATCTGCCTGC
20801 CTCAGCCTCC CAAAGTGCTG GGATTACAGG CATGAGCCAC CATGCCTGCC
20851 CGGGACCCTT GTTTTAGAAG GATGACTGCT GCTATAATGT AGAAAGTGAT
20901 TTGGAAGAGG GGAGGAGTGG GGCACGAAAG ATGGTTAGTA GATGGGGGTG
20951 GTAATGCTTA CCTTTCAGTA TTTGGAGGCT TCGGAGTCCT CAAAAATTCT
21001 CTTCCTTGAT TGGAGTCCTC CCAGCCAATA GAGGGCTTCA CACAAACAGT
21051 TTCTTGGGTT TTGAATTGTT TGACCAGAGC TTTCTTCCGA CAAAAGGTTG
21101 GGGTGATTCA TTCACTTACC ACACCTTGCC TGAACATTCA CTTGGGGCTG
21151 CCGGTTATGA AGGCTATTGT TCTCCAGCCT GTCACAGACG CTTTGAAGAC
21201 CTGTGCCTCA GCTGGTTCTA AGGAGTCAGT TTGTTCAGCT CCGTGCCAGG
21251 TTTCCAACTT ATGAAATGTG CTGGAGATTA ACACCTCTCC TGCCATTTTA
21301 TCCCTACTAT AATTGCCAGT CAAAGGATTC CTGCAGTTGC CTCTGGCAGC
21351 CATAACTGAT GAATGTTCTG CCAGCTGCTC TGAGGACCTA GAAGAGCAGT
21401 TTTCTATCCA GGACCAGTTT CCAAGGGTGG GAGGGTGAAA TATATCCTCC
21451 AGTGTGACAT TTCATCTCCC AGTGATGGGT GGCTTGGGCC CTTTGAAGTT
21501 GGCTCTGAGG AACCACACAC TTGGGTCTGA GCAGCCAGCA GCTTATCACA
21551 TCTGGTGATC AATCCTTCAA AGGTTCCTCC TGAAGTCTGA ATTTTTGGAG
21601 GTCAAATGGA TTCCACCTGG GAGGGGCTTC TGCTTCAACT CAGGACATGG
21651 GGAGAAGGCT GTTCCTCTTC CAGGGGGAGG CAGTTTTCAT GGCATTGAGA
21701 TGTCCTCTCA CTTATTCCCC ACCCACCCAC CAAGTCCTTT GTAAGAGGAG
21751 TAGGGGGAGA GGAGAGCGCC TGCAGCCTCC TGCTCACATT CCTAGACACC
21801 GACTCACTGA GCCCGTCGCC GCTGGAACAG CAGAGCTGTG TGAAATGTCA
21851 AGAGGAGTTA TGCTCATAGG CTCCCTGGCC TCAGTCTCTT TGTGGCTTGC
21901 ATATTCTTCC ATTAGTACTG TGTTCATCAC ATGGAAATCA GAGGGTACAA
21951 TTAAAAGATA ATTTGCTAGT CCCAGACTTA ATTTGGGGCC CCCTTCTTGC
22001 CTGATTGAAT TACAGGGGAA CATAATAGAT TTTTGGTGAG AAATAGTTGT
22051 CTGTGTGGCT GGGAGAAAGA TTGCTCCCAG CTCTCCAGCT GGGCAGCCCT
22101 TTCAGTATCC CGTATGTTAT TTCCCCACTT CCAGCCCACC TCACCTCCTC
22151 TGTGGCCCTT GTGTGTCCCC TCGGCTAGGA TCCTGACCTC CTGCTCAAGA
22201 GTTTAAACTC AACTTGAGAC CCAAGGAAAA TAGAGAGCCC TCTGCAACCT
22251 CATAGGGGTG AAAAATGTTG ATGCTGGGAG CTATTTAGAG ACCTAACCAA
22301 GGCCCAGACA GAGAGAGTGA CTTGCTAAAG GCCACATAGC TAGCCCACAG
22351 TAGTTGTAAC AATAGTCTTA ATGATATTAA TGGCTAACAT TTATCAACCT
22401 TTAATGTGTC CCAGACTTTG TGCCAAGGGC TTACATGCAG TGCATTGTCG
22451 CATTCAAACC CAGACAGTCT GGCTCTGGGC CCAGGCTGAG CTTTGGTATA
```

<div align="center">

FIG.3-9

</div>

```
22501 GCATGGTAGA ACGTTGTCTA TAATGTCTAG TCTGGGTTCA AATCCTGGCT
22551 TCACTTCTCA CATTTACAGC TGAGTGACCT CAGGCAAGTG ATTTAACCTC
22601 CCTGTACCTC AGTTGCTTTA TCTGTAAAGA GAAAAATCAC AGCACTGTGG
22651 AATAGTGGGG GTTAAAATTC ATTCATACAA GTAGTGCTGC AAGCAATGTT
22701 TAATACAGGG TGAGCACCTG TTCAGTGCTT CCTTCTTCTG GCTGCCTCTG
22751 GGGCTAGAGT GTGGTGTCTT CGTGGTATAG ATAGATAGAT ATGGCTGAGC
22801 TCTGCACAAA CACCAAGAGC TGTTCTTCAC TATTAGAGGT AGTAAACAGA
22851 GTGGTTGAGC TCTGTGGTTC TAGAACAGAG GCCGGCAAGC TATGGCCCAT
22901 TGCCTATTTT AATACGGCCT GTGATTGATT GATTTTTTTT TTCTTTTTGA
22951 GACAGAGTTT CACTCTTGTT GCCCAGGCTG GAATGCAATG GCACGAACTC
23001 AGCTCACCGC AACCTCTGCC TCCTGGGTTC AAGCGATTCT CCTGTCTCAG
23051 CCTCTCGAGT AGCTGGGATT ACAGGCATGT GCCACCACGC CTGGCTAATT
23101 TTTGTATTTT TAGTAGAGAC AGGGTTTCTC CATGTTGGTC AGGCTAGTCT
23151 CGAACTTCCA ACCTCAGGTG ATCTGCCCGC CTCAGCCTTC CAAAGTGCTG
23201 GGATTACAGG CGTGAGCCAC CATGACTGGC CTGATTGACT GATTTTTTTA
23251 GTAGAGATAG GGTCTTGGTT TGTTACCCAG GCTGGTCTCA AACTTCTGGC
23301 TTCAAGCAGT CCTCCCTCCT TGGCCTCTCG AATGCTGGGA TTATAGGCAT
23351 GAGCCACTAT GCCTGGCCTA TATGACCTGT GATTTTTAAT GGTTAGGGGA
23401 AAAAAAGCAA AAGAATGCTT TGTGACATGT GGAAATTACA TGAAACTCAA
23451 ATATCAGTGT CCCAGCCTGG GCAACAAAGT GAGACCCTGT CTCTACAAAA
23501 AATAAAAAAA AATAAGCCAG GGCCGGGCGC AGTGGCTCAC ACCTATAATC
23551 TCAGCACTTT GGGAGGCCGA GGCAAGTGGA TCACCTGAGG TCAGGAGTTC
23601 AAGACCAGCC TGACCAATAT GGTGAAACCC TGTCTGTACT AAAAACACAA
23651 AAATTAGCCG AGCATGGTGG CATGCGCCTG TAGTCCCAGC TACTTGGGAG
23701 GCTGAGACAA GAGAATTGCT TGAACCTGGG AGGCGGAGGT TGCAGTGAGC
23751 CAAGATCGCG ACACTACACT GCAGCCTGGG CAACAGAGCG AGACTCCGAC
23801 ACACGCACGC ACGCACACAC ACACACACAC ACACACACAC ACGCTGGGTA
23851 TGGTGGCCAG CACGTGTGGT CCCAGGATGC ACTGGAGGCT TAGGTAGGAG
23901 GATCACTTGA GCTTAGGTGG TTGAGACTAC AATGAACCAT GTTTATACCA
23951 CTGCACTTTA GCCAGGGCAA CAGTGTGAGA CTGAATCTCA AAAGAAAAAA
24001 AAAAAAAAGA AAAAAATCTT TCCATAAGTA AATATCTGTT GGAACATAGC
24051 CATGTCCCTT AGTTTATGTT TTATATATGG CTGCTTTTGC CCTATAATGA
24101 CACAATTGAG TGGCCACGAC AGTCTGTATG GCCTGCAGAG CCTAAGATAT
24151 TTGCTCTCTG GCCCTTTACA GAAAAAGTGC CTTGACCTGT GCTCTAGAGC
24201 CATATGTACC AGGTTTGAAA CTCAGCCTCA CAGCTGGGTG TGATGGCACG
24251 CATCTGTAGT CCCAGCTACT CTGGAGGCTG AGGTGAGAGG ATCACTTGAG
24301 TCCAGAAGGT CGAGGTCAAG ATTGTAGTGA GCCATGATGG CATCACCGCA
24351 CTCCAGCCTG AGTGACAGAG AGAGACCCTG ACTCAAAAAA AAAAAAACAA
24401 AAAAAAAAAA CACCCTCACC ACTTATCAGC TATTTGTCTT GAGAATAGTG
24451 ACATAACCCC TCAGAACCTA TTTCCTAATC TGTTAAATGA GGCTGATGAC
24501 GTTTCCTCCT TTTACTGGCA ATTTAAACAT GATGGATAAT AAATGCTAAG
24551 CACTTAACAC AGGGCCTAGA AGATATTAAC TGCTCAATAA ATGGTAGCTT
24601 CTTAACAGTA TTCAAACCCA TGTGCTCTTA TCACATGCAT TGTTGTCCCT
24651 GTGTCCAGTT GGTGGAATGG GAAAAGGCTC CCTTGTAACC CCATCTACCA
24701 TCTTTATCAG ACTTTCCTGC CATGGTTCAC AGTAAGAGAT AGAAGCTGCA
24751 CGGTGACTTC TGGCTCTTTA CAATGGTGAG CGGTGTGTGC CTGGTAAGGG
24801 AGAGCTGATG TCACTGCCCC AAATCCAGTA GTGAGATCTG AGTGTTCTGG
24851 TTTCCTCCAG CAGCCTTGCT TTTTCCTTTA CAATCCTGCA GGCAGGGAGA
24901 CAAGGGCTTT CTACATGGTA GGCTCTGGTT TGGTCATCGT CACAACTGGG
24951 GGCTGTTCAG GTGGGCTCCC ATTCCAGATA CCTAGGCTTA TCAATCCCTT
```

FIG.3-10

```
25001 TTGGCACCCC AGGCCTTTTT CTCCCTCATG CCCCATTTTT CAGTTTGAAA
25051 AGCATGGTTA TCACAGGACA AGTAGAAGAA GCTCCACTGT CCACTGAGGC
25101 CAATGGATGG TGTTCTGCAT GTGAACACTC AGTGAATAGT GAGTGAATGA
25151 GAGTAACCTG GGCTCCATCC TATTTGCAGA GAGCTTTGGA AAAGATTTTT
25201 CTCCTTAAAG AGCCAGAATG AAGCCTGGTA GTGGGAGAGC TCCAGCTCTA
25251 GAGTCACATG AGCCTACATT TAAATTCCAG CCCTGCCACT GACTCCCTTT
25301 TTGACCTTGA GTGAGTTACC TAATCTCTCT GTACCTCACT TTTCTTGTCT
25351 GTAGAGTGGG AATAATTCCT GTCTCAGAGA AATAAAAGAG TGCATATAGT
25401 GTTTGCCACA TGGAGACACA TCAGGTGTAG GTTAATACTC TGGGCCTTGT
25451 TTCCTTATTT GCAACACAGC CCTGCCCTGG AGTGGAAGTG GCACCTCCCA
25501 TTGGTCAGCT CTTGAGGCTG TCCCCAGGAC AGGCAGAGGG AGGGAATGAA
25551 TGGGAGCCCT AGTGCCAGGA CAGAACAGAT GGCAGCTCAG AGCTAGGATG
25601 GCTCTCTGGA CCTGTCTCTC CTACCAGAGG TCCCCCCGTC TGGTGTGGCT
25651 CTTCCTGGAC CTGGCATCCT CTGCTTTTTT TTTTTTTCCA CCTCCAAGCA
25701 GAATTACTGT CCTGTAGGCA GCTCCTCTGC TTGAGGACAT CTGGGGCCAG
25751 ATATGTTCAC ACTCTATCCT GCCTTGCCCT TCCCTGAGCT CAGGATGGAC
25801 GCTCAATTGG TCCCAGTTAT TGTCTGCAGC GCCTGCCTGC AGCCTCGATC
25851 CAGCCCAGCT CCACCCCTTG CCTGCAAGGT CTGTTTCCTA ACAGCTGCTC
25901 CAACCACACA CCTCGGTTCT GCGGGAGCCC CTCCTCTTCC TCCCTCCCTC
25951 CCTCATTCAG GGGTGGGACT GAAGAAGAAG GCTAACTTGA CAGCAGCGCT
26001 TCTTTCTTAG CTAGTCACCG GCCCCTGCTC AAGAATGCCA GTGTGTGTGT
26051 AGCCTCCACA GAGAGGTCGT TTTCTCGGAG TCCAGAGGGG CCGCCTGAGC
26101 TTCTGAGAAC TAGGGAGGAG CCATCCCAGC CATGAGCCCC TGTGGGAATC
26151 TGCTGGGGGC CAAGTGGCCT GGAGTCCTCA GGCTCCCGCA GCTGCTCCGG
26201 AGGGAGAGGT GAGCTCAGGG CAGCCTGCCT GCAGCCAGAG GTGCCGGGAG
26251 CCCCGGGCCT GTCATGGTGG CCATCTACAG CCGGCCTGAG GCAGTCACAG
26301 ACGGATTTGC AGCTGAGCCT GTCTATCTGG TGTGGGAAGA AGATGGGGAG
26351 TTACTTGTCA GTCCCGGCTT ACTTCACCTC CAGAGACCTG TTTCGGTGAG
26401 TTGGTCTCCG AGTTCCCCTC TCCATCTCTC CTGGCCCCTG GTCCTGAGAG
26451 GAGGGTGGTC TCCCTAAATC TCCTTCTCAC TTAGTCCTTT ACCATCGGTT
26501 CTGCCGGGCA GAAGCCAGCG GAGGTTATAC CCAAGGAGAA TCGGCCTTGT
26551 GAGGTACCCC CATTATGTCC TGGAAGTGGT GAGGGGAGGG ATATACCCAG
26601 AAGGAACTTC TTAGGGAGCT CCAGCTCCCC TTCTATCCCA GACAAACCTG
26651 AAGGAGCCTC CAAAAGATGC CACTGACCTG CCCATTGTAG ATGTTACTGC
26701 TTCCGGGGGG AATAGCCCAA ATAGAGTGCT GTTTCCAGCT CTCACATGTC
26751 TTACCTGCGG GCCATGCTGC CTGCCCAGGA ATTTGTCCCA ACAAGCAGGA
26801 TGGGCAGGTT TTGCCAAACT GTGGAAACTG GCAAGTCCTG GGTGTGGGTA
26851 GCCTGGTACA CAGTAGGCAC CTTATAAACG TTTGTTCTCT TAATGGCAGG
26901 CACATTTGCC TCTGGCCTTG AAGGGCTTCT GAGCTCCCAG GTGAATGTAG
26951 TTGCTGGGGA AAGACCTGGG CGAGTGCTTC TAAGACTGGA GCAATGGGCT
27001 TTAGAGTGTT CCTGAGCTGC TGGGCCAGCC CCCACACCTC CTCAGTCCCT
27051 AGGCCTAAGT ACCTCCACGA GCCTCTCTCT GTGGGGCTTC TCAGAGGGAG
27101 ATGTGGAAAC TCTACCTCTA ACCTGGCTTT CTTTGCTCAT TGCCCCACTC
27151 CACCTCCCAT AGAAACTCCC CAGGGGGTTT CTGGCCCTCT GGGTCCCTTC
27201 TGAATGGAGC CATTCCAGGC TAGGGTGGGG TTTGTTTTCA TTCTTTGGGA
27251 GCAGCCTGTT GTTCCAAAAA GGCTGCCTCC CCCTCACCAG TGGTCCTGGT
27301 CGACTTTTCC CTTCTGGCTT CTCTAAGCTA GGTCCAGTGC CCAGATCTTG
27351 CTGCCGGGAT ACTAGTCAGG TGGCCAGGCC CTGGGCAGAA AAGCAGTGTA
27401 CCATGTGGTT TTGTGGAATG ACCGGACCCT GGTAGATTGC TGGGAAGTGT
27451 CTGGACAGGG GGAAGGGGGA AGGGAACTGG TCCTCAATGC TGACTCTACC
```

FIG.3-11

```
27501 AAGCGCCCTG CTAGACACTT TATCCTTTAA TCTCTCAACA GCCTAAAGAG
27551 ATTATATATC CCCATTTTAC AGATGAGGCA ACCAGTTTCA ACAGAGTTAA
27601 CATATGGAGC CTCACTGGGC AGCTTTTTCT GTCTTCCTGA CTTTCTCTCA
27651 TCCTTCAGGG GGCTGCAGGT TTGTTTTCTT CTCCTAGTGG AGAGGAAATT
27701 CTCAGGTTTG TTTTCCTCTC CTAGCAGAGA GTAAAAAAAG GGATAGTTTG
27751 CCTGACTTGT TGAAGGTGTG GCTGAGATTG TTTTCTAAAG AGCCAATGGA
27801 AATTGATCTT GAGTTTAGGA GAAAGCTTTT ACATGTGGAA TTAAGATGCC
27851 AAGTGTTGAA GTAGCCACAT TTCAGGTCCT CATTAATTTC TCTTAATCCT
27901 GGGAAGGCAG CTTAGGAGAA GGGTTGTTCC TTTAGGAGCC AGGAACTATA
27951 CCCCTTTTAC CCTTGGAGAG GCAGGGAAGC CAGGGAGGAC ACAACTTCTC
28001 AGGAAGAGGA GAAGCTAGAG CAGATAGTGA ACTCTCAACC TGAACCTTTA
28051 AGGGCCAGAC CACTAATGCC ACCCAAGTCC ACCTGCCGTT TGTCTTGTTC
28101 TGTCCCAGGC TTTCTGGAGA ACCTGATCTT CTTGCCCCTA CCCCCAAGCT
28151 CCGTTTGCCC AGCTAGAGTC TGGGGGGTAC TGACTGACTT TCGTAGACAT
28201 TCTTCCCTTC CCCAAATAAG AGGCCACATT CCTGAAGTCA CTTCTGAAGA
28251 GATAGCTGCC ACACAGGGCT CTTTCCCCCC AGGGAGGGAC CACCCAGACC
28301 CTCTGCTCTC CCAGGTATCC GTTACCACAT CACTACCTGG TCAGAAAGCT
28351 GTTTCTGCCA TTAGCCCCTC CCTCTTTTAT TATAGGATAT CCTCAAGGGC
28401 TCCTCTTTGG GCCTCAGTTT CATCCTTGGC AGAAAGTAGA AGCTAGACTT
28451 CTTGGGCTCC TGAACAGGGT CCTTGCTGGA TTCTGTGAAA CAAATTAAGT
28501 TCTTGACCCT AGGCCTCTGG GGGAGTACAA AGTCTATGGG AGTTCTGGGG
28551 CTGTGGTTGC AAGGAAAGTG ACGCAACCAG ATTCCATGGG GACATGATCA
28601 GGCGTGACAT GTGAGGGAGG AAGAGGGAGC AAGGGAATGA AGAATACAAC
28651 TTCTGTGTCC CATACACCCC TGCCTGACAG GCCATACATA CTCAGCAGAG
28701 AATGCACTGT CTTTCCTACC ACACTAGCGT GAGGAGTGAG CTGCAATTAC
28751 CACTGTGCTT CCAAGTAAGA AAATACCTCA AATTGGAATT TACAAAAGAG
28801 GTAAATTAGG GAGTGGCTTT TGTCGGACAT CTTTAAAGCA TTTTTCTTTT
28851 TATAGAATTT CACTTAATGT CCAATACTGA TTTAATGAGC TTGGGTTTAC
28901 ACATTATCTC TTGAAGAAAA CAAATGAACC TTTGTGTTCC AAAGCAATCC
28951 ATGTTTAAAG GGAAAAAATT ATGCATAACT CTGCCCAGCT TCACAGTAAC
29001 CTTTGGCAGG TGCCTTAGGT CCTCTGGGAC TCTTTTCCTT ATCTGAAAAA
29051 TGAAGGACTT GGATCAGGTG AATGGTTCCC AGCTCTGCAA CTTATGTGGC
29101 TCCTCAGAGG CACACAAGCT CTTTTCCATT ATTTGCCAAA TAATGGAGGC
29151 CCTGTCTTTA ACTGCAGTAC AACTACACAA AATACTTGAA ACTACAGTCT
29201 TCCTGGTTTT TGGTTGGAAC TGAATCAGTG CACTCTAGCA ACACTTATTT
29251 CTTGCTGTTC GTAGGCTTCA TTATGTGTTT GGTTAATTTT TTAAAACAAC
29301 AATAACATAT TCCATAATAA TTACAGCTTA ATTGGCAGAC TGTTTCAGTC
29351 TATAGGATCT GCAGGAAGGA GGAGTAATAA AGGGATTTTT GACTGAGCTC
29401 TTATGGAACA GAGTCTCTCT AGGCCCCTGT CATATCTGCC CTTCTGGGCC
29451 CTGGGGAAAA GTTGGCATCC CCAGTTGTGG TGCTCTCCAG GTGCCCTCAG
29501 GCTGTGGTGG AGGGAGCTTC CCATTCTCTC CTTCAGCCCA CTCAATTCAG
29551 AGGCTAGGGG CTGAAAGAAG CTTCTCTACA ACTGGCTGTT CACTGGGAGG
29601 TTAAGGGATG ACCATCCAGC CAGGCCTTCC TCAGGACATG GGAGGGCTTA
29651 TGCTTTAACA TGTGTAAATC CACTGCAATA ATGACTGGTT CTTTTACCCC
29701 ATAAGGTTGA GAATTTACCT GTAAACATTT TTGTCTGAAG AATTTGGATG
29751 TAAGTGAGGG CTGGGCCTCT ATCTTATCTC ACTTGGCTTC TCTCAGCACA
29801 GCACCTTGCC TGCTTGTTCT TACACATCCT AGATGCACAG TAACTATTTC
29851 CTAATTATTA GAAATCTATT AGAATCAATT GATTTCAGCT GGGCTTGGTG
29901 GCTCCTTCCT GTAATCCCAG CACTTTGGGA GGCTAAGGCT GGAGGATCAC
29951 CTGAGTCCAG GAGTTTAAGA CCAGCCTGGG CAACATAGGG AGACCCTGTC
```

FIG.3-12

```
30001 TCTACAAAAA ATAAAAAATT AGCCAGGCAT GGTGGTGTGC ACCTGTAGTC
30051 CCAGCTACTC AGGAGGCTGA GGCAGGAGGA TCTCTTGAGC CTGGGAGGTC
30101 AGACTACAGT GAGCAATGAT TGTGCCACTG CACTCCAGCC TGGGTGACAG
30151 AGTAAGACTC TGTCTCTTAA AAAAAAAAAA AAAAAAGTTG ATTTCTATTT
30201 GGATAGATAA ATAATTCATT TTAGGACCTT TCTTTTTCAC TTACAGAAAT
30251 CTGTTTCATT CTGGGCTGAG AAGCAGGTCC ATATTGCTAG GCATAGGAGA
30301 AAAAGGGGTC TGTCTGCATT TGCCCTTGGT GGTCTCAAAT TGGGGAGGGA
30351 AAGAAATGAA CACTTACTGG CTACCTTCTG TGAGCCAGGC ATCATGCAAG
30401 ACATCTGTAC ATAATTTAAT TCTCATAACC CCATAAGATA TTATTAGCAA
30451 TGTACAAGTG AGGAAACTGA GGCTCAGAGT CATGAAGTAA CTGGCCTTGG
30501 GTGACACAGA TGGTAAATGG CAGAGAAGGA ATATGGATCC AGGTCTTGAA
30551 AGAGAAAATC TCAACTGATT ATCTTTTTTA AAAAACTCAT ATGTTCTCTG
30601 CTGACTCAAA AGGTCTCTGT GTGGATCTGG GTTGACCCAC TGAACTGACC
30651 ATCAGGGTTC CATGCACTTT GTATCTGCCC AAGCCCTCAG AACCCCTCAG
30701 TAATGTTTTG GAAGATGAGT TTTGGAGGTT GTCCTTAGGC ATAGCCTCAG
30751 CGTATGTAGG CCTCTAGGTG ATCTCCCCTA ACCTGAGGAT TTCAGCTCAA
30801 TTCACTCTGG CTCCTCAGGA CAGTGGGATG ACTGGTTCAG ACCTCAGCTT
30851 TACCACCTCC CAGCTGGGTA CTCTTCTACC TACAGCCAGG GCAGATTTTG
30901 ACTTTCACTT GAAACTTCCA AAAATTGAAA GGTAGAAAAA CAGCCTTGGC
30951 TTTGGGAAGA ACGTATGATG TCCATGGCCT CTAAGCATCT GAGGTGGGAC
31001 ATGTTCGAGT AGCACCTTAC AGTTCCAAAG TGTGTTCTGG GTTCTTTGTT
31051 TAAAAGAACA GAGACTGCTG GGGAATTGAA CACTGTGAAG TATATGAAGG
31101 AGGAGAATTG TGCTATTTAA CATTCAGTAC TTGGGCTAAA GGAGAAGCAT
31151 CACGAAGTGT TAACACTCAA AGGGTCTTGA GCTGTCAGGG CTCCAGCTTC
31201 CTTATTTTCA CAGGTGAGAA TCCTGAGGCT CAGCTGTTGA GATGTGCTGT
31251 CTCACTCCGG TGACATAGTA CAGTGGATGT GGCTTTGCAG CCAAGCACAC
31301 ATAGCTTCAC ATTCCAGCTC CATCAATTAT GTATTGGGCA GCTTTGCAGA
31351 ATGATTTGAC TTTAACTCTG CTTTTCAGTC TTCTGTAAAA CAGGGATAAT
31401 CCTGCTACCG TAGGGTTGTC AGGATTAGAG ATAATATAAA TAAGGTACCT
31451 CATATAGGAC CTGGATTATG GCTGGCATTC AATAAATAGT AGCTGTTAAT
31501 TGATAGCTAA GCTAGAACTC TGAAGTCTAC CATGGCAACT TCTTAAGTGG
31551 TCTGAGAACC CAGTTGTGTT CTGTGGCAAA ACACAGCTTA GGGATCCATA
31601 CCCAGCCCTC CTGTCAGCTG TTCACCTTCC AGTTCTTCAG AGACATGTGT
31651 GGCAGTGACT TTGGCCACAT AGCTGGCTGT GCCCTTTAAA GGCATTCCTT
31701 GACACAGATA TGTGGACTGG TGACGTTGCT CTCCAGCCAG GTGTTCTTCC
31751 CAGCAGGCTG GCCTGGCTGT CTCCTGCATG CCTGTACTTG TTTGTCTCCC
31801 TGCTCCCTCT CCTGGGCCTG GCCAGAGCTA CTTGCAGCAA ACAAAAGCAG
31851 GATATTGGCA ATGGAAAGGA GGGTGTGTTC TGGTGCTCCC ATGCCCTGCG
31901 GCGCACATAC CATTGCAAGG GCGTAACAGA GCCCAGGCCT GCATTTGGGT
31951 GCAAATAAGT CTGCACACAG AAGAAAAGAA GGACCTGGTG ACCAGGAGCC
32001 ATGGAACCCT TGTGCTCCCC TACCTGGGCT ACTGGTTCTT GCCACTCCTA
32051 CCATTTTCAG TTTGGAAATA TTTGTTAAGG CTTTGCTCTT CCAGGTCCTT
32101 TGCTTGGTGC TGAGTCTACC AAGAGTAAGT GGGATGCTGT TTTTGTCCTC
32151 AGGGAGCTAA CAGTCTAGTG AAGAAGAAAG ATGGTTGCCC AGGAACTTCT
32201 AAGTCAGAAG GCAGGAGGCA AGAAGGAAGC CCCTGCTCCT ACTGCCAGCC
32251 CTCTGTTGGG CACCCCATAG TTCTTCAGAA CCACATTTAA TCCTCACTGC
32301 AGGCCAGGCA TAGTGGCTCA CACCTGTAAT CGCAGCACTT CGGGAGGCCA
32351 AGGCGGGCAG ATCACTTGAG GTCGGGAGTT CGAGACCAGC CTCACCAACA
32401 TGGGGAAACC CCGTCTCTAC TAAAAATAGA AAAATTAGCC GGGTGTGGTG
32451 GCATGCGCCA GTAATCCCAG CTACTCAGGA GGCTGAGGTG GGAAAATCAC
```

FIG.3-13

```
32501 TTGAACTCGG GAAGCAGAGG TTGCAGTGAG CCGAGATTGT GCCACTGCAC
32551 TCCAGCCTGG GCGATAAGAG CAAAATTCCA TCTCAAAAAA AAAAAGAAAA
32601 AAGAAAAAAT CCTCACTGCT ACCTTGAAAG TAGGTGATGA CATTGCCATT
32651 TCACAAATGA GAAGTGAAGG GGCTAGCCCA AGATCACTTA GGTGGTAAAT
32701 GGTGGTGCTA AGATTAGAAC CTCAGATCAT CTAGGGAAAA ACACAGATAT
32751 GCACAGAGTT AAGGGGACCC AGGGTATTGT TTGTCCTCTT GTTTCACAGG
32801 TGGGGAAACA ACCCAGAGAG GGAAAGGGGC TTGTCCAAGG CAATTTAGCA
32851 CCCAAGAACT TGAACCCATA TCTCTCTCCT CCTCATTTAG AGCTCATCCC
32901 ACATGTATCT TATATTGAGA GGAGTGTGAG CCACATACCA AGAACAGTCT
32951 TCCCCTCTGC CTCCAACCTC ACTGTGCAGT TTTGAGACAC TTCACAGCCA
33001 TACTCTTCAT GCCATACCCA GCCCTTAAGA CCCTGAAGTT CCCCTTCCAT
33051 AAGACAAGTA GGAAAAGCTA TAGGGTAAAA ATAGCCATCA GTGTTTGTTG
33101 AGCACCCAGG AGGAATTGGG CACTCCAGAA AGATAAAGGG ATTCTCAGGG
33151 ACTTGCTTCT CTAGACTTCC CTAGCTCAGC TGCTTCAACT CATTCCTGCC
33201 CCTCTTCTCT ACCTCCCGCA GTGCTCAGAA GTAGTAGAAC TCACTGTGGC
33251 CTCTCACCTT GCATTGTTGA GTTTTATTTA GACTTTCTCT TCCTCAACTC
33301 TTCATAAGCT CATGAAAGGT GAAGTAGGGT GCCCTGTGTA TTTATCTTTT
33351 ATATCTGCAG TGCTTAGCAA GTTATAATAA TGCACTTGCC TGGCAAAAGG
33401 CTTTCTCTCA TACATTAGCT TATTTCCTCT TCACATTGGC TCTTTGTAGT
33451 AATAGGATGC TATTAGTTAT TTTCAATGAG AGAAAGCTAC TAAGAGAAGT
33501 TGTCCAGCTA GTGACAGTAA GTGGCTGATA AAGTGAGCTG CCATTACATT
33551 GTCATCATCT TTAATAGAAG TTAACACATA CTGAGTTTCT ACTATATTGG
33601 GTCTTTTTTT TTTTTTTTTT TTTTTTTTTA GAGACGGAAT CTTGCTCTGT
33651 TGTCCAGGCT GGAACGCAGT GGTGCAATTT TGGGTCACCA CAACCTCCGC
33701 TTCCCAGGTT CAAGCGATTC TCCTGCCTCA GCCTCCTGAG TAGCTGGGAC
33751 TACCAGTGCA CGCCACCACG CCCGGCTAAT TTTTGTATTT TTAGTAGAGA
33801 CAGGGTTTCA CCATGTTGGC CAGGCTGGTC TTGAACTCCT GACCTTGTGA
33851 TCTGCCCGCC TCAGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGCCACC
33901 GCGCCCTGCC TATATTAGGA CTTTTATATA AGCTATCTCT AGCTAGCTAG
33951 CTAGCTAGCT ATAATGTTTT TTGAGACAGA GTCTGACTCT GTCACCCAGG
34001 CTGGAGTGCA GTGGCGTGAT CTCGACTCAC TGCAACCTCC ACCTCCTGGG
34051 TTCCAGTGAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG ATTATAGGTG
34101 CATGCCACCA CGCCCAGCTA ATTTTTTGTA TTTTTAGTAG ACCAGGTTTC
34151 ACCATGTTGG CCAGGCTGGT CTCGAACTCC TGACTTCAAG TGATCCACCC
34201 GCCTCGGCCT CCCAAAGTGC TGGGATTATA AGCATAAGCC ACTGTGCCCA
34251 GCTGCTCTCT ATATTTTTAA TACATATTAT TTCCATTAAT TTTCACAGCA
34301 GTTCATTTTA TAGATGAGGA AACTAGGCCA GAGAAGTAAA ATATCTTGCC
34351 CAAGATGATG TAACTAGTAA GTGGCAGGAT CAAGATTCAA ACCAAGCAAT
34401 GTTCAAACCT CTTGGAAGCA AGAATGTGGC CACTGTGGAA GGTGCAAGGC
34451 CTTGACAACA AGAATAGGGA AAAGAAGGAA CTAGAAGGAA AGAGATGGCA
34501 TGGGCTCAGC AGGCCAGGGA GCTCTTAGCT GTGTGTGTTG GGAAGCTCAG
34551 AAGGGAGGAA GAGGTTGTCT GTGCAGGTAA GTCCTGAGAA CACACCAGAC
34601 TTTTGAGAGG TGGAGCTTCA TAGCCAGGTC ATTAGGGGAG AAGGGAGCTA
34651 TAGATTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTAG AGACGGGGTC
34701 TTACTATGTT GCCCAGGCTG GTCTTGAACT CCTGGGCTCA AGTGATCCTC
34751 CCACCTCAGC CTCCCAAAGT GCTGGGATTA GAGGCATCAG CCACCCCGCC
34801 CAGCGAGCTA TGGATCTAAC ATGTACATCT TACACAGTGC TAATAGAATG
34851 TTGGGTTTCT TCCCCAATAT TTTATTTTGA AAAAAAATTC AAATATATAG
34901 AAAAGTTGAA AAATGTAGTT CAAAGAACAC CTACATACCT TTCACATAGA
34951 TTCATGATTT GTTAATGTTA TGCCACTTTG TATATATCTC TCTCCCTCCT
```

<div align="center">

FIG.3-14

</div>

```
35001 ATCTGTATAC TTTTATTTAT TTATTTTTGC TGAACTATTT CAGAGTAACT
35051 TAAAGGCATC TTGATTTTAC CCTTGAACAG TTCAATATGT TTCTGCTAAG
35101 AATTCTCCTA TATAAGTCAG ATATCATTAC ATCTAAGAAA ATTCACGGCA
35151 ATTTTACAAT ATAATATTAT AGTCCAAATC CATATTTCCT CAGTTGTTCC
35201 AAAAAATGTT CATGGCTGTT TCCTTTTTTA ATCTAAATTT GAATCCAAGT
35251 TTGAGGCATT GTATTTGGTT GCTGTGTCTC TAGGGTTTTT AAAATCTGTG
35301 CCTTTTCTTC TCCCCATGAC TTTTTAGAAG AGTCAAGACC GGTTATTCTT
35351 ATAGAATAAC CCACATTCTA GATTTGCCTG ATTAGTTTTT TTATACTTAA
35401 CGTATTTTTG GCAAGAACAT TACATTGGTA ACGCTGTTGG TGATGGGTCA
35451 GTTTTGAAGA GTGGAGATGA TTAAACTGCT TTTGTTCATT GAAGTATCTG
35501 TCAAGACCAG AGATCCTTAA CTGGTGCCAT AAATAGGTTT CAGAGAATCC
35551 TTTATATATA CACCCTGTCC CCCACCTAAA TTATATACAC ATCTTCTTTA
35601 TATATTCATT TTTCTAGGGG AGGCTTCTTG GCTTTTATCA AATTCTCAGA
35651 GGGCCCCAAG ACCCAAAGAG GTTATGAAAC ACTAGTCTGT CCACTGAGGC
35701 AGGCAACACA GAGCTGGTTT CTGGGGCCTT GTTCAGTCTG AACCAGCTTC
35751 CCTTGGGGAG ATAGCACAAG GCTGTAACTT TGCCCCATCT TGGCTTTGGA
35801 TCAAAGAGGA CTGTCCATTT TGTTGTCATA CCTAGGAACC AGGGACAGCT
35851 TATGTGGCCT GGTTCCAGGG ATCCAGGAGA ATTTCAGTTC TTGTCTTGCC
35901 TTTCAGGTGT TCAGAATGCC AGGATTCCCT CACCAACTGG TACTATGAGA
35951 AGGATGGGAA GCTCTACTGC CCCAAGGACT ACTGGGGGAA GTTTGGGGAG
36001 TTCTGTCATG GGTGCTCCCT GCTGATGACA GGGCCTTTTA TGGTGAGTGA
36051 ATCCCTTCAT ATCTGCCCCT CTTGGTCTTC AGAGTCCATT GACAGTGCTT
36101 CCAGTTCCCT GTGGCCTGTT AATCTTTTAG TCTTTCCATC AGCCAGGGCA
36151 TCTCCCTTTA TTTATTCATT CATTCAACTA GCAGGTATCA ATTGAGCACC
36201 TACTAAGTGA AAGGTAAGAT CCTTCCCTCA AAGACTTAAT AGTTGAACGT
36251 TGGGAGTGGG AGGAGAGGCA GGCAGAGAGG AGACACAATA TAGTTGGATA
36301 AGGACCTCCA AGGAGAGTGT TACAGGCTGA GAGGAGGATA TACTTAGGTT
36351 GTCTTTAGGG AATCAGAAAA GGAGACTCTG GAATAGGCTG GCAGAGAGAG
36401 GGGCTACCTC CTATACCTGC TCTGGACAAA CGACTTTAAG CATAGTGACA
36451 GATTTGCCAA CCCTGTATTG GAAGAACTGA TCTTTTTTAG TGGGGATGAT
36501 TACTTCTGGG GATTTCTTCT CATAACTGAG ACCAAAACAG TTTTGTGCAG
36551 TCTCAGAAAT GACAGGAGGT ACCAATCTGA CACTTCCTTT GGAAGCTCTA
36601 GGGCAGAGAG TGAAAGAGTG GATTTTGACG GGGGCCTTGC TTGGAGGTCA
36651 TTCACCCACC CCTGTCCTCA CTCCAGCAAC AGTGATAACT CACTTCCTTC
36701 CTCCCTTTGT ACACCCTTCT CCCCACCTGC TCACAGGTGG CTGGGGAGTT
36751 CAAGTACCAC CCAGAGTGCT TTGCCTGTAT GAGCTGCAAG GTGATCATTG
36801 AGGATGGGGA TGCATATGCA CTGGTGCAGC ATGCCACCCT CTACTGGTAA
36851 GATAGTGGTC CTTTGTCTAT CCTCTCCCAT ATAAGAGTGG CTGGCGGGGA
36901 GGGACAGTGG CAGGGTGAGT TGGGCAGAAG GAGTGTTAGG GTAGTCAGAG
36951 CATTGGATTC TTACCACAGC AGTGCTCTTA ACCAGCTCTT TAACTTGTAA
37001 GCAGAATGAT TTACACATGT CTCTACCCTT TTTCCTTACC AACCTTGAAA
37051 ATGTCTTCAC TCTGCCCTGC AATCCTCCCA GTGGGAGGCA CTCTTCAAGG
37101 ACGATCCCAG AACATTAAAG TCAAAGACCC CTTAGAGCTC ACCCTGTCCA
37151 ACCACCTTGG TTGATAAAAG AAGTCAGCCT GGGGCCCATG GAATAGAATA
37201 GTACAAGGGC AAGGTTCTCA TTGTGAGTCA AAGGTAGAGT GAAGAGAACC
37251 CAGACCATCT CACCCCAACC CAGGCCAGTG TTTTTCCAAA TATACCACTT
37301 GCTGCAGATC TAGCTCAGCA CCCCCAGTCC CAGCCCACCC TGAGAACCCA
37351 GGCTCCTCAT TCTGAGCAGC CAGCTAGAAT CATGACAAAG AGGGTGGTAG
37401 TGAGACTATG GGTACTGTTG CTTAAAGCCA CATGGTGCAG TGGTTGCTGG
37451 GGGGCTTCTG TGTGGGACTC TAGCATCTTA TTCCCCCCTG TGCCCTCTCC
```

FIG.3-15

```
37501 CCAGTGGGAA GTGCCACAAT GAGGTGGTGC TGGCACCCAT GTTTGAGAGA
37551 CTCTCCACAG AGTCTGTTCA GGAGCAGCTG CCCTACTCTG TCACGCTCAT
37601 CTCCATGCCG GCCACCACTG AAGGCAGGCG GGGCTTCTCC GTGTCCGTGG
37651 AGAGTGCCTG CTCCAACTAC GCCACCACTG TGCAAGTGAA AGAGTAAGTA
37701 TTTTGAGAAC CCTTCAGCAG GGGTTCTTGA GCAGAGTCTG TAAATGGGCC
37751 TCAGAGGGCT TAGACCTCCA AAGTCTCATG CAGAACTCCC TTTATTCTCA
37801 TCTCATATCT TTCTCCTGGA CCCCACTATG CTGTAACCGT ACCTGGGCCT
37851 TGGCACTTAC TGTTCTCTCT GCCCAGGCTA CTTCCTACCC GATACTTAAG
37901 GCAAGAATCA CTCACCTTTC AGGTGTCAGG TTTCAGGTCA TGTTTGCTCT
37951 TTGAAATCAT CTGGCTTGAT TATGTGTATT AGTTGTTTAT CTTCTATCCC
38001 CTCCACTAGA ATGTAAATTC CAGAAGAAAC TTGCTGTCTT ATTCAGTGCT
38051 GCATGCCCAG GGCTTGGAAG AGTACCTGGC ATATAGTAGG AGTTGATTGA
38101 TTATTATTTT GTCAGTCGAG AGAATGAATG GAGAAAATGT GGTCCATGGC
38151 CCAAAAGAAG TTAAGACCCT ATCCTAGATT CAGGCCAGAG ACCAGATGGA
38201 GAAAGAGTCT GTGTCTATCT AATACCAGTA ATGTCGTACC TCTGGCCGCT
38251 TACCATGTAA ATATTGATTG TGTATCTACC ATGTGTTGGA CACTAGGCTA
38301 GTGCTTGCAC AGCAGGTGAA AGATACTAGA GTTTGGGAAG TCAGGAGGAG
38351 CTAAGGTCTG TTCTACAACC TTATTAGATG AAGAGGAGAG GGAATTGTGT
38401 TCAGGGCAGA GGGAGAAGCA TTTCTCCAAA AGTAGGAGTC TTAATCATGT
38451 CTGATGTAGG TTGAGTGTGG CCAGAAAAGG GGCTGTTAAG TATAGAGGGC
38501 CTGGATTATG AAAATCCAGC AGATCCATTG AGAGTTTAAG CAGCAAGGTG
38551 TTGTGACCAA GTTAACATTT TAGAAGGATC ACTGGTATGG AGGTTGGATT
38601 GGAGAGGGGA AAGCCTAAAG GTATAGAGAC TAGTTAGGAA GCTATTGTAG
38651 GCTGGGCATG GTGGTTCATG CCTGTAATCT CAGCACTTTG GGAGGCTGAG
38701 GTGGGAGGAT TGCTTGAGGC CAGGAGTTGA AGACCAACCT GGCCAACATA
38751 GCAAGACCCC GTCTCTGTTT TTCTTAATTA AAAGAAAAGT CCAGACGTAG
38801 ACATAGTGGC TCACGCCTGT AATGCCAGCA CTTTGGGAGG CCAAGGTGGG
38851 CAGATTGCTT GAGGTCAAGA GTTTGGGATT AGGCCAGGCG CAGTGGCTCA
38901 CGCCTGTAAT CCCAGCACTT TGGGAGGCCG AGGTGGGCGG ATCACAAGGT
38951 CAGGAGATCA AGACCATCCT GGCTAACACA ATGAAACCCC GTCTCTACTA
39001 AAAGTACAAA AATTAGCCGG GCATGGTGGC GGACGCCTGT AGTCCCAGCT
39051 ACTCGGGAGG CTGAGGCAGG AGAATGGCGT GAACCTAGGA GGCGGAGCTT
39101 GCTGTGAGCA GAGATCACGC CACTGCACTC CAGCCTGAGC GACAGAGCGA
39151 GACTCCATCT CAAAAAAAAA AAAGAGTTTG GGATTAGCCT GGCCAACATG
39201 GCAAAACCCC ATCTCTACAA AAAGTACAAA AAAATTAGCT GGGTATGGTG
39251 GTGCGCGCCT GTAATCCCAG TTACTCAGGA GGCTGAGGCA TGAGAATTGC
39301 TTGAGCCTGG GAGGTGGAGG TTGCAGTGAG CCCAGATCAT GCCACTGCAC
39351 TCCAGCCTGG ATGACAGAGT AAGATGCCAT CTCAAATAAA AATTAAAAAC
39401 AAAGTTTAAA AAAAAAATAG AAGCTATTAC CGTGATCCAG GTAAGAGATG
39451 TGAATAACTA CAATGATGGA AGAAGGCAG AGTTCTTAGA GATGGGAGTA
39501 GGAGAGATGA GGGAACTCCA GATTGGGAAG ATGATGTTCA AGTTTCTGGC
39551 TTAGGCCACA GGGTGAGTGG CAATTCCCTT CACTGAGATG GGGCATCCTG
39601 GAAAAGGTGT TGCCTTTCTG TGTGGGTATC CTGGGCCCCT TAGGGGCCAC
39651 TGGTGGCCTG GGACCTGGTA AACCTTCCCT GCACAAGCAG AATTGGTCAA
39701 GCAGGTTTTT AGGACATCTT TACCCTGCCT CAACTCTTGT CTGGCCCAGG
39751 GTCAACCGGA TGCACATCAG TCCCAACAAT CGAAACGCCA TCCACCCTGG
39801 GGACCGCATC CTGGAGATCA ATGGGACCCC CGTCCGCACA CTTCGAGTGG
39851 AGGAGGTAGA GTGTGTGTCT AATCTGTCTT GTGAGGGTGG GACATGGAAC
39901 AGATCCTCTG GGAAATCAGG CTGTAGCCTT TACCTTTTCC TACCCCCAGC
39951 CCATCTCTTT GTCTTAGCAT TGAGCCTGTG ACCACTGGTG ACCTATTTCA
```

FIG.3-16

```
40001 GCGTAACAGG TTCCCAGGGT AGCAGGGATG GTTGATGGAC GGGAGAGCTG
40051 ACAGGATGCC AGGCAGAGGG CACTGTGAGG CCACTGGCAG CTAAAGGCCA
40101 CCATTAGACA AGTTGAGCAC TGGCCACACT GTGCCTGAGT CATCTGGGTT
40151 GGCCATGGGT GGCCTGGGAT GGGGCAGCCT GTGGGAGCTT TATACTGCTC
40201 TTGGCCACAG GTGGAGGATG CAATTAGCCA GACGAGCCAG ACACTTCAGC
40251 TGTTGATTGA ACATGACCCC GTCTCCCAAC GCCTGGACCA GCTGCGGCTG
40301 GAGGCCCGGC TCGCTCCTCA CATGCAGAAT GCCGGACACC CCCACGCCCT
40351 CAGCACCCTG GACACCAAGG AGAATCTGGA GGGGACACTG AGGAGACGTT
40401 CCCTAAGGTG CCACCTCCCA CCCTGGCTCT GTTCTGTCCT ATGTCTGTCT
40451 CTCGGATGAA GCTGAGCTGG CTTTCAGAAG CCTGCAGAGT TAGGAAAGGA
40501 ACCAGCTGGC CAGGGACAGA CTATGAGGAT TGTGCTGACC CAGCTGCCCC
40551 TGTGGGGATC ACAGTTTACA GCCAGAGCCT GTGCGGACCC AGCTGTCTGC
40601 CAGGTTTCCT TAGAAACCTG AGAGTCAGTC TCTGTCCACT GAACTCCTAA
40651 GCTGGACAGG AGGCAGTGAT GCTAAACCCT GAAGGGCAAC ATGGCCTATG
40701 GAGAAAGCAT GGAGCTCAGA GCCTGGAGTA CGGGCACAGA TAGGATTGAA
40751 TAAATTGTGT AGAAAGACTT TGAAAACAAT AAAGCAAAAG ATGAATGAAC
40801 GTTTTTTTTA GACTTGAGGG ACCAACAACC CCCAAACCCC AGATTCTGCC
40851 AGGTCCATGG GGAAGGAGAA GTTGCCTTGA GTGGAAGCCC CAAGTAGGGA
40901 GACTTACAGA AAAGAAGTCA AGAGCACTGG CTCCCAGGCA GAAATACTGA
40951 TACCCTACTG GGGCTTCAGG CTGAGCTCCT CCCTTCACAA ATCACTTCAT
41001 CTCTCTGAGC CTGTTTCTGC ATCTGTGACA TAAGATGGTA AGATAAAGGT
41051 GGCTGTCTCA CCAATTATGT AAGGATTAAA TGTGGAAAAG GACATAAAGT
41101 TGTATAGTGC TGCCATAGGG ACAGTGTTCA GTAAACGTGA CACATTCTTA
41151 GTATCACTAA GAATCAGGTT CTTGGCCAGG CACCGTGGCT CATGCCTGTA
41201 ATCCCAACAC TCTGGGAGGC CTAGGTCGGA GGATGGCTTG AACACAGGAG
41251 TTTGAGACCA GCCTGAGCAA CATAGTGAGA CACTGTCTCT ACAAAAAAAA
41301 AATAATAATA ATAATTGTTT TTAATTAGAT GGGCAGGGCA CTGTGGCTCA
41351 CACCTGTAAT CCCAGCACTT TGGGAGGCCA AGGCCGGAGG ATTGCTTGAG
41401 GCCAGGAGTT CAGGAGCAGC CTGGGCCACA TTCCTGTCTC TACAAAGAAT
41451 AAAAAAGTTA ACTGGGCATG GTGGCACATG CCTGTAATCC CAGCTACTCA
41501 AGAGGCTGAG GAGGAGGATT GCCTGAGCCC AGGAGTTCAA GACTGCAGTG
41551 AGCCTTGATC ACACCACTGT ACTACAGCTT GGGCAACAGA GTGAGACCTT
41601 GTCTCCAAAA AAAAAAGTTT GTTTTTTTTT ATCCACTCTC CTCACCAAAC
41651 AAACTGAGTA AGTTAGAGCC CTCTCAGCTG GCATGTGTTG GAAACAGTGC
41701 CCTCTCATTA AAGTGCTGCC CTCACTCCCA TTGCCTCTTG GCCTTGGTCA
41751 GTATGATGAA ATTAGTGGGA GGCAGGGCAA CAGAGGGCAG GGAAGAGCTA
41801 GAAATCCATG GCCTGGAAAA GGGAAGATTT GGGAGTGGCC AGGTATCTGT
41851 AGAGCCACCA TGCAGAGGAG GGGGGCAGCT AGCCTTGTGT GCTCTGGTGG
41901 GCATGGTCAG CAGGAGGCAG AGCAAAAGGA CAAGGGTAAG TAAACCTGTA
41951 GGTCGGGACA AGCCAAGAGC CATCCAGCGT CAGTCCTCTC TGGGTAGCCC
42001 AAGTAAAGCA GGAGCATACC CCAGAGAGAA AGTTCGCAGG GCTGTTCACC
42051 TGCAGTGCTG TGGACTTCAA CCTTCTTGTT CCTTCTTCAG TAAGTGAAAA
42101 TAACAGTCAT TGACCATGAC TATTATCGAC CGCTTTTGAA AATGTAAACA
42151 TAGTGACTTT ATTGCTGTAA AAATCATACG TGTTTATCAT CTTAAAATTC
42201 AGGAAACATG GACAGGTACA AAGATGTGCA AAATATCATC CAAAATCCCA
42251 TTTGCTGGCC AGGCACGGTG GCTCACGCCT GTAATCCCAG CACATTGGGA
42301 GGCCGAGGCG GGCAAATCAC TTGAGGTCAG GAGTTTGAGA CCAGCCTGGC
42351 CAACATGGTG AAACCCTATC TCTACTAAAA ATACAATAAT TAGGCTGGGC
42401 GCAGTGGCTC ACGCCTATAA TCCCAGCACT TTGGGAGGCC GAGGTGGGCG
42451 AATCACAAGG TCAGGAGTTT GAGACTAGCC TGGCCAATAT GGTGAAACCC
```

FIG.3-17

```
42501 CATCTCTACT AAAAATACAA AAATTAGGGC CGGGTGTGGT GGCTCACGCC
42551 TGTAATCCCA GCACTTAGGG AGGCCGAGAC AGATGGATCG CGAGATCAGG
42601 AGTTCGAGAC CAACCTAGCC AACATGGTGA AACCCCATCT CTACTAAAAA
42651 AATACAAAAA TTATTCGGTT GTGGTGGCAC ACGCCTGTAA TCCCAGCTAC
42701 TTGGGAGGCT GAGGCAGGAG AATCTCTTGA ACCTGGGAGG CAGAGGTTGC
42751 AGTGAGTGGA GATCCCGCCG TTGCACTCCA GCCTGGGCGA CAGAGTGAGA
42801 CTCCATCAAA AAAAAAAAAA AAAAAAAAAA AAATTAGCCG GGCGTGGTGG
42851 CGTGCACCTA TACTCCCAGC TACTTGGGAG GCTGAGGCAG GAGAATCGCT
42901 TGAACCTGGA AGGCGGAGGT CGCAGTGAGC CGAGATCGTG CCATTGCACT
42951 TCAGCCTGGG CGACAGAGCG AGACTCTGTC TCAAAAATAA TAATAATAAC
43001 AATAACTAGC CGGGCCTGGT GGCACATGCC TGTAGTCCCA GTTACTCAGG
43051 AGGCGGAGGC ATGAGACTCA GGTGAACTAG GGAGACAGAG GTTGCAGTGA
43101 GCCAAGATCA CACCACTGCA CTCCAGCCTG GTTGACAGAG CGAGACTCTG
43151 TCTCAAAAAA AAAAAAATCC CATTTGCTCA TTTTTTGGAT ACTAGTATAA
43201 CTATCACTCT AAACCAGTTA GTACTTAAAT CAAGCAGATA TGGGAGATGG
43251 TGAATTACCA TCTACAGTGT TGTCATATAT GTCACATACT GAGCATTATC
43301 AGCTAGTAGA ATCTAGTTAA TTGTTCTATG TGTGATGTAT GCAGAGTTCC
43351 CATTTTGAAT GTGTTTTTAC TATGCTTAAA TAAATGACTG ATGTCAGCAA
43401 CCCCAAAATG ATACATCTGA TGTAAGAGCC CCTGTTCCCC AATAATAACA
43451 TCTAAACTAT AGACATTGGA ATGAACAGGT GCCCCTAAGT TTCCTCCCTC
43501 CAGGGTTTCT TGGCCGGTCT CTGAGGACTA CACATCCCTA CTCCCGTCTT
43551 TCCTCATCTT CAGGCGCAGT AACAGTATCT CCAAGTCCCC TGGCCCCAGC
43601 TCCCCAAAGG AGCCCCTGCT GTTCAGCCGT GACATCAGCC GCTCAGAATC
43651 CCTTCGTTGT TCCAGCAGCT ATTCACAGCA GATCTTCCGG CCCTGTGACC
43701 TAATCCATGG GGAGGTCCTG GGGAAGGGCT TCTTTGGGCA GGCTATCAAG
43751 GTGAGCGCAG GCAACAATTG CTTTGCTCTT CTGCCCCCAG TCCCTCTGTC
43801 ACTGTCTTTC GGGGATTTCT CATCACTTGG CCCCACCCCA CACCATGCAG
43851 GATGCCAGGC CTCCTTCCTG GCTTTGGGTG TTGGTGTGAG AGGTATCCTT
43901 CACCCCCACC CAGGCCACCT AAGGTCAATG TTGCTGTTAC AGTGAGCTTG
43951 TGGACCTGGA GATCCAGGTT GGGTTGAGCT GTGCCTGTGG CCCTCCTGCC
44001 TCCAGTCAGT GGGTGTTTGT TAGGTGCCTG CAGACCTCAG TACCGGGCAT
44051 GCTACAAGGA GCACACAGGG GAATGGCTCC TGCCTCCCTG GTGAACAGTC
44101 TCAGGGACTA ACCTCTCTCT TTCTCTCCTC CTCCTCCTCT TCTGCTGAGA
44151 ACTGGGAGGG GGGGTCAGGT AAGACGTGTG TCTCAGCTTG GGGGCAGCAG
44201 GGCTGGAGAG CTCACCCCCG ATCCACCCAG CTCCCTGGTG CATGTCTTTG
44251 GCACTGACCT TCCTGCCCCC AGACTTCTGT TCACTCAGGA GACTCACTTC
44301 TATGCCAAAT GACCAGAGCC CCTGCTTGGC TTGGCAGCAT CCCCTCCTGC
44351 CTTCTTCCCC ACTTCCCTTT TCTGGGTTCT TGCCTGTCCT CTGTGCATGC
44401 CCAGCTCTCC AGGAAAGAGG GTTTGCTTCC GTGTGAGTCC CATGTTGCTC
44451 CACGCTGCAT CTTCCACACA TGAACTCTGT CATTCTGACC CGGCTCAGTG
44501 TGCCCTCCAA GGGATGGGAT GGCCAGCTGC ATAGATTTTC TCAAACAGTT
44551 CTCCAGAACT TCCTCTGGTC TCAGCACCAT TAACAGTCAC CCTCCCTGTA
44601 GGTGACACAC AAAGCCACGG GCAAAGTGAT GGTCATGAAA GAGTTAATTC
44651 GATGTGATGA GGAGACCCAG AAAACTTTTC TGACTGAGGT AAGAAGATGG
44701 AGGGGGCCCG GGAGGTTGGT GTCACCATTG GAAGAGAGAA GACCTTACAA
44751 ATAATGGCTT CAAGAGAAAA TACAGTTTGG AATTACTGTC TTAAAGACTA
44801 AGCAGAAAAG AGCCCTAGAG GAATATCCCA CTCCCTCTAA ATTACAGCGT
44851 AATTATTTGT TCAATGAACA CTTACTAAAA GCAACACAAA CAGGGTACAA
44901 GGGATGCAGT AACAAAAGAT ACAGGGTTCA GAAGAGCTCT CAGGTTATGA
44951 GGATGATGGA CATGAAAACA CTCCAATTTA GTACAACTCA ATGTTATAAT
```

<div align="center">

FIG.3-18

</div>

```
45001 CCTCACCTGA ACGCCCTGCT AAGGGAGCCT GGAGGGGAGC TCCCTGAGCA
45051 CTCACACTCC TTGGGCATTT ACAGTTTTCA CTACCCCTCC CAAGTTACTT
45101 CATGGAGTAA CTTAAGTTGG GGACACCTGT GGTCTGGGTA TTGCCCTCCA
45151 AGCCACTTGG CCACTCCCAC CCCAGTTCTC CCAATGCAGT TCCAAGGGTA
45201 AGGCCTATGA AGCCATCTCC ATCTATATGG TGGTGGTCTT CCCTCATCCT
45251 GATCTTAGTG CCCTGTCATA TCACAAGATA GGAGGTAGGA GATACAGGTG
45301 GTAACACTTG TCAAGCTGAT TCCTTGGAGG GAAGAGGTAA GGAAGACAGT
45351 GAGAAGTTAA CCACCAGCTT TCCTTGGCTT CCCCCACCCC CAGGTGAAAG
45401 TGATGCGCAG CCTGGACCAC CCCAATGTGC TCAAGTTCAT TGGTGTGCTG
45451 TACAAGGATA AGAAGCTGAA CCTGCTGACA GAGTACATTG AGGGGGGCAC
45501 ACTGAAGGAC TTTCTGCGCA GTATGGTGAG CACACCACCC CATAGTCTCC
45551 AGGAGCCTTG GTGGGTTGTC AGACACCTAT GCTATCACTA CCCTAGGAGC
45601 TTAAAGGGCA GAGGGGCCCT GCTTTGCCTC CAAAGGACCA TGCTGGGTGG
45651 GACTGAGCAT ACATAGGGAG GCTTCACTGG GAGACCACAT TGACCCATGG
45701 GGCCTGGACC ACGAGTGGGA CAGGGCTCAA CAGCCTCTGA AAATCATTCC
45751 CCATTCTGCA GGATCCGTTC CCCTGGCAGC AGAAGGTCAG GTTTGCCAAA
45801 GGAATCGCCT CCGGAATGGT GAGTCCCACC AACAAACCTG CCAGCAGGGC
45851 GAGAGTAGGG AGAGGTGTGA GAATTGTGGG CTTCACTGGA AGGTAGAGAC
45901 CCCTTCCTAT GCAACTTGTG TGGGCTGGGT CAGCAGCTAT TCATTGAGTT
45951 TGTCTGTGTC ACTGAAACTG ACCCCAGCCA ACTGTTCTCA GTTCACAGCC
46001 CTGTTTTCAA AGAATTACAC ATCTCTAAAG GCAAACAGGG CACGGACAAG
46051 GCAAACTGGA GAGGCAAACT GTAGCCTGAG ATGGCCTGGG CTTGCCATCA
46101 CAGGTATTCA GGTGCTGAGG GCCCTTAGAC CAACTAGAGC ACCTCACTGC
46151 CTAGGAAATC AATGAAGGGG AAATGAGTTC TAGCGGAGCC CTGAAGGATC
46201 AGAATTGGAT AAAGTTCTTA TTGGCAGAGA GGCACCAGGA TTGAAGTGAC
46251 AGGAGCAAAG ACCTGGGAGG AAAGAGGAGA AAATCATCTA TTTCACCTGG
46301 AAACAAATGA TTCCAAGCAT AGAAATAATA ACAGCTGACA AGTACTGAGT
46351 GCCCTCTATA TGCTAGGCAC TGGGCTGAGG GATTAACATG CATGTGCATG
46401 TTTATTCCTC ATGACAACCT TGGTTTCCAG ATAAGCTGGA CTGGAAAGGG
46451 ACAGAGCTGG GATCCTGGGC TAATCAGTCT GGTCGCCAAG CCTGAGACTT
46501 TAGCCACTGC CCTTCACATG GGGGTCCATG AAAATAGTAG TAGTCTGGAA
46551 CAGTTTGGGG GTACATCAAG GTCGCTGTGT TTTAAGCTAT GGAGTCTGGA
46601 CTATAGGAGA CAAATGTAAA AGAGTTTTTT GGTTGACTGG CTTTTTGGTT
46651 TTTTTGTTTG TTGTTTGTT TGTTTGTTTG TTTGTTTGTT TTTTCCTGTT
46701 TCTGGGGCTT GAATCAGGAA GGAGGTTTTT TTGTTGTTGT TGTTTTGAGA
46751 AAGGATATTG CTCTGTTGCC CAGACTGGAG TGCAGTGGCA CGATCATGGC
46801 TCACTACAGC TTCGACCTCC TGGGCTCAAG CAATCCTCCT GCCTTAGCCT
46851 CCCAAGTAGC TGGACTACAG GTGTGTACCA CCACACCTAA TTTTTTGAAT
46901 TTTTTTTTCT TTTTTTTTTT TTTTTTTTTT GGTAGAGACA GGTTCTCACT
46951 TTGTTGCCCA GGCCTGAATC TCAAACTCCT GGGCTCAAGC ATTCCTCCTG
47001 CCTCGCCCTC CCAAAGTGTT GGGATTACAG TTGTGAGCCA CCATGCCCGG
47051 CAGGAAAAGA TTTTTAAGCA AGAAAGCTTA AGAGCTGTGG TTTTTCCAAA
47101 ATGAGTCTGG GCTGGCACAG TGGCTCATGC CTGTAATCCC AGCACTTTTT
47151 TGGGAGGCCG AGGTGAGTGG ATCACTTGAG GTCAGGAGTT TGAGACCAGC
47201 CTGGCCAACT GGTGAAACCC CTGTTTCTAC TAAAGAAAAA AATGCAAAAA
47251 TTAGCTGGGC GTGGTGGTGC ACGCCTGTAG TCCCAGCTAC TCAGGAGGCC
47301 GAGGCAGGAG AATAGCTTGA ACCTGGGAGG CAGAAGTTGC AGTGAGCCAA
47351 GATCACACCA CTGCATTCCA GCCTGGGTGA CAGAGTGAGA CTTCATCTCA
47401 AAAAAAAAAA AAAAGAGAGA CTGATATGGT TAGTACATTG GGGTGGAATG
47451 CGGAGGGTCC AGGGAATGGA GCCCTGCATA GGGGGCTAAT GAAACATTTC
```

FIG.3-19

```
47501 AGATTTCTGA ATTAAGGTAG TGGCTGTGGG GACAGGAGCC TGGGAGGCAG
47551 GGTGGAGTCA GAATGGAGAG ACTGGTTGGC AATGAGGGAA CAGGAGGAGG
47601 AGGAGGAGGA GTTACGAGTG GCTTGAGGTG TCACTTACCA GACATTTGGG
47651 GGATGGGGGA TAGCCGTGAT TGTTGAGCAA CTGGTTTGGG AAGAGCTAGC
47701 ATTGATCCCT GCTGTTCTGT GCTAGCAGAA CCTATCAGCA TCTTCTGGGC
47751 AGGAAACTGG CTCCATGAGA CTGGCTTAGG GAGAGGCTGC TAGTCACCTA
47801 ATCTGCAGAG AAGGGGCAGC TGGAGCTGTG GGACAGAAGA GGCATCCATG
47851 TAGCTGGTGG GGGTGTCTCA GCTTGTGAAG AGGAGATGGC TTTGAGCAGG
47901 GCTGACACTG AAAAGGCTGG AAGAAAAAAA CAGACACACA AGAGTCTCAG
47951 GATCAGGTAG CATAGGAAAG TTGTGGACAG TCTTTGAGGA GCACTCCCTC
48001 AGGCAGGCAG GCAGGCAGGT CATGAGCTAT AGCGATTCAG GAAGAGCTCC
48051 CTGGGTGTGT GAGCAGCTCC AGGAGCCTAA GGGATGAAAG TAGTATTGCA
48101 GGGGGCTGGA GAGCAAGGAG TGGCTCCTTC TACATTTGCA AGGGAAGGAG
48151 AAAGGAAGTT GCTCCTGAGA GTGGTAAGAG TCAGTGGTGG AGGCCTGGAG
48201 AGGAGACATA ACAAACAAAT TTGTTGACAA ACATTTTGGT AGGAAGGGGG
48251 AGAGCTTAAA GTTTAGACAG TGGGGAAGGT GGAGTCTTAG AGGAGGTGAA
48301 TGTCTGAAAG ACAGAGCTAG CTGGAGCAAG AAGTCACTTC TCTGTTGCAG
48351 GCAGGAAGGA TCCAAAGTGG CTCAAGCCAG AGATTGGGAG AGTGGGGAGG
48401 AGGGAGCAGC CTGGATCTAA GTAAAATGGG TAGAGGTGGA GGGGGTGCTG
48451 CAACGGCCAG GGTTTTCTGA AGTTGGGGAC ATTAGGAGAG AGCTGTGAGG
48501 GCTTTGGCCA GCCACTGTGC TAGTGATTGG TGAACCAAAG GATGGGCAGG
48551 AGATGGCAGC AGGGAAGCAG AGGAAGTCCA GGCTTCCTGT TGGTATTGGG
48601 ACAAGGGAGA GGCCATAGGA GGCCCTGGCC CTGTTGTCCA GGTTGGGTTC
48651 TGAAGCTGGG TGGGCATGGC CTGGTAGGAG AGCATCTATG GCGCCCAATT
48701 CCAGATTCAG GGTCTAGTTG ATTTGCTGGC CCTGTAGCCT CAGCTCATGC
48751 TTCTGTTCCA GGCCTATTTG CACTCTATGT GCATCATCCA CCGGGATCTG
48801 AACTCGCACA ACTGCCTCAT CAAGTTGGTA TGTCCCACTG CTCTGGGCCT
48851 GGCCTCCAGG GTCCTATCCT TCCTGGCTTC CTTGTCACAA AGGAGGCTGA
48901 CTTGTCCCCT CTGGCTAGAG GGCAGAGGTG TTGCCTAGGA GCTCCTATCT
48951 TTCCCTTCCT GCTTCTTCCA ATGCCCTTCT CTGTCCTCTG GGAGCTCCGA
49001 GACACACACA GACATAATTT CACCTTCTCT CATTAGCAAC CTTTGAAATA
49051 ATTTGATTAG AAGGGACTTC AGAAGTTTGT TGACTATATG TAGAAAACCC
49101 TGTCATTTTA CCTGCTTTTG CCCCATAGTA GTCTTGTAAA ACAGTTCATT
49151 GCTGACCCCA TTTTACAGTG GTGGCACCTG AAGCCTCAGC CTGAGGCCAC
49201 CGAGCTAGTA AATTTACAGG GACCAGTTTG AGACCAGCAT TCCTCCCACT
49251 GCCCCTCAGC TGTGGTGGTT ACAATGTTGT TTGTCTTACT GACTTGCTAT
49301 CTGGCTTCCT GGGTGTCTAC CGGCTGGCCC TGGCTCTGCC CTCTAGACCC
49351 ACACCACGCA ATCTTCATTC CTTTCCCACA TGACTGCCCT GTAGCTATTC
49401 AAAGAGCTTG TCTCCCCCAA GTCTCCCCAT CTACTGCCTC CACCTTGCCT
49451 TTTTCTGTCT TATCCTGGTT CTAGCCACTG CCTGAAATCA TTTTAGGAAT
49501 AAGACAGGAC AGGGAAAAAC AAAAGCAACC CCCTGTCCCA CCTCTGAGTT
49551 CCACTCTCCA AGTCCCTGAG CCTCACCTCC AGGGCTCCAG TGGCTCTGCC
49601 ATGAACCCAC TGTGGGCTGG GAGTCTGCTG TGCACAGATA CCAGACCCTC
49651 AGAAACACAA ATGCCAAGTG TGTCTGTTTT TTTGTTTTGT TTTGTTTTGT
49701 TTTTTAGATG GAGTCTCATT CTGTTTCCCA GGCTGGAGTG CAGTGGTGCA
49751 ATCTTGGCTT ACTGCAGCCT CTACCTCCCG GGTTCTAGTG ATTGTTCTGC
49801 TTCAGCCTCC CAGTAGCTAG GACTACAGGC GTGTGCCACC ACGCCCAGCT
49851 AATTTTTTTT TTTTTTTTTT TGTATTTTTA GTAGAGACAG GGTTTTGCCA
49901 TGTTGGCCAG GCTGGTCTTG AACTCCTGAC CTCAGGTGAT TCACCCGCCT
49951 TGGCCTCCCA AAGTTCTGGG ATTACAGGTG GAAGCCACCG TGCCTGGCCT
```

<div align="center">FIG.3-20</div>

```
50001  GAGTGTGTCT  ATTTGATAGA  GCTTTCTGCT  CTGATTCTCC  CTTGCTATAC
50051  ACCTTTTCTC  CCCTTCTCAG  TGGCTTCTCT  TGCCTATGCT  TCCTCCCCAG
50101  GGCCAGGTTT  GAGAACATCC  CCATGAAGTC  CTGACCTGTC  TTTTATCCTA
50151  CCAGGACAAG  ACTGTGGTGG  TGGCAGACTT  TGGGCTGTCA  CGGCTCATAG
50201  TGGAAGAGAG  GAAAAGGGCC  CCCATGGAGA  AGGCCACCAC  CAAGAAACGC
50251  ACCTTGCGCA  AGAACGACCG  CAAGAAGCGC  TACACGGTGG  TGGGAAACCC
50301  CTACTGGATG  GCCCCTGAGA  TGCTGAACGG  TGAGTCCTGA  AGCCCTGGAG
50351  GGGACACCCG  CAGAGGGAGG  ACAGATGCTG  CCCTTGCATC  AGAGCCCTGG
50401  GAATTCCAGG  GGAGGCCTGT  GAAGCGTAGG  ACCGGATACC  CAGAGCTGAG
50451  GATATTTTTC  CCTTGCCAGG  TGGGGCCTCA  CGATTTAGCT  CCTGAGCTCA
50501  GGGGGCTGGG  AACTGATCAG  TGTCCCATCA  TGGGGGATAA  GGTGAGTTCT
50551  GACTGTGGCA  TTTGTGCCTC  AGGGATCGCT  AAGAGCTCAG  GCTATTGTCC
50601  CAGCTTTAGC  CTTCTCTCTC  CATGGTGAGA  ACTGAAGTGT  GGTGCCCTCT
50651  GGTGGATAAT  GCTCAAACCA  ACCAGAGATG  CTGGTTGGGA  TTCTTGAAAT
50701  CAGGGTTGTG  AGGCCTCAGA  AATGGTCTGA  ATACAATCCA  TTTTGGAGTC
50751  TGAGGCCCAG  AGAAGTTCAG  TGAATTGCCT  AGGAGCATAC  AGCTGCCTAA
50801  TGGCAGAGGC  TAGATGAACC  CTAGTCTGGT  TCTTTTCCAC  TTTAACGTGC
50851  AGTTTCATCC  TAGGCAGTGT  TATGTTATAA  GGGCTCTCCA  AGGCAGTTCA
50901  CCTACGGCTG  AGGAAGGACT  ATTTTCAGGT  GGTGTCTGCG  CAGGACAGCC
50951  TGTGGGGTGT  CCCTACAGAA  CCTGTTCTAG  CCCTAGTTCT  TAGCTGTGGC
51001  TTAGATTGAC  CCTAGACCCA  GTGCAGAGCA  GGTAAGGGAT  GTAAACTTAA
51051  CAGTGTGCTC  TCCTGTGTTC  CCCAAGGAAA  GAGCTATGAT  GAGACGGTGG
51101  ATATCTTCTC  CTTTGGGATC  GTTCTCTGTG  AGGTGAGCTC  TGGCACCAAG
51151  GCCATGCCCG  AGGCAGCAGG  CCTAGCAGCT  CTGCCTTCCC  TCGGAACTGG
51201  GGCATCTCCT  CCTAGGGATG  ACTAGCTTGA  CTAAAATCAA  CATGGGTGTA
51251  GGGTTTTATG  GTTTATAACG  CATCTGCACA  TCTTTGCCAC  GTTCGTGTTT
51301  CATTGGTCTT  AAGAGAAGGA  CTGGCAGGGT  TTTTTTGTTT  TAGATGGAGC
51351  CTCACTTCGT  TGCCCAGGCT  GGAGTGCAGT  GGCACAATCT  GGGCTCACTG
51401  CAACCTCTGC  CTTCTGGGTT  CAAGTGATTC  TCCTGCCTCA  GCCTCCCAAG
51451  TAGCTGGGAC  TACCGGCACA  CACCACCATG  CCCGGCTAAT  TTTTTGTATTT
51501  TTAGTAGAGA  CAGGGTTTCA  CCATGTTGGC  CAGGCTGGTC  TTGAACTCCG
51551  GACCTCAGGT  GATCCGCCTG  CCTCAGCCTC  TAAAAGTGCT  GGAATTAATA
51601  GGCGTGAGCT  ACCTCGCCCG  GCCAGGTTTT  TTTTTTTTTT  TTTTTAGTTG
51651  AGGAAACTGA  GGCTTGGAAG  AGGGCAGTGG  CTTGCACATG  GTCGATAAGG
51701  GGCAGATGAG  ACTCAGAATT  CCAGAAGGAA  GGGCAAGAGA  CTGTTCATGT
51751  GGCTGTCTAG  CTAGCTCTTG  GGCCAAATGT  AGCCCTTCTC  AGTTCCCTTC
51801  AAGTAGAAGT  AGCCACTCTA  GGAAGTGTCA  GCCCTGTGCC  AGGTACCACG
51851  TGGACAGAGT  GAGGAATCTT  GGAAAGATTC  CTACCTTTAG  GAGTTTAGTC
51901  AGGTGACAGC  ATATCTCAGC  GACTCAAACA  CACACACATT  CAAAGCCTTC
51951  TGTAATTCCT  ACAAAGTTGT  GAGGGGTAGA  GGAGAGGAGA  GACAAGGGAT
52001  GGTTAGGATA  ATGAAGGAAT  GTTTTGTTTT  TGTTTTTGTT  TTTGAGATGG
52051  AGTTTCACTC  TGTCACCCAG  GCTGGAGTGC  AGAGGTGCAA  TCTTGGCTCA
52101  CTGCAGCCTC  CGCCTCCCAG  GTTCAAGCAA  TCCTCCTGCC  TCAGCCTCCC
52151  AAGTAGCTGG  GACTACAGGT  GTGCGCCACC  ACGCCTGGCT  AATTTTTGTA
52201  TTTTCAGTAG  AGACAGGGTT  TCGCCATATT  GGCCAGGCTG  GTCTCAAATG
52251  CCTGACCTCA  GGTGATACAC  CCGCTTCAGC  CTCCCAAAGT  GCTGAGATTA
52301  CAGGCATGAG  CTACCGTGCC  TGGCCATGAA  GGAAGATTTG  TTTTAAAAAA
52351  TTGTTTTCTT  TAATATTAAT  TGAACACCTC  TGTTCAGAGC  ACTGGGCTGG
52401  TGCCAGAGGG  TTTCAGACAT  GAATCAGATC  CAGCACCTCA  TAGAGCCTTA
52451  ATCTGGCACA  CACACACAGC  CACAAGGAGA  CACAGACAAG  GCAGGGTAGG
```

<center>FIG.3-21</center>

```
52501 ATGAGTGGAA GCTAGGAGCA GATGCTGATT TGGAACACTT GGCTTCTGCA
52551 GTGAAGCCCC TTCTTAGTCC TCTTCAGTAA CCCAGCTCTC AGTGGATACA
52601 GGTCTGGATT AGTAAGATTT GGAGAGATGA TTGGGGATTG GGGAGAGCTC
52651 TCTAACCTAT TTTACCACCT CCTCTTCTGC CATTCTTCCT GTCCACATCC
52701 CCAGCATCCC TTTCCCTTGC CAAGTATCTG TGGCCTCTGT AGTCCTTTGT
52751 AAACAGCTGT CTTCTTACCC TACAGATCAT TGGGCAGGTG TATGCAGATC
52801 CTGACTGCCT TCCCCGAACA CTGGACTTTG GCCTCAACGT GAAGCTTTTC
52851 TGGGAGAAGT TTGTTCCCAC AGATTGTCCC CCGGCCTTCT TCCCGCTGGC
52901 CGCCATCTGC TGCAGACTGG AGCCTGAGAG CAGGTTGGTA TCCTGCCTTT
52951 TTCTCCCAGC TCACAGGGTC CTGGGACGTT TGCCTCTGTC TAAGGCCACC
53001 CCTGAGCCCT CTGCAAGCAC AGGGGTGAGA GAAGCCTTGA GGTCAAGAAT
53051 GTGGCTGTCA ACCCCTGAGC CATCTGACAA CACATATGTA CAGGTTGGAG
53101 AAGAGAGAGG TAAAGACATA GCAGCAAGTA ATCTGGATAG GACACAGAAA
53151 CACAGCCATT AAAAGAAAGT TTAAAAGAAG GAAATTCACC CAAACCATTT
53201 GAATACAGTA AGTGTATTCA TCTTTCGATA TTCCCCTGTC CATATCTACA
53251 CATATACTTT TTTTTATAGT AAATAGTTCT GTATTTTGCC CTGCATTTCC
53301 CTTGTGTTTA CTATCCAGTC TTCCTGTTTA TCATTTTTGT CGACAACATG
53351 AAATTCTATT GAGAGACTGT CTGAACATAT TGTAATGTAG ATGTTCAGGT
53401 TTTTCCAGTT TCTCTTTACA ATAGGTATTT AACTACAGTG AGCAGTTTTA
53451 TGCATTTAGC TAATTTCTCC TTTGAGGAAG TATTTTCAAA ATTACCTTTA
53501 TTCTTCTCAG GTAATAATTT CATTATTACC AAAGTTACCC TAGGTCTTTT
53551 CAAGTGTGTG GTTAAAAAAC GAGAATCTGG CTGGGCGCGA TGGCTCACAC
53601 CTGTAATCCC AGCACTTTGG GAGGCTGAGG CTGGTGGATC ACCTGAGGTC
53651 TGGAGTTCGA GACCAGCCTG GCCAACATGG TGAAACCCCA TCTCTACTAA
53701 AAATACAAAA CTTAGCCAGG CATGGTGGCA GGTGCCTGTA ACCCCAGCTA
53751 CTTGGGAGGC TGAGGCAGGA GAATTGCTTG AACCCAGGGG CGGAGGTTGC
53801 AGTGAGCCGA TATCACGCCA TTGCACTCCA GCCTCGGCAA CAAGAGTGAA
53851 ACTCTGTCTC AAAAATGGGG TTCTTTTCCT GCCATCAAAA ATCATGTTTC
53901 TTTTAAAAAC AAGTTCAAAC ATTACCAAAG TTTATAGCAC AGGAAATACG
53951 TCTTCTGTAA TCTCCCTTAA CCAATATATC CCTCAACATT CTCCTCACCC
54001 CCAACTCCAC CCTCCCAGGA TAACCAGTTG GGACATAATC TTTATTTAAA
54051 AATGGTTTCC GGATAGAGAA AGCGCTTCGG CGGCGGCAGC CCCGGCGGCG
54101 GCCGCAGGGG ACAAAGGGCG GGCGGATCGG CGGGGAGGGG GCGGGGCGCG
54151 ACCAGGCCAG GCCCGGGGGC TCCGCATGCT GCAGCTGCCT CTCGGGCGCC
54201 CCCGCCGCCG CCCTCGCCGC GGAGCCGGCG AGCTAACCTG AGCCAGCCGG
54251 CGGGCGTCAC GGAGGCGGCG GCACAAGGAG GGGCCCCACG CGCGCACGTG
54301 GCCCCGGAGG CCGCCGTGGC GGACAGCGGC ACCGCGGGGG GCGCGGCGTT
54351 GGCGGCCCCG GCCCCGGCCC CCAGGCCAGG CAGTGGCGGC CAAGGACCAC
54401 GCATCTACTT TCAGAGCCCC CCCCGGGGCC GCAGGAGAGG GCCCGGGCTG
54451 GGCGGATGAT GAGGGCCCAG TGAGGCGCCA AGGGAAGGTC ACCATCAAGT
54501 ATGACCCCAA GGAGCTACGG AAGCACCTCA ACCTAGAGGA GTGGATCCTG
54551 GAGCAGCTCA CGCGCCTCTA CGACTGCCAG GAAGAGGAGA TCTCAGAACT
54601 AGAGATTGAC GTGGATGAGC TCCTGGACAT GGAGAGTGAC GATGCCTGGG
54651 CTTCCAGGGT CAAGGAGCTG CTGGTTGACT GTTACAAACC CACAGAGGCC
54701 TTCATCTCTG GCCTGCTGGA CAAGATCCGG GCCATGCAGA AGCTGAGCAC
54751 ACCCCAGAAG AAGTGAGGGT CCCCGACCCA GGCGAACGGT GGCTCCCATA
54801 GGACAATCGC TACCCCCCGA CCTCGTAGCA ACAGCAATAC CGGGGGACCC
54851 TGCGGCCAGG CCTGGTTCCA TGAGCAGGGC TCCTCGTGCC CCTGGCCCAG
54901 GGGTCTCTTC CCCTGCCCCC TCAGTTTTCC ACTTTTGGAT TTTTTTATTG
54951 TTATTAAACT GATGGGACTT TGTGTTTTTA TATTGACTCT GCGGCACGGG
```

FIG.3-22

```
55001 CCCTTTAATA AAGCGAGGTA GGGTACGCCT TTGGTGCAGC TCAAAAAAAA
55051 AAAAAAAAAT GATTTCCAGC GGTCCACATT AGAGTTGAAA TTTTCTGGTG
55101 GGAGAATCTA TACCTTGTTC CTTTATAGGC CAAGGACCGC AGTCCTTCAG
55151 TAACACCAGT GTAAAAGCTT GAGGAGAAAT TGTGAAGCTA CACAGTATTT
55201 GTTTTCTAAT ACCTCTTGTC ATTCTAAATA TCTTTAATTT ATTAAAAAAT
55251 ATATATATAC AGTATTGAAT GCCTACTGTG TGCTAGGTAC AGTTCTAAAC
55301 ACTTGGGTTA CAGCAGCGAA CAAAATAAAG GTGCTTACCC TCATAGAACA
55351 TAGATTCTAG CATGGTATCT ACTGTATCAT ACAGTAGATA CAATAAGTAA
55401 ACTATATTGA ATATTAGAAT GTGGCAGATG CTATGGAAAA AGAGTCAAGA
55451 CAAGTAAAGA CGATTGTTCA GGGTACCAGT TGCAATTTTA AATATGGTCG
55501 TCAGAGCAGG CCTCACTGAG GTGACATGAC ATTTAAGCAT AAACATGGAG
55551 GAGGAGGAGT AAGCCTGAGC TGTCTTAGGC TTCCGGGGCA GCCAAGCCAT
55601 TTCCGTGGCA CTAGGAGCCT GGTGTTTCCG ATTCCACCTT TGATAACTGC
55651 ATTTTCTCTA AGATATGGGA GGGAAGTTTT TCTCCTATTG TTTTTAAGTA
55701 TTAACTCCAG CTAGTCCAGC CTTGTTATAG TGTTACCTAA TCTTTATAGC
55751 AAATATATGA GGTACCGGTA ACATTATGCC CATTTCTCAC AGAGGCACTA
55801 CTAGGTGAAG GAGTTTGCCT GACGTTATAC AACCAGGAAG TAGCTGAGCC
55851 TAGATCCCTT CCACCCACCC CATGGCCCTG CTCATGTTCC ACCTGCCTCT
55901 AATTTACCTC TTTTCCTTCT AGACCAGCAT TCTCGAAATT GGAGGACTCC
55951 TTTGAGGCCC TCTCCCTGTA CCTGGGGGAG CTGGGCATCC CGCTGCCTGC
56001 AGAGCTGGAG GAGTTGGACC ACACTGTGAG CATGCAGTAC GGCCTGACCC
56051 GGGACTCACC TCCCTAGCCC TGGCCCAGCC CCCTGCAGGG GGGTGTTCTA
56101 CAGCCAGCAT TGCCCCTCTG TGCCCCATTC CTGCTGTGAG CAGGGCCGTC
56151 CGGGCTTCCT GTGGATTGGC GGAATGTTTA GAAGCAGAAC AAGCCATTCC
56201 TATTACCTCC CCAGGAGGCA AGTGGGCGCA GCACCAGGGA AATGTATCTC
56251 CACAGGTTCT GGGGCCTAGT TACTGTCTGT AAATCCAATA CTTGCCTGAA
56301 AGCTGTGAAG AAGAAAAAAA CCCCTGGCCT TTGGGCCAGG AGGAATCTGT
56351 TACTCGAATC CACCCAGGAA CTCCCTGGCA GTGGATTGTG GGAGGCTCTT
56401 GCTTACACTA ATCAGCGTGA CCTGGACCTG CTGGGCAGGA TCCCAGGGTG
56451 AACCTGCCTG TGAACTCTGA AGTCACTAGT CCAGCTGGGT GCAGGAGGAC
56501 TTCAAGTGTG TGGACGAAAG AAAGACTGAT GGCTCAAAGG GTGTGAAAAA
56551 GTCAGTGATG CTCCCCCTTT CTACTCCAGA TCCTGTCCTT CCTGGAGCAA
56601 GGTTGAGGGA GTAGGTTTTG AAGAGTCCCT TAATATGTGG TGGAACAGGC
56651 CAGGAGTTAG AGAAAGGGCT GGCTTCTGTT TACCTGCTCA CTGGCTCTAG
56701 CCAGCCCAGG GACCACATCA ATGTGAGAGG AAGCCTCCAC CTCATGTTTT
56751 CAAACTTAAT ACTGGAGACT GGCTGAGAAC TTACGGACAA CATCCTTTCT
56801 GTCTGAAACA AACAGTCACA AGCACAGGAA GAGGCTGGGG GACTAGAAAG
56851 AGGCCCTGCC CTCTAGAAAG CTCAGATCTT GGCTTCTGTT ACTCATACTC
56901 GGGTGGGCTC CTTAGTCAGA TGCCTAAAAC ATTTTGCCTA AAGCTCGATG
56951 GGTTCTGGAG GACAGTGTGG CTTGTCACAG GCCTAGAGTC TGAGGGAGGG
57001 GAGTGGGAGT CTCAGCAATC TCTTGGTCTT GGCTTCATGG CAACCACTGC
57051 TCACCCTTCA ACATGCCTGG TTTAGGCAGC AGCTTGGGCT GGGAAGAGGT
57101 GGTGGCAGAG TCTCAAAGCT GAGATGCTGA GAGAGATAGC TCCCTGAGCT
57151 GGGCCATCTG ACTTCTACCT CCCATGTTTG CTCTCCCAAC TCATTAGCTC
57201 CTGGGCAGCA TCCTCCTGAG CCACATGTGC AGGTACTGGA AAACCTCCAT
57251 CTTGGCTCCC AGAGCTCTAG GAACTCTTCA TCACAACTAG ATTTGCCTCT
57301 TCTAAGTGTC TATGAGCTTG CACCATATTT AATAAAATTGG GAATGGGTTT
57351 GGGGTATTAA TGCAATGTGT GGTGGTTGTA TTGGAGCAGG GGGAATTGAT
57401 AAAGGAGAGT GGTTGCTGTT AATATTATCT TATCTATTGG GTGGTATGTG
57451 AAATATTGTA CATAGACCTG ATGAGTTGTG GGACCAGATG TCATCTCTGG
```

FIG.3-23

```
57501 TCAGAGTTTA CTTGCTATAT AGACTGTACT TATGTGTGAA GTTTGCAAGC
57551 TTGCTTTAGG GCTGAGCCCT GGACTCCCAG CAGCAGCACA GTTCAGCATT
57601 GTGTGGCTGG TTGTTTCCTG GCTGTCCCCA GCAAGTGTAG GAGTGGTGGG
57651 CCTGAACTGG GCCATTGATC AGACTAAATA AATTAAGCAG TTAACATAAC
57701 TGGCAATATG GAGAGTGAAA ACATGATTGG CTCAGGGACA TAAATGTAGA
57751 GGGTCTGCTA GCCACCTTCT GGCCTAGCCC ACACAAACTC CCCATAGCAG
57801 AGAGTTTTCA TGCACCCAAG TCTAAAACCC TCAAGCAGAC ACCCATCTGC
57851 TCTAGAGAAT ATGTACATCC CACCTGAGGC AGCCCCTTCC TTGCAGCAGG
57901 TGTGACTGAC TATGACCTTT TCCTGGCCTG GCTCTCACAT GCCAGCTGAG
57951 TCATTCCTTA GGAGCCCTAC CCTTTCATCC TCTCTATATG AATACTTCCA
58001 TAGCCTGGGT ATCCTGGCTT GCTTTCCTCA GTGCTGGGTG CCACCTTTGC
58051 AATGGGAAGA AATGAATGCA AGTCACCCCA CCCCTTGTGT TTCCTTACAA
58101 GTGCTTGAGA GGAGAAGACC AGTTTCTTCT TGCTTCTGCA TGTGGGGGAT
58151 GTCGTAGAAG AGTGACCATT GGGAAGGACA ATGCTATCTG GTTAGTGGGG
58201 CCTTGGGCAC AATATAAATC TGTAAACCCA AAGGTGTTTT CTCCCAGGCA
58251 CTCTCAAAGC TTGAAGAATC CAACTTAAGG ACAGAATATG GTTCCCGAAA
58301 AAAACTGATG ATCTGGAGTA CGCATTGCTG GCAGAACCAC AGAGCAATGG
58351 CTGGGCATGG GCAGAGGTCA TCTGGGTGTT CCTGAGGCTG ATAACCTGTG
58401 GCTGAAATCC CTTGCTAAAA GTCCAGGAGA CACTCCTGTT GGTATCTTTT
58451 CTTCTGGAGT CATAGTAGTC ACCTTGCAGG GAACTTCCTC AGCCCAGGGC
58501 TGCTGCAGGC AGCCCAGTGA CCCTTCCTCC TCTGCAGTTA TTCCCCCTTT
58551 GGCTGCTGCA GCACCACCCC CGTCACCCAC CACCCAACCC CTGCCGCACT
58601 CCAGCCTTTA ACAAGGGCTG TCTAGATATT CATTTTAACT ACCTCCACCT
58651 TGGAAACAAT TGCTGAAGGG GAGAGGATTT GCAATGACCA ACCACCTTGT
58701 TGGGACGCCT GCACACCTGT CTTTCCTGCT TCAACCTGAA AGATTCCTGA
58751 TGATGATAAT CTGGACACAG AAGCCGGGCA CGGTGGCTCT AGCCTGTAAT
58801 CTCAGCACTT TGGGAGGCCT CAGCAGGTGG ATCACCTGAG ATCAAGAGTT
58851 TGAGAACAGC CTGACCAACA TGGTGAAACC CCGTCTCTAC TAAAAATACA
58901 AAAATTAGCC AGGTGTGGTG GCACATACCT GTAATCCCAG CTACTCTGGA
58951 GGCTGAGGCA GGAGAATCGC TTGAACCCAC AAGGCAGAGG TTGCAGTGAG
59001 GCGAGATCAT GCCATTGCAC TCCAGCCTGT GCAACAAGAG CCAAACTCCA
59051 TCTCAAAAAA AAAAA  (SEQ ID NO:3)
```

FEATURES:
```
Start:    3000
Exon:     3000-3044
Intron:   3045-45393
Exon:     45394-45525
Intron:   45526-45761
Exon:     45762-45818
Intron:   45819-50154
Exon:     50155-50329
Intron:   50330-51076
Exon:     51077-51132
Intron:   51133-52775
Exon:     52776-52933
Intron:   52934-55922
Exon:     55923-56064
Stop:     56065
```

FIG.3-24

CHROMOSOME MAP POSITION:
Chromosome 22

ALLELIC VARIANTS (SNPs):
DNA

Position	Major	Minor	Domain
941	A	T	Beyond ORF(5')
2612	G	A	Beyond ORF(5')
5080	G	A	Intron
6599	-	A C	Intron
6983	C	G	Intron
9885	A	-	Intron
12538	G	T	Intron
17707	T	C	Intron
18219	-	A	Intron
19670	C	T	Intron
21153	G	T	Intron
24566	C	-	Intron
26604	G	A	Intron
27255	C	G	Intron
27399	T	C	Intron
28088	G	A	Intron
28734	G	A	Intron
29246	-	T	Intron
29490	G	A	Intron
29934	T	C	Intron
34480	A	G	Intron
38812	T	C	Intron
40731	C	G	Intron
41303	T	A	Intron
41305	-	A	Intron
41457	G	C	Intron
43168	A	- T	Intron
43357	T	G	Intron
45664	T	C	Intron
47549	A	C	Intron
47908	C	A	Intron
52267	C	A	Intron
54654	T	C	Intron
54679	C	G	Intron
54693	A	C	Intron
54706	T	C	Intron
54712	T	C	Intron
54799	T	C	Intron
54819	G	A	Intron
55499	C	T	Intron
56825	C	A	Beyond ORF(3')
58871	T	A	Beyond ORF(3')

Context:

FIG.3-25

DNA
<u>Position</u>
941   GAGTAAGTGGGTGGTCAGGTTACAGACTTAATTTTGGGTTAAAAAGTAAAAACAAGAAAC
AAGGTGTGGCTCTAAAATAATGAGATGTGCTGGGGGTGGGGCATGGCAGCTCATAAACTG
ACCCTGAAAGCTCTTACATGTAAGAGTTCCAAAAATATTTCCAAAACTTGGAAGATTCAT
TTGGATGTTTGTGTTCATTAAAATCTCTCACTAATTCATTGTCTTGTCCACTGTCCGTAA
CCCAACCTGGGATTGGTTTGAGTGAGTCTCTCAGACTTTCTGCCTTGGAGTTTGTGAGAG
[A,T]
GATGGCATACTCTGTGACCACTGTCACCCTAAAACCAAAAAGGCCCCTCTTGACAAGGAG
TCTGAGGATTTTAGACCCAGGAAGAATGAGTGATGGGCATATATATATCCTATTACTGAG
GCATGAGAAGAGTGGAATGGGTGGGTTGAGGTGGTGTTTTAAGGCCTCTTGCCAGCTTGT
TTAACTCTTCTCTGGGGAACGAGGGGGACAACTGTGTACATTGGCTGCTCCAGAATGATG
TTGAGCAATCTTGAAGTGCCAGGAGCTGTGCTTTGTCTATTCATGGCCCCTGTGCCTGTG

2612   TGAGTTGGAACAGTTTGATACCAAAACCATCCCCCCGCCCCCCAACCCCCAGCCTAGGGT
CCGTGGAAAAATTGGCCCCTGGTGCCAAAAAGGTTGAGGACTGCTGATCTAGAGGACCAA
TTTATTCAATGTTGGTTGAGTAAATGAGCTCTTGGATTAGGTGATGGAAAAATCTGAAAA
AACAGGGCTTTTGAGGAATAGGAAAAGGCAGTAACATGTTTAACCCAGAGAGAAGTTTCT
GGCTGTTGGCTGGGAATAGTCATAGGAAGGGCTGACACTGAAAAGAAGGAGATTGTGTTC
[G,A]
TTTCTTCTTCTCAGAGCTATAAGCAAAGGCTGAAAGTTCTAGAAAAAAGGCAAGTTTTGTT
TCAGTAGAAAAAAGGATAATCAGAACCATTTTTAGAAAATGGAATGAGACTACTTTTGAG
GCCATGAGTTCCTTGTCCCTGGAGAGATGAGCAGAGGTTGGACAAGTGCTTACCAGAGAT
CTTGTGGAGGCAGAAACTGTGCATCTAGCAGAGCATTGGCCTAACCCTTTCAAATGAGAT
GCTGTTAACTCAGTCTTATTCTACATGGTAGGAATCCTGTCCCTTTGCCTCCTGCTACTT

5080   ACAACGTAAAATAGTTGAAATTTGTTGGTGGAAAGAAGAGCAGTCCACTCCAGAGGCTGG
ATGGGCATGCCTGGCCCCCAAGGTCTGAAGTGGTAGGGCTGTGCCTATATCCTGAGAATG
AGATAGACTAGGCAGGCACCTTGTGCTGTAGATTCCAGCTCCTGCACATAGCTCTTGTTG
TAAAACATCCCTGTGCTTATACCAAGTAATTGAGTTGACCTTTAAACACTTGCCTCTTCC
CTGGGAACCATATAGGGGATTGGCCTGGAGACGTCTGGCCTCTGGAAGAGTTGGAAAGCA
[G,A]
CCATCATTATTATCCTTTCCTTTCAGCTATAACTCAGAGCTCTCAAGTCTTTTCTGTGGA
TCTTATTGCCTTGGTTCTTGCCCCTTTTACTCCCAGGGAAGTTGATTCTGTCTTTTCTGT
TCCATTTAGTATGACAGGAGCAGAGAATGTCAGAGCTGTAAGGGACCTTATAGTTAAAGC
CTTTGGCTGGTCCTTTCATTTTATAGCTGGGACTAATAAGTAACGTCAAAACCCAATGAG
TTCACAGATTGGGTCTCGCCTTGGCATGTAACCCATATGTTCATATTCTTGCTGTTTTCC

6599   CTGTAATCCTAGCACTCTGGGAGGCCGAGGCAGAAGGATCGCTTGAGCCCATGAGCCCAG
GAGTTTGAGACCAGCCTGGCCAACATGGCAAAACTCCACCTCTACAAAAAATACAAAAAT
ATTAGCCAGGCGTGATGGCACACACCTGTAGTCCCAGCTACTTGGGAAGCTGAGGAGCGA
TGATTACCTGAGCCCAGGGATATCAAGGCTGTAGTGAGCTGTGATCATGCCACTGTACTC
CATCCAGCTGGGGGACAGAGTGAAACCCCTGTCTCAAAACAAAACAAATGAAAAAAAAAA
[-,A,C]
CCTTAATAATCAGTAACTGTCACTTTATATTATGTTGTGAGTGTGTGTCTATATACACCT
ATATGTATACATTTCTCTTATTACACATTCATTGGTGATCTGATGTGGAGCCCCAGGGAT
TAAGGGCAACTTTGAACTACCCTGACACAATCAAGCCAAATATCATTCCCGTGGAGGAAG
TAGAGTATCTAGGTTCTGTCTCCTAGTTGCAGCTTTACCTTGAGGACAGAGACTCTAATC
CAGCTGTGCTGAAGGAGCACATCTCCTGACTTCTGAGCTTTCCCCTGGTAAATTCAAACT

FIG.3-26

6983   CACATTCATTGGTGATCTGATGTGGAGCCCCAGGGATTAAGGGCAACTTTGAACTACCCT
GACACAATCAAGCCAAATATCATTCCCGTGGAGGAAGTAGAGTATCTAGGTTCTGTCTCC
TAGTTGCAGCTTTACCTTGAGGACAGAGACTCTAATCCAGCTGTGCTGAAGGAGCACATC
TCCTGACTTCTGAGCTTTCCCCTGGTAAATTCAAACTGGATGTCACGGCGCCCTCAGATA
GAGCCTGGTAATTTGCCCTGGGGAGAGTGACTGTCTTTTGGATCTAATTTGACTTTTGCC
[C,G]
CAGTTGGAGGAAAATCTTCAGGGCTAGGAAGGATTGTATTTGTCTGACCCCAGAGATAAC
CTGGGTTTTGAGGAACATGGGGCATCAACCTGAATGGTCTTGTAAGATCTCTCCCACGCC
AGCTTGCCAGTGTTTCTCTGATGAATTTAGAGTACCTGAGTAGTGCAGGCCTGCTGGGAG
GAGGACTCTCCCTCTGTGCTACTCAGAGAAATTCATTCTTCAAGGCCCCCTTCCAGCCTT
GCTCTTACCCAGCTGGGCTACAGTTACAATAAAGGAAATGACTTTTCTTCTCCCCTTCCC

9885   GGCGTGCCACCACACCTTGCCATTTTTTTTTTATTTTAAGTAGAAACAAGGTCTTATTAAT
ACTATGTTGCCCAGGCTGGTCTTGAACTCCAGCGATCCTCCTGCCCCAGCCTCCCAAAGT
GCTTGGGATTACGGAAGTAAGCCACTGTGCCTGGCCAGTGCAACCCCCATTTTATACTAA
AACAGGAAGGCCCAGAAAAGGTTTGGAGTAACTTGTCCAGGGTCACACAGATGATATTTGA
ACTCAGGTCTCCCTGGCTCCCAAGAGAGTCTGCTTTCCACTAGGACTCCCAGGAGAAAAA
[A,-]
AAAAAAAAAAACAGTAGACTTGGAGACAGAAAATCTGATTTGAGTCTTAGTTGAGCTAGG
CTAACTGTGTAACTGTGGGCAAGTTCCTTAGCCCCTGTGAGCCTCAGTTTCTTATCTGTA
AAATGTCATAAAAGAAATCCATCTCATGGAGTAGTTGTGATGATCAAGGACTCTGAAAAC
ATTAGAATGGTTTAATGTGAAGGATTAGCAGCAGCACATGGCAACATTGTGCATCTTATA
TTAACTATCCAAATATATCAAGCGTCATTTGCTATATATAAAAGTCATCAAATTAGGCAC

12538   ACTTGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCC
CAGATCACGCCACTGCACTCCAGCCTGGTGACAGAGTAAGACTCCATCTCAAAAAAAAAA
AAAAAAAAAAAAAATTCCTTAATTTGGCCTACAGTAGAGCCCTCCGTAATGTGGCCTCTCT
CCACATCTCCACAACCTCCTGCTCCCTGCACTTCAGCCTCACCTCTCTTCTGGACAGGCC
CTCCTTCTGACAAGGGCTTTGTTCATTCTGCTCCCTCTGCCTAGAATGCCCCCCTTACTCT
[G,T]
TTCACTTAACTCCTGCTTATCGTTTAGATCTTTACCTGGATGGCTCAGAGAAATATAGAA
GTAATTCCTCACCCTGAAAAATAGGTTAGGTCCCTGTTTTATGTTTTCATAGACCTTTCC
TTTGAGGCTTTTTTTTAAAAAAGTAGTTTTAATCTCACATTTATTCATGTGATCATCTCCT
TAATGATATCTTAAGACCTCTAATAGAACAATTTGGTCATGGACTGTGGGGTTTTTGCCC
CTCATTGTGTCAGCACTGAGCATATTGTTGGCATAGGAGGGATATTTGTTGAATGAATTG

17707   GTAGTGGGTGCTCAGAGTGTTTGCTGGGTGAATGATGTATTTGTTGAACGACTCTTTGGA
CACTTGAATAAAGTCCATCCAGTATGCACCATTACCATCTCTTCGCTCTACAATATTCTT
TTAGGCAAGAGCTTATCTTTTGAGGTGATAAGATAAGCTCAAACTTATGTAGACTAAGAC
CTCAGTCTGTAAATGTCATCCCTAAGTCTTAAACCATCAAAACCAGGGCCTCAAGGAATG
GCATGCCTTCTGCAACTGTAGCAACCTGCTGTGCTTATTTTGCCGTGTTTTTCATTTTTC
[T,C]
CCCAAAAGCTAGAGTCCCTTCTCCCATGGGCAGTGCTGGAAGTGTGCTAACAAATTCTTT
CTCCATACTGCTTACGATTACAAAAAAAAACCCTCAGCATCTCATGCCAGACTTGAGTTAA
GGTTGTTTTCTTTTGTGTGTCAGCTGTATTCTGGTCATGACTTCCTGATGATGCCCTATA
GAGATTTTGCTGAGATCAGAGGGTGCTCCACTGCCATCAGTAGCACTGACTCTTGCAGAA
GCACCGTTTCTGAAGTTGGCTAATGTCATCCCTCACGTTTGTTTGTTTGAAATTTGTTTT

FIG.3-27

18219   TGCCATCAGTAGCACTGACTCTTGCAGAAGCACCGTTTCTGAAGTTGGCTAATGTCATCC
         CTCACGTTTGTTTGTTTGAAATTTGTTTTAGTTCCAGAGATAGCACTTTCATGGAATGAC
         GCTATCTTCTAGAATCACTTTTTTTTTTTTTTTTTTGAGTTGGAGTCTCGCTGTGTCGCCAGG
         CTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAATCTCCACCTTCCGGGTTCAAGTGAT
         TCCCCTGCCTCAGCCTCCCGAGGAGCTGTTACTACAGGCGCACACCCCCACTCCTGGCTA
         [-,A]
         TTTTATGTGTTTTTAGTAGAGACGGGGTTTCACCGTGTTGGCCAGGATGGTCTCGATCTCC
         TGACTTTGTGATCTGCCTGCTTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGTCAC
         CGCGCCTGGCCTAGAATCACCTTTTTATACCATAACGTGAGCACCACTGCCGCGTCACCA
         AGGAAAGAGAGAGGCAGCTACTGTGGGGTTACAAATGGGTAAGAGTGGCACCAGGAAGGT
         GAAAGTCTCTACTTAGCCAAGGCTTAACAAAATGTCAATCACCAAACATTTATTTATTAA

19670   GACCCCCATGATGAGCAACTATAGCACTAGAACAGTGATAATAACTAATGTTTATAATGC
         ATCTTCAGTTTACAGAGGGCTTTTGTACTCATCATCTAGTTTAGTTCCTGCAACAACCTC
         TTGAGGAATATAGCACAAGCAGGACAAGGGAAGCCCAGAGATGTTAAATAATTTATCCAA
         GTTTATGCTGCTGGGAAGGGCAGCACTGAAATTAAAAGAAAAGTTTTCTGAGCTCAAATC
         CCATGCCCTTTCCTCAATGTGAGCTCTAGCAAGGTATTCAGGAATCCTGCCTCTACAGTT
         [C,T]
         AGAGCCTCAAATTGCTGGGTATGTTGAGTTCTTGTATCTGATTTTTTCTAGATTTCCTGCC
         CACATTCTTACTGTCTGGATATCAGGAAAGAGTTTATCAAATGCCTGTGGAAATCCAAGA
         TAAGGTCTCATGATGAGTAACCCAGTGAAAACATGAAGTCAAGTCTAACTAGTCACTACT
         ATTTCACTACTGCTGACTCCTGATGATCAGCTCCTTTTCTAAGTGCTTACTGTCCACTTA
         TTCCATCATCTGCCTAGAATTTATGTGAAGGAATCAAAGCAAAAGGATCATAAGGCTTCC

21153   GGACCCTTGTTTTAGAAGGATGACTGCTGCTATAATGTAGAAAGTGATTTGGAAGAGGGG
         AGGAGTGGGGCACGAAAGATGGTTAGTAGATGGGGGTGGTAATGCTTACCTTTCAGTATT
         TGGAGGCTTCGGAGTCCTCAAAAAATTCTCTTCCTTGATTGGAGTCCTCCCAGCCAATAGA
         GGGCTTCACACAAACAGTTTCTTGGGTTTTGAATTGTTTGACCAGAGCTTTCTTCCGACA
         AAAGGTTGGGGTGATTCATTCACTTACCACACCTTGCCTGAACATTCACTTGGGGCTGCC
         [G,T]
         GTTATGAAGGCTATTGTTCTCCAGCCTGTCACAGACGCTTTGAAGACCTGTGCCTCAGCT
         GGTTCTAAGGAGTCAGTTTGTTCAGCTCCGTGCCAGGTTTCCAACTTATGAAATGTGCTG
         GAGATTAACACCTCTCCTGCCATTTTATCCCTACTATAATTGCCAGTCAAAGGATTCCTG
         CAGTTGCCTCTGGCAGCCATAACTGATGAATGTTCTGCCAGCTGCTCTGAGGACCTAGAA
         GAGCAGTTTTCTATCCAGGACCAGTTTCCAAGGGTGGGAGGGTGAAATATATCCTCCAGT

24566   CTACTCTGGAGGCTGAGGTGAGAGGATCACTTGAGTCCAGAAGGTCGAGGTCAAGATTGT
         AGTGAGCCATGATGGCATCACCGCACTCCAGCCTGAGTGACAGAGAGAGACCCTGACTCA
         AAAAAAAAAAAAACAAAAAAAAAAAAACACCCTCACCACTTATCAGCTATTTGTCTTGAGAA
         TAGTGACATAACCCCTCAGAACCTATTTCCTAATCTGTTAAATGAGGCTGATGACGTTTC
         CTCCTTTTACTGGCAATTTAAACATGATGGATAATAAATGCTAAGCACTTAACACAGGGC
         [C,-]
         TAGAAGATATTAACTGCTCAATAAATGGTAGCTTCTTAACAGTATTCAAACCCATGTGCT
         CTTATCACATGCATTGTTGTCCCTGTGTCCAGTTGGTGGAATGGGAAAAGGCTCCCTTGT
         AACCCCATCTACCATCTTTATCAGACTTTCCTGCCATGGTTCACAGTAAGAGATAGAAGC
         TGCACGGTGACTTCTGGCTCTTTACAATGGTGAGCGGTGTGTGCCTGGTAAGGGAGAGCT
         GATGTCACTGCCCCAAATCCAGTAGTGAGATCTGAGTGTTCTGGTTTCCTCCAGCAGCCT

FIG.3-28

26604　　GATTTGCAGCTGAGCCTGTCTATCTGGTGTGGGAAGAAGATGGGGAGTTACTTGTCAGTC
　　　　　CCGGCTTACTTCACCTCCAGAGACCTGTTTCGGTGAGTTGGTCTCCGAGTTCCCCTCTCC
　　　　　ATCTCTCCTGGCCCCTGGTCCTGAGAGGAGGGTGGTCTCCCTAAATCTCCTTCTCACTTA
　　　　　GTCCTTTACCATCGGTTCTGCCGGGCAGAAGCCAGCGGAGGTTATACCCAAGGAGAATCG
　　　　　GCCTTGTGAGGTACCCCCATTATGTCCTGGAAGTGGTGAGGGGAGGGATATACCCAGAAG
　　　　　[G.A]
　　　　　AACTTCTTAGGGAGCTCCAGCTCCCCTTCTATCCCAGACAAACCTGAAGGAGCCTCCAAA
　　　　　AGATGCCACTGACCTGCCCATTGTAGATGTTACTGCTTCCGGGGGGAATAGCCCAAATAG
　　　　　AGTGCTGTTTCCAGCTCTCACATGTCTTACCTGCGGGCCATGCTGCCTGCCCAGGAATTT
　　　　　GTCCCAACAAGCAGGATGGGCAGGTTTTGCCAAACTGTGGAAACTGGCAAGTCCTGGGTG
　　　　　TGGGTAGCCTGGTACACAGTAGGCACCTTATAAACGTTTGTTCTCTTAATGGCAGGCACA

27255　　TGGGGAAAGACCTGGGCGAGTGCTTCTAAGACTGGAGCAATGGGCTTTAGAGTGTTCCTG
　　　　　AGCTGCTGGGCCAGCCCCCACACCTCCTCAGTCCCTAGGCCTAAGTACCTCCACGAGCCT
　　　　　CTCTCTGTGGGGCTTCTCAGAGGGAGATGTGGAAACTCTACCTCTAACCTGGCTTTCTTT
　　　　　GCTCATTGCCCCACTCCACCTCCCATAGAAACTCCCCAGGGGGGTTTCTGGCCCTCTGGGT
　　　　　CCCTTCTGAATGGAGCCATTCCAGGCTAGGGTGGGGTTTGTTTTCATTCTTTGGGAGCAG
　　　　　[C.G]
　　　　　CTGTTGTTCCAAAAAGGCTGCCTCCCCCTCACCAGTGGTCCTGGTCGACTTTTCCCTTCT
　　　　　GGCTTCTCTAAGCTAGGTCCAGTGCCCAGATCTTGCTGCCGGGATACTAGTCAGGTGGCC
　　　　　AGGCCCTGGGCAGAAAAGCAGTGTACCATGTGGTTTTGTGGAATGACCGGACCCTGGTAG
　　　　　ATTGCTGGGAAGTGTCTGGACAGGGGGAAGGGGGAAGGGAACTGGTCCTCAATGCTGACT
　　　　　CTACCAAGCGCCCTGCTAGACACTTTATCCTTTAATCTCTCAACAGCCTAAAGAGATTAT

27399　　AGATGTGGAAACTCTACCTCTAACCTGGCTTTCTTTGCTCATTGCCCCACTCCACCTCCC
　　　　　ATAGAAACTCCCCAGGGGGTTTCTGGCCCTCTGGGTCCCTTCTGAATGGAGCCATTCCAG
　　　　　GCTAGGGTGGGGTTTGTTTTCATTCTTTGGGAGCAGCCTGTTGTTCCAAAAAGGCTGCCT
　　　　　CCCCCTCACCAGTGGTCCTGGTCGACTTTTCCCTTCTGGCTTCTCTAAGCTAGGTCCAGT
　　　　　GCCCAGATCTTGCTGCCGGGATACTAGTCAGGTGGCCAGGCCCTGGGCAGAAAAGCAGTG
　　　　　[T.C]
　　　　　ACCATGTGGTTTTGTGGAATGACCGGACCCTGGTAGATTGCTGGGAAGTGTCTGGACAGG
　　　　　GGGAAGGGGGAAGGGAACTGGTCCTCAATGCTGACTCTACCAAGCGCCCTGCTAGACACT
　　　　　TTATCCTTTAATCTCTCAACAGCCTAAAGAGATTATATATCCCCATTTTACAGATGAGGC
　　　　　AACCAGTTTCAACAGAGTTAACATATGGAGCCTCACTGGGCAGCTTTTTCTGTCTTCCTG
　　　　　ACTTTCTCTCATCCTTCAGGGGGCTGCAGGTTTGTTTTCTTCTCCTAGTGGAGAGGAAAT

28088　　AAGAGCCAATGGAAATTGATCTTGAGTTTAGGAGAAAGCTTTTACATGTGGAATTAAGAT
　　　　　GCCAAGTGTTGAAGTAGCCACATTTCAGGTCCTCATTAATTTCTCTTAATCCTGGGAAGG
　　　　　CAGCTTAGGAGAAAGGGTTGTTCCTTTAGGAGCCAGGAACTATACCCCCTTTTACCCTTGGA ·
　　　　　GAGGCAGGGAAGCCAGGGAGGACACAACTTCTCAGGAAGAGGAGAAAGCTAGAGCAGATAG
　　　　　TGAACTCTCAACCTGAACCTTTAAGGGCCAGACCACTAATGCCACCCAAGTCCACCTGCC
　　　　　[G.A]
　　　　　TTTGTCTTGTTCTGTCCCAGGCTTTCTGGAGAACCTGATCTTCTTGCCCCTACCCCCAAG
　　　　　CTCCGTTTGCCCAGCTAGAGTCTGGGGGGTACTGACTGACTTTCGTAGACATTCTTCCCT
　　　　　TCCCCAAATAAGAGGCCACATTCCTGAAGTCACTTCTGAAGAGATAGCTGCCACACAGGG
　　　　　CTCTTTCCCCCCAGGGGAGGGACCACCCAGACCCTCTGCTCTCCCAGGTATCCGTTACCAC
　　　　　ATCACTACCTGGTCAGAAAGCTGTTTCTGCCATTAGCCCCTCCCTCTTTTATTATAGGAT

FIG.3-29

28734   AAGTAGAAGCTAGACTTCTTGGGCTCCTGAACAGGGTCCTTGCTGGATTCTGTGAAACAA
ATTAAGTTCTTGACCCTAGGCCTCTGGGGGAGTACAAAGTCTATGGGAGTTCTGGGGCTG
TGGTTGCAAGGAAAGTGACGCAACCAGATTCCATGGGGACATGATCAGGCGTGACATGTG
AGGGAGGAAGAGGGGAGCAAGGGAATGAAGAATACAACTTCTGTGTCCCATACACCCCTGC
CTGACAGGCCATACATACTCAGCAGAGAATGCACTGTCTTTCCTACCACACTAGCGTGAG
[G,A]
AGTGAGCTGCAATTACCACTGTGCTTCCAAGTAAGAAAATACCTCAAATTGGAATTTACA
AAAGAGGTAAATTAGGGAGTGGCTTTTGTCGGACATCTTTAAAGCATTTTTCTTTTTATA
GAATTTCACTTAATGTCCAATACTGATTTAATGAGCTTGGGTTTACACATTATCTCTTGA
AGAAAACAAATGAACCTTTGTGTTCCAAAGCAATCCATGTTTAAAGGGAAAAAATTATGC
ATAACTCTGCCCAGCTTCACAGTAACCTTTGGCAGGTGCCTTAGGTCCTCTGGGACTCTT

29246   AATCCATGTTTAAAGGGAAAAAATTATGCATAACTCTGCCCAGCTTCACAGTAACCTTTG
GCAGGTGCCTTAGGTCCTCTGGGACTCTTTTCCTTATCTGAAAAATGAAGGACTTGGATC
AGGTGAATGGTTCCCAGCTCTGCAACTTATGTGGCTCCTCAGAGGCACACAAGCTCTTTT
CCATTATTTGCCAAATAATGGAGGCCCTGTCTTTAACTGCAGTACAACTACACAAAATAC
TTGAAACTACAGTCTTCCTGGTTTTTGGTTGGAACTGAATCAGTGCACTCTAGCAACACT
[-,T]
ATTTCTTGCTGTTCGTAGGCTTCATTATGTGTTTGGTTAATTTTTTAAAAACAACAATAAC
ATATTCCATAATAATTACAGCTTAATTGGCAGACTGTTTCAGTCTATAGGATCTGCAGGA
AGGAGGAGTAATAAAGGGATTTTTTGACTGAGCTCTTATGGAACAGAGTCTCTCTAGGCCC
CTGTCATATCTGCCCTTCTGGGCCCTGGGGAAAAGTTGGCATCCCCAGTTGTGGTGCTCT
CCAGGTGCCCTCAGGCTGTGGTGGAGGGAGCTTCCCATTCTCTCCTTCAGCCCACTCAAT

29490   AACTACAGTCTTCCTGGTTTTTGGTTGGAACTGAATCAGTGCACTCTAGCAACACTTATT
TCTTGCTGTTCGTAGGCTTCATTATGTGTTTGGTTAATTTTTTTAAAAACAACAATAACATA
TTCCATAATAATTACAGCTTAATTGGCAGACTGTTTCAGTCTATAGGATCTGCAGGAAGG
AGGAGTAATAAAGGGATTTTTTGACTGAGCTCTTATGGAACAGAGTCTCTCTAGGCCCCTG
TCATATCTGCCCTTCTGGGCCCTGGGGAAAAGTTGGCATCCCCAGTTGTGGTGCTCTCCA
[G,A]
GTGCCCTCAGGCTGTGGTGGAGGGAGCTTCCCATTCTCTCCTTCAGCCCACTCAATTCAG
AGGCTAGGGGCTGAAAGAAGCTTCTCTACAACTGGCTGTTCACTGGGAGGTTAAGGGATG
ACCATCCAGCCAGGCCTTCCTCAGGACATGGGAGGGCTTATGCTTTAACATGTGTAAATC
CACTGCAATAATGACTGGTTCTTTTACCCCATAAGGTTGAGAATTTACCTGTAAACATTT
TTGTCTGAAGAATTTGGATGTAAGTGAGGGCTGGGCCTCTATCTTATCTCACTTGGCTTC

29934   GGACATGGGAGGGCTTATGCTTTAACATGTGTAAATCCACTGCAATAATGACTGGTTCTT
TTACCCCATAAGGTTGAGAATTTACCTGTAAACATTTTTGTCTGAAGAATTTGGATGTAA
GTGAGGGCTGGGCCTCTATCTTATCTCACTTGGCTTCTCTCAGCACAGCACCTTGCCTGC
TTGTTCTTACACATCCTAGATGCACAGTAACTATTTCCTAATTATTAGAAATCTATTAGA
ATCAATTGATTTCAGCTGGGCTTGGTGGCTCCTTCCTGTAATCCCAGCACTTTGGGAGGC
[T,C]
AAGGCTGGAGGATCACCTGAGTCCAGGAGTTTAAGACCAGCCTGGGCAACATAGGGAGAC
CCTGTCTCTACAAAAAATAAAAAATTAGCCAGGCATGGTGGTGTGCACCTGTAGTCCCAG
CTACTCAGGAGGCTGAGGCAGGAGGATCTCTTGAGCCTGGGAGGTCAGACTACAGTGAGC
AATGATTGTGCCACTGCACTCCAGCCTGGGTGACAGAGTAAGACTCTGTCTCTTAAAAAA
AAAAAAAAAAAAGTTGATTTCTATTTGGATAGATAAATAATTCATTTTAGGACCTTTCTT

FIG.3-30

34480   CTGACTTCAAGTGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTATAAGCATAAGC
CACTGTGCCCAGCTGCTCTCTATATTTTTAATACATATTATTTCCATTAATTTTCACAGC
AGTTCATTTTATAGATGAGGAAACTAGGCCAGAGAAGTAAAATATCTTGCCCAAGATGAT
GTAACTAGTAAGTGGCAGGATCAAGATTCAAACCAAGCAATGTTCAAACCTCTTGGAAGC
AAGAATGTGGCCACTGTGGAAGGTGCAAGGCCTTGACAACAAGAATAGGGAAAAGAAGGA
[A,G]
CTAGAAGGAAAGAGATGGCATGGGCTCAGCAGGCCAGGGAGCTCTTAGCTGTGTGTGTTG
GGAAGCTCAGAAGGGAGGAAGAGGTTGTCTGTGCAGGTAAGTCCTGAGAACACACCAGAC
TTTTGAGAGGTGGAGCTTCATAGCCAGGTCATTAGGGGAGAAGGGAGCTATAGATTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGAGACGGGGTCTTACTATGTTGCCCAGGCTG
GTCTTGAACTCCTGGGCTCAAGTGATCCTCCCACCTCAGCCTCCCAAAGTGCTGGGATTA

38812   AAATCCAGCAGATCCATTGAGAGTTTAAGCAGCAAGGTGTTGTGACCAAGTTAACATTTT
AGAAGGATCACTGGTATGGAGGTTGGATTGGAGAGGGGAAAGCCTAAAGGTATAGAGACT
AGTTAGGAAGCTATTGTAGGCTGGGCATGGTGGTTCATGCCTGTAATCTCAGCACTTTGG
GAGGCTGAGGTGGGAGGATTGCTTGAGGCCAGGAGTTGAAGACCAACCTGGCCAACATAG
CAAGACCCCGTCTCTGTTTTTTCTTAATTAAAAGAAAAGTCCAGACGTAGACATAGTGGCT
[T,C]
ACGCCTGTAATGCCAGCACTTTGGGAGGCCAAGGTGGGCAGATTGCTTGAGGTCAAGAGT
TTGGGATTAGGCCAGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAG
GTGGGCGGATCACAAGGTCAGGAGATCAAGACCATCCTGGCTAACACAATGAAACCCCGT
CTCTACTAAAAGTACAAAAAATTAGCCGGGCATGGTGGCGGACGCCTGTAGTCCCAGCTAC
TCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTAGGAGGCGGAGCTTGCTGTGAGCAGA

40731   GTTCTGTCCTATGTCTGTCTCTCGGATGAAGCTGAGCTGGCTTTTCAGAAGCCTGCAGAGT
TAGGAAAAGGAACCAGCTGGCCAGGGACAGACTATGAGGATTGTGCTGACCCAGCTGCCCC
TGTGGGGATCACAGTTTACAGCCAGAGCCTGTGCGGACCCAGCTGTCTGCCAGGTTTCCT
TAGAAACCTGAGAGTCAGTCTCTGTCCACTGAACTCCTAAGCTGGACAGGAGGCAGTGAT
GCTAAACCCTGAAGGGCAACATGGCCTATGGAGAAAGCATGGAGCTCAGAGCCTGGAGTA
[C,G]
GGGCACAGATAGGATTGAATAAATTGTGTAGAAAGACTTTGAAAACAATAAAGCAAAAGA
TGAATGAACGTTTTTTTTTTAGACTTGAGGGACCAACAACCCCCAAACCCCAGATTCTGCCA
GGTCCATGGGGAAGGAGAAGTTGCCTTGAGTGGAAGCCCCAAGTAGGGAGACTTACAGAA
AAGAAGTCAAGAGCACTGGCTCCCAGGCAGAAATACTGATACCCTACTGGGGCTTCAGGC
TGAGCTCCTCCCTTCACAAATCACTTCATCTCTCTGAGCCTGTTTCTGCATCTGTGACAT

41303   CTCTGAGCCTGTTTCTGCATCTGTGACATAAGATGGTAAGATAAAGGTGGCTGTCTCACC
AATTATGTAAGGATTAAATGTGGAAAAGGACATAAAGTTGTATAGTGCTGCCATAGGGAC
AGTGTTCAGTAAACGTGACACATTCTTAGTATCACTAAGAATCAGGTTCTTGGCCAGGCA
CCGTGGCTCATGCCTGTAATCCCAACACTCTGGGAGGCCTAGGTCGGAGGATGGCTTGAA
CACAGGAGTTTGAGACCAGCCTGAGCAACATAGTGAGACACTGTCTCTACAAAAAAAAAA
[T,A]
AATAATAATAATTGTTTTTTAATTAGATGGGCAGGGCACTGTGGCTCACACCTGTAATCCC
AGCACTTTGGGAGGCCAAGGCCGGAGGATTGCTTGAGGCCAGGAGTTCAGGAGCAGCCTG
GGCCACATTCCTGTCTCTACAAAGAATAAAAAAGTTAACTGGGCATGGTGGCACATGCCT
GTAATCCCAGCTACTCAAGAGGCTGAGGAGGAGGATTGCCTGAGCCCAGGAGTTCAAGAC
TGCAGTGAGCCTTGATCACACCACTGTACTACAGCTTGGGCAACAGAGTGAGACCTTGTC

FIG.3-31

41305   CTGAGCCTGTTTCTGCATCTGTGACATAAGATGGTAAGATAAAGGTGGCTGTCTCACCAA
          TTATGTAAGGATTAAATGTGGAAAAGGACATAAAGTTGTATAGTGCTGCCATAGGGACAG
          TGTTCAGTAAACGTGACACATTCTTAGTATCACTAAGAATCAGGTTCTTGGCCAGGCACC
          GTGGCTCATGCCTGTAATCCCAACACTCTGGGAGGCCTAGGTCGGAGGATGGCTTGAACA
          CAGGAGTTTGAGACCAGCCTGAGCAACATAGTGAGACACTGTCTCTACAAAAAAAAAAATA
          [-.A]
          TAATAATAATTGTTTTTTAATTAGATGGGCAGGGCACTGTGGCTCACACCTGTAATCCCAG
          CACTTTGGGAGGCCAAGGCCGGAGGATTGCTTGAGGCCAGGAGTTCAGGAGCAGCCTGGG
          CCACATTCCTGTCTCTACAAAGAATAAAAAAGTTAACTGGGCATGGTGGCACATGCCTGT
          AATCCCAGCTACTCAAGAGGCTGAGGAGGAGGATTGCCTGAGCCCAGGAGTTCAAGACTG
          CAGTGAGCCTTGATCACACCACTGTACTACAGCTTGGGCAACAGAGTGAGACCTTGTCTC

41457   CTAAGAATCAGGTTCTTGGCCAGGCACCGTGGCTCATGCCTGTAATCCCAACACTCTGGG
          AGGCCTAGGTCGGAGGATGGCTTGAACACAGGAGTTTGAGACCAGCCTGAGCAACATAGT
          GAGACACTGTCTCTACAAAAAAAAAAATAATAATAATAATTGTTTTTTAATTAGATGGGCAG
          GGCACTGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGCCGGAGGATTGCT
          TGAGGCCAGGAGTTCAGGAGCAGCCTGGGCCACATTCCTGTCTCTACAAAGAATAAAAAA
          [G.C]
          TTAACTGGGCATGGTGGCACATGCCTGTAATCCCAGCTACTCAAGAGGCTGAGGAGGAGG
          ATTGCCTGAGCCCAGGAGTTCAAGACTGCAGTGAGCCTTGATCACACCACTGTACTACAG
          CTTGGGCAACAGAGTGAGACCTTGTCTCCAAAAAAAAAAAGTTTGTTTTTTTTTTATCCACT
          CTCCTCACCAAACAAACTGAGTAAGTTAGAGCCCTCTCAGCTGGCATGTGTTGGAAACAG
          TGCCCTCTCATTAAAGTGCTGCCCTCACTCCCATTGCCTCTTGGCCTTGGTCAGTATGAT

43168   AGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCTGGAAGGCGGAGGTCGCAGTG
          AGCCGAGATCGTGCCATTGCACTTCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAA
          TAATAATAATAACAATAACTAGCCGGGCCTGGTGGCACATGCCTGTAGTCCCAGTTACTC
          AGGAGGCGGAGGCATGAGACTCAGGTGAACTAGGGAGACAGAGGTTGCAGTGAGCCAAGA
          TCACACCACTGCACTCCAGCCTGGTTGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAAA
          [A.-.T]
          CCCATTTGCTCATTTTTTTGGATACTAGTATAACTATCACTCTAAACCAGTTAGTACTTAA
          ATCAAGCAGATATGGGAGATGGTGAATTACCATCTACAGTGTTGTCATATATGTCACATA
          CTGAGCATTATCAGCTAGTAGAATCTAGTTAATTGTTCTATGTGTGATGTATGCAGAGTT
          CCCATTTTGAATGTGTTTTTACTATGCTTAAATAAATGACTGATGTCAGCAACCCCAAAA
          TGATACATCTGATGTAAGAGCCCCTGTTCCCCAATAATAACATCTAAACTATAGACATTG

43357   AGGCATGAGACTCAGGTGAACTAGGGAGACAGAGGTTGCAGTGAGCCAAGATCACACCAC
          TGCACTCCAGCCTGGTTGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAAAATCCCATTTG
          CTCATTTTTTTGGATACTAGTATAACTATCACTCTAAACCAGTTAGTACTTAAATCAAGCA
          GATATGGGAGATGGTGAATTACCATCTACAGTGTTGTCATATATGTCACATACTGAGCAT
          TATCAGCTAGTAGAATCTAGTTAATTGTTCTATGTGTGATGTATGCAGAGTTCCCATTTT
          [T.G]
          AATGTGTTTTTACTATGCTTAAATAAATGACTGATGTCAGCAACCCCAAAATGATACATC
          TGATGTAAGAGCCCCTGTTCCCCAATAATAACATCTAAACTATAGACATTGGAATGAACA
          GGTGCCCCTAAGTTTCCTCCCTCCAGGGTTTCTTGGCCGGTCTCTGAGGACTACACATCC
          CTACTCCCGTCTTTCCTCATCTTCAGGCGCAGTAACAGTATCTCCAAGTCCCCTGGCCCC
          AGCTCCCCAAAGGAGCCCCTGCTGTTCAGCCGTGACATCAGCCGCTCAGAATCCCTTCGT

FIG.3-32

45664   CCAGCTTTCCTTGGCTTCCCCCACCCCCAGGTGAAAGTGATGCGCAGCCTGGACCACCCC
          AATGTGCTCAAGTTCATTGGTGTGCTGTACAAGGATAAGAAGCTGAACCTGCTGACAGAG
          TACATTGAGGGGGGGCACACTGAAGGACTTTCTGCGCAGTATGGTGAGCACACCACCCCAT
          AGTCTCCAGGAGCCTTGGTGGGTTGTCAGACACCTATGCTATCACTACCCTAGGAGCTTA
          AAGGGCAGAGGGGCCCTGCTTTGCCTCCAAAGGACCATGCTGGGTGGGACTGAGCATACA
          [T,C]
          AGGGAGGCTTCACTGGGAGACCACATTGACCCATGGGGCCTGGACCACGAGTGGGACAGG
          GCTCAACAGCCTCTGAAAATCATTCCCCATTCTGCAGGATCCGTTCCCCTGGCAGCAGAA
          GGTCAGGTTTGCCAAAGGAATCGCCTCCGGAATGGTGAGTCCCACCAACAAACCTGCCAG
          CAGGGCGAGAGTAGGGAGAGGTGTGAGAATTGTGGGCTTCACTGGAAGGTAGAGACCCCT
          TCCTATGCAACTTGTGTGGGCTGGGTCAGCAGCTATTCATTGAGTTTGTCTGTGTCACTG

47549   AATTAGCTGGGCGTGGTGGTGCACGCCTGTAGTCCCAGCTACTCAGGAGGCCGAGGCAGG
          AGAATAGCTTGAACCTGGGAGGCAGAAGTTGCAGTGAGCCAAGATCACACCACTGCATTC
          CAGCCTGGGTGACAGAGTGAGACTTCATCTCAAAAAAAAAAAAAAAAAGAGAGACTGATATG
          GTTAGTACATTGGGGTGGAATGCGGAGGGTCCAGGGAATGGAGCCCTGCATAGGGGGCTA
          ATGAAACATTTCAGATTTCTGAATTAAGGTAGTGGCTGTGGGGACAGGAGCCTGGGAGGC
          [A,C]
          GGGTGGAGTCAGAATGGAGAGACTGGTTGGCAATGAGGGAACAGGAGGAGGAGGAGGAGG
          AGTTACGAGTGGCTTGAGGTGTCACTTACCAGACATTTGGGGGATGGGGGATAGCCGTGA
          TTGTTGAGCAACTGGTTTGGGAAGAGCTAGCATTGATCCCTGCTGTTCTGTGCTAGCAGA
          ACCTATCAGCATCTTCTGGGCAGGAAACTGGCTCCATGAGACTGGCTTAGGGAGAGGCTG
          CTAGTCACCTAATCTGCAGAGAAGGGGCAGCTGGAGCTGTGGGACAGAAGAGGCATCCAT

47908   GGAGTTACGAGTGGCTTGAGGTGTCACTTACCAGACATTTGGGGGATGGGGGATAGCCGT
          GATTGTTGAGCAACTGGTTTGGGAAGAGCTAGCATTGATCCCTGCTGTTCTGTGCTAGCA
          GAACCTATCAGCATCTTCTGGGCAGGAAACTGGCTCCATGAGACTGGCTTAGGGAGAGGC
          TGCTAGTCACCTAATCTGCAGAGAAGGGGCAGCTGGAGCTGTGGGACAGAAGAGGCATCC
          ATGTAGCTGGTGGGGGGTGTCTCAGCTTGTGAAGAGGAGATGGCTTTGAGCAGGGCTGACA
          [C,A]
          TGAAAAGGCTGGAAGAAAAAAAACAGACACACAAGAGTCTCAGGATCAGGTAGCATAGGAA
          AGTTGTGGACAGTCTTTGAGGAGCACTCCCTCAGGCAGGCAGGCAGGCAGGTCATGAGCT
          ATAGCGATTCAGGAAGAGCTCCCTGGGTGTGTGAGCAGCTCCAGGAGCCTAAGGGATGAA
          AGTAGTATTGCAGGGGGCTGGAGAGCAAGGAGTGGCTCCTTCTACATTTGCAAGGGAAGG
          AGAAAGGAAGTTGCTCCTGAGAGTGGTAAGAGTCAGTGGTGGAGGCCTGGAGAGGAGACA

52267   TTGTGAGGGGTAGAGGAGAGGAGAGACAAGGGATGGTTAGGATAATGAAGGAATGTTTTG
          TTTTTGTTTTTGTTTTTGAGATGGAGTTTCACTCTGTCACCCAGGCTGGAGTGCAGAGGT
          GCAATCTTGGCTCACTGCAGCCTCCGCCTCCCAGGTTCAAGCAATCCTCCTGCCTCAGCC
          TCCCAAGTAGCTGGGACTACAGGTGTGCGCCACCACGCCTGGCTAATTTTTTGTATTTTCA
          GTAGAGACAGGGTTTCGCCATATTGGCCAGGCTGGTCTCAAATGCCTGACCTCAGGTGAT
          [C,A]
          CACCCGCTTCAGCCTCCCAAAGTGCTGAGATTACAGGCATGAGCTACCGTGCCTGGCCAT
          GAAGGAAGATTTGTTTTAAAAAATTGTTTTCTTTAATATTAATTGAACACCTCTGTTCAG
          AGCACTGGGCTGGTGCCAGAGGGTTTCAGACATGAATCAGATCCAGCACCTCATAGAGCC
          TTAATCTGGCACACACACACAGCCACAAGGAGACACAGACAAGGCAGGGTAGGATGAGTG
          GAAGCTAGGAGCAGATGCTGATTTGGAACACTTGGCTTCTGCAGTGAAGCCCCTTCTTAG

FIG.3-33

54654   GGCCCCGGCCCCGGCCCCCAGGCCAGGCAGTGGCGGCCAAGGACCACGCATCTACTTTCA
GAGCCCCCCCCGGGGCCGCAGGAGAGGGCCCGGGCTGGGCGGATGATGAGGGCCCAGTGA
GGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCACCTCAACC
TAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCCAGGAAGAGGAGATCT
CAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGCCTGGGCTT
[T,C]
CAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCTTCATCTCTGGCCT
GCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCCAGAAGAAGTGAGGGTCCCC
GACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCCGACCTCGTAGCAACAG
CAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCCTG
GCCCAGGGGGTCTCTTCCCCTGCCCCCTCAGTTTTCCACTTTTGGATTTTTTTTATTGTTAT

54679   GGCAGTGGCGGCCAAGGACCACGCATCTACTTTCAGAGCCCCCCCCGGGGCCGCAGGAGA
GGGCCCGGGCTGGGCGGATGATGAGGGCCCAGTGAGGCGCCAAGGGAAGGTCACCATCAA
GTATGACCCCAAGGAGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCT
CACGCGCCTCTACGACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGA
GCTCCTGGACATGGAGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGA
[C,G]
TGTTACAAACCCACAGAGGCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAG
AAGCTGAGCACACCCCAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCAT
AGGACAATCGCTACCCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAG
GCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCCTGGCCCAGGGGGTCTCTTCCCCTGCCCC
CTCAGTTTTCCACTTTTGGATTTTTTTTATTGTTATTAAACTGATGGGACTTTGTGTTTTT

54693   AGGACCACGCATCTACTTTCAGAGCCCCCCCCGGGGCCGCAGGAGAGGGCCCGGGCTGGG
CGGATGATGAGGGCCCAGTGAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGG
AGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACG
ACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGG
AGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCA
[A,C]
AGAGGCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACC
CCAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTAC
CCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGA
GCAGGGCTCCTCGTGCCCCTGGCCCAGGGGGTCTCTTCCCCTGCCCCCTCAGTTTTCCACT
TTTGGATTTTTTTTATTGTTATTAAACTGATGGGACTTTGTGTTTTTTATATTGACTCTGCG

54706   TACTTTCAGAGCCCCCCCCGGGGCCGCAGGAGAGGGCCCGGGCTGGGCGGATGATGAGGG
CCCAGTGAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCA
CCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCCAGGAAGA
GGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGC
CTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCTTCAT
[T,C]
TCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCCAGAAGAAGTGA
GGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCCGACCTCGT
AGCAACAGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCG
TGCCCCTGGCCCAGGGGGTCTCTTCCCCTGCCCCCTCAGTTTTCCACTTTTGGATTTTTTTT
ATTGTTATTAAACTGATGGGACTTTGTGTTTTTTATATTGACTCTGCGGCACGGGCCCTTT

FIG.3-34

54712   CAGAGCCCCCCCCGGGGGCCGCAGGAGAGGGCCCGGGCTGGGCGGATGATGAGGGCCCAGT
GAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCACCTCAA
CCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCCAGGAAGAGGAGAT
CTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGCCTGGGC
TTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCTTCATCTCTGG
[T,C]
CTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCCAGAAGAAGTGAGGGTCC
CCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCCGACCTCGTAGCAAC
AGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCC
TGGCCCAGGGGTCTCTTCCCCTGCCCCCTCAGTTTTCCACTTTTGGATTTTTTTTATTGTT
ATTAAACTGATGGGACTTTGTGTTTTTATATTGACTCTGCGGCACGGGCCCTTTAATAAA

54799   GTATGACCCCAAGGAGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCT
CACGCGCCTCTACGACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGA
GCTCCTGGACATGGAGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGA
CTGTTACAAACCCACAGAGGCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCA
GAAGCTGAGCACACCCCAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCA
[T,C]
AGGACAATCGCTACCCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAG
GCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCCTGGCCCAGGGGTCTCTTCCCCTGCCCC
CTCAGTTTTCCACTTTTGGATTTTTTTTATTGTTATTAAACTGATGGGACTTTGTGTTTTT
ATATTGACTCTGCGGCACGGGCCCTTTAATAAAGCGAGGTAGGGTACGCCTTTGGTGCAG
CTCAAAAAAAAAAAAAAAAAAATGATTTCCAGCGGTCCACATTAGAGTTGAAATTTTCTGGT

54819   GGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCC
AGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTG
ACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGG
CCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCCAGA
AGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCC
[G,A]
ACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGG
CTCCTCGTGCCCCTGGCCCAGGGGTCTCTTCCCCTGCCCCCTCAGTTTTCCACTTTTGGA
TTTTTTTATTGTTATTAAACTGATGGGACTTTGTGTTTTTATATTGACTCTGCGGCACGG
GCCCTTTAATAAAGCGAGGTAGGGTACGCCTTTGGTGCAGCTCAAAAAAAAAAAAAAAAAA
TGATTTCCAGCGGTCCACATTAGAGTTGAAATTTTCTGGTGGGAGAATCTATACCTTGTT

55499   TTGTTTTTCTAATACCTCTTGTCATTCTAAATATCTTTAATTTATTAAAAAATATATATAT
ACAGTATTGAATGCCTACTGTGTGCTAGGTACAGTTCTAAACACTTGGGTTACAGCAGCG
AACAAAATAAAGGTGCTTACCCTCATAGAACATAGATTCTAGCATGGTATCTACTGTATC
ATACAGTAGATACAATAAGTAAACTATATTGAATATTAGAATGTGGCAGATGCTATGGAA
AAAGAGTCAAGACAAGTAAAGACGATTGTTCAGGGTACCAGTTGCAATTTTAAATATGGT
[C,T]
GTCAGAGCAGGCCTCACTGAGGTGACATGACATTTAAGCATAAACATGGAGGAGGAGGAG
TAAGCCTGAGCTGTCTTAGGCTTCCGGGGCAGCCAAGCCATTTCCGTGGCACTAGGAGCC
TGGTGTTTCCGATTCCACCTTTGATAACTGCATTTTCTCTAAGATATGGGAGGGAAGTTT
TTCTCCTATTGTTTTTAAGTATTAACTCCAGCTAGTCCAGCCTTGTTATAGTGTTACCTA
ATCTTTATAGCAAATATATGAGGTACCGGTAACATTATGCCCATTTCTCACAGAGGCACT

FIG.3-35

56825   ACTGATGGCTCAAAGGGTGTGAAAAAGTCAGTGATGCTCCCCCTTTCTACTCCAGATCCT
GTCCTTCCTGGAGCAAGGTTGAGGGAGTAGGTTTTGAAGAGTCCCTTAATATGTGGTGGA
ACAGGCCAGGAGTTAGAGAAAGGGCTGGCTTCTGTTTACCTGCTCACTGGCTCTAGCCAG
CCCAGGGACCACATCAATGTGAGAGGAAGCCTCCACCTCATGTTTTTCAAACTTAATACTG
GAGACTGGCTGAGAACTTACGGACAACATCCTTTCTGTCTGAAACAAACAGTCACAAGCA
[C,A]
AGGAAGAGGCTGGGGGACTAGAAAGAGGCCCTGCCCTCTAGAAAGCTCAGATCTTGGCTT
CTGTTACTCATACTCGGGTGGGCTCCTTAGTCAGATGCCTAAAACATTTTTGCCTAAAGCT
CGATGGGTTCTGGAGGACAGTGTGGCTTGTCACAGGCCTAGAGTCTGAGGGAGGGGAGTG
GGAGTCTCAGCAATCTCTTGGTCTTGGCTTCATGGCAACCACTGCTCACCCTTCAACATG
CCTGGTTTAGGCAGCAGCTTGGGCTGGGAAGAGGTGGTGGCAGAGTCTCAAAGCTGAGAT

58871   CGTCACCCACCACCCAACCCCTGCCGCACTCCAGCCTTTAACAAGGGCTGTCTAGATATT
CATTTTAACTACCTCCACCTTGGAAACAATTGCTGAAGGGGAGAGGATTTGCAATGACCA
ACCACCTTGTTGGGACGCCTGCACACCTGTCTTTCCTGCTTCAACCTGAAAGATTCCTGA
TGATGATAATCTGGACACAGAAGCCGGGCACGGTGGCTCTAGCCTGTAATCTCAGCACTT
TGGGAGGCCTCAGCAGGTGGATCACCTGAGATCAAGAGTTTGAGAACAGCCTGACCAACA
[T,A]
GGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCAGGTGTGGTGGCACATACCTG
TAATCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCGCTTGAACCCACAAGGCAGAGGT
TGCAGTGAGGCGAGATCATGCCATTGCACTCCAGCCTGTGCAACAAGAGCCAAACTCCAT
CTCAAAAAAAAAAA

FIG.3-36

ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF

FIELD OF THE INVENTION

The present invention is in the field of kinase proteins that are related to the serine/threonine kinase subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect protein phosphorylation and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Protein Kinases

Kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Uncontrolled signaling has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and psoriasis. Reversible protein phosphorylation is the main strategy for controlling activities of eukaryotic cells. It is estimated that more than 1000 of the 10,000 proteins active in a typical mammalian cell are phosphorylated. The high energy phosphate, which drives activation, is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc), cell cycle checkpoints, and environmental or nutritional stresses and is roughly analogous to turning on a molecular switch. When the switch goes on, the appropriate protein kinase activates a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.

The kinases comprise the largest known protein group, a superfamily of enzymes with widely varied functions and specificities. They are usually named after their substrate, their regulatory molecules, or some aspect of a mutant phenotype. With regard to substrates, the protein kinases may be roughly divided into two groups; those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity and phosphorylate threonine and tyrosine residues. Almost all kinases contain a similar 250–300 amino acid catalytic domain. The N-terminal domain, which contains subdomains I–IV, generally folds into a two-lobed structure, which binds and orients the ATP (or GTP) donor molecule. The larger C terminal lobe, which contains subdomains VI A–XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Subdomain V spans the two lobes.

The kinases may be categorized into families by the different amino acid sequences (generally between 5 and 100 residues) located on either side of, or inserted into loops of, the kinase domain. These added amino acid sequences allow the regulation of each kinase as it recognizes and interacts with its target protein. The primary structure of the kinase domains is conserved and can be further subdivided into 11 subdomains. Each of the 11 subdomains contains specific residues and motifs or patterns of amino acids that

are characteristic of that subdomain and are highly conserved (Hardie, G. and Hanks, S. (1995) *The Protein Kinase Facts Books*, Vol I:7–20 Academic Press, San Diego, Calif.).

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic-ADPribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The cyclic-AMP dependent protein kinases (PKA) are important members of the STK family. Cyclic-AMP is an intracellular mediator of hormone action in all prokaryotic and animal cells that have been studied. Such hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cyclic-AMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K. J. et al. (1994) *Harrison's Principles of Internal Medicine*, McGraw-Hill, New York, N.Y., pp. 416–431, 1887).

Calcium-calmodulin (CaM) dependent protein kinases are also members of STK family. Calmodulin is a calcium receptor that mediates many calcium regulated processes by binding to target proteins in response to the binding of calcium. The principle target protein in these processes is CaM dependent protein kinases. CaM-kinases are involved in regulation of smooth muscle contraction (MLC kinase), glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM kinase I phosphorylates a variety of substrates including the neurotransmitter related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) *EMBO Journal* 14:3679–86). CaM II kinase also phosphorylates synapsin at different sites, and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. Many of the CaM kinases are activated by phosphorylation in addition to binding to CaM. The kinase may autophosphorylate itself, or be phosphorylated by another kinase as part of a "kinase cascade".

Another ligand-activated protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) *J. Biol Chem.* 15:8675–81). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

The mitogen-activated protein kinases (MAP) are also members of the STK family. MAP kinases also regulate intracellular signaling pathways. They mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S. E. and Weinberg, R. A. (1993) *Nature* 365:781–783). MAP kinase signaling

pathways are present in mammalian cells as well as in yeast. The extracellular stimuli that activate mammalian pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1).

PRK (proliferation-related kinase) is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaroytic cells (Li, B. et al. (1996) *J. Biol. Chem.* 271:19402–8). PRK is related to the polo (derived from humans polo gene) family of STKs implicated in cell division. PRK is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation. Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

The cyclin-dependent protein kinases (CDKs) are another group of STKs that control the progression of cells through the cell cycle. Cyclins are small regulatory proteins that act by binding to and activating CDKs that then trigger various phases of the cell cycle by phosphorylating and activating selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to the binding of cyclin, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue.

Protein tyrosine kinases, PTKs, specifically phosphorylate tyrosine residues on their target proteins and may be divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane protein-tyrosine kinases are receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor and other specific proteins. Growth factors (GF) associated with receptor PTKs include; epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Such receptors that function through non-receptor PTKs include those for cytokines, hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes.

Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells where their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Carbonneau H and Tonks NK (1992) *Annu. Rev. Cell. Biol.* 8:463–93). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

LIM Domain Kinases

The novel human protein, and encoding gene, provided by the present invention is related to the family of serine/threonine kinases in general, particularly LIM domain kinases (LIMK), and shows the highest degree of similarity to LIMK2, and the LIMK2b isoform (Genbank gi8051618) in particular (see the amino acid sequence alignment of the protein of the present invention against LIMK2b provided in

FIG. 2). LIMK proteins generally have serine/threonine kinase activity. The protein of the present invention may be a novel alternative splice form of the art-known protein provided in Genbank gi805161 ; however, the structure of the gene provided by the present invention is different from the art-known gene of gi8051618 and the first exon of the gene of the present invention is novel, suggesting a novel gene rather than an alternative splice form. Furthermore, the protein of the present invention lacks an LIM domain relative to gi8051618. The protein of the present invention does contain the kinase catalytic domain.

Approximately 40 LIM proteins, named for the LIM domains they contain, are known to exist in eukaryotes. LIM domains are conserved, cystein-rich structures that contain 2 zinc fingers that are thought to modulate protein-protein interactions. LIMK1 and LIMK2 are members of a LIM subfamily characterized by 2 N-terminal LIM domains and a C-terminal protein kinase domain. LIMK1 and LIMK2 mRNA expression varies greatly between different tissues. The protein kinase domains of LIMK1 and LIMK2 contain a unique sequence motif comprising Asp-Leu-Asn-Ser-His-Asn in subdomain VIB and a strongly basic insert between subdomains VII and VIII (Okano et al., *J. Biol. Chem.* 270 (52), 31321–31330 (1995)). The protein kinase domain present in LIMKs is significantly different than other kinase domains, sharing about 32% identity.

LIMK is activated by ROCK (a downstream effector of Rho) via phosphorylation. LIMK then phosphorylates cofilin, which inhibits its actin-depolymerizing activity, thereby leading to Rho-induced reorganization of the actin cytoskeleton (Maekawa et al., *Science* 285: 895–898, 1999).

The LIMK2a and LIMK2b alternative transcript forms are differentially expressed in a tissue-specific manner and are generated by variation in transcriptional initiation utilizing alternative promoters. LIMK2a contains 2 LIM domains, a PDZ domain (a domain that functions in protein-protein interactions targeting the protein to the submembranous compartment), and a kinase domain; whereas LIMK2b just has 1.5 LIM domains. Alteration of LIMK2a and LIMK2b regulation has been observed in some cancer cell lines (Osada et al., *Biochem. Biophys. Res. Commun.* 229: 582–589, 1996).

For a further review of LIMK proteins, see Nomoto et at, *Gene* 236 (2), 259–271 (1999).

Kinase proteins, particularly members of the serine/threonine kinase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of kinase proteins. The present invention advances the state of the art by providing previously unidentified human kinase proteins that have homology to members of the serine/threonine kinase subfamily.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human kinase peptides and proteins that are related to the serine/threonine kinase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity in cells and tissues that express the kinase. Experimental data as provided in FIG. 1

5

indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

DESCRIPTION OF THE FIGURE SHEETS

FIG. 1 provides the nucleotide sequence of a cDNA molecule that encodes the kinase protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

FIG. 2 provides the predicted amino acid sequence of the kinase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIG. 3 provides genomic sequences that span the gene encoding the kinase protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in FIG. 3, SNPs were identified at 42 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a kinase protein or part of a kinase protein and are related to the serine/ threonine kinase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human kinase peptides and proteins that are related to the serine/threonine kinase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these kinase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the kinase of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known kinase proteins of the serine/threonine kinase subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The art has clearly established the commercial importance of

6

members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known serine/threonine kinase family or subfamily of kinase proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the kinase family of proteins and are related to the serine/threonine kinase subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the kinase peptides of the present invention, kinase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the kinase peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the kinase peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated kinase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as

7
8

provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. For example, a nucleic acid molecule encoding the kinase peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the kinase peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The kinase peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a kinase peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the kinase peptide. "Operatively linked" indicates that the kinase peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the kinase peptide.

In some uses, the fusion protein does not affect the activity of the kinase peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant kinase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A kinase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the kinase peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the kinase peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A. M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D. W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part* 1, Griffin, A. M., and Griffin, H. G.,

eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444–453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., *Nucleic Acids Res.* 12(1):387 (1984)) (available at http://www.gcg.com), using a NWS-gapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11–17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (*J. Mol. Biol.* 215:403–10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (*Nucleic Acids Res.* 25(17):3389–3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the kinase peptides of the present invention as well as being encoded by the same genetic locus as the kinase peptide provided herein. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a kinase peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by the same genetic locus as the kinase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of

the proteins) have significant homology when the amino acid sequences are typically at least about 70–80%, 80–90%, and more typically at least about 90–95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Paralogs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the kinase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the kinase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a kinase peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., *Science* 247:1306–1310 (1990).

Variant kinase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., *Science* 244:1081–1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as kinase activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., *J. Mol. Biol.* 224:899–904 (1992); de Vos et al. *Science* 255:306–312 (1992)).

The present invention further provides fragments of the kinase peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a kinase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the kinase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the kinase peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in kinase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pro-

teolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins—Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York 1–12 (1983); Seifter et al. (*Meth. Enzymol.* 182: 626–646 (1990)) and Rattan et al. (*Ann. N.Y. Acad. Sci.* 663:48–62 (1992)).

Accordingly, the kinase peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature kinase peptide is fused with another compound, such as a compound to increase the half-life of the kinase peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature kinase peptide, such as a leader or secretory sequence or a sequence for purification of the mature kinase peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a kinase-effector protein interaction or kinase-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, kinases isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant

brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. A large percentage of pharmaceutical agents are being developed that modulate the activity of kinase proteins, particularly members of the serine/threonine kinase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to kinases that are related to members of the serine/threonine kinase subfamily. Such assays involve any of the known kinase functions or activities or properties useful for diagnosis and treatment of kinase-related conditions that are specific for the subfamily of kinases that the one of the present invention belongs to, particularly in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

The proteins of the present invention are also usefull in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the kinase, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the kinase protein.

The polypeptides can be used to identify compounds that modulate kinase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the kinase. Both the kinases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the kinase. These compounds can be further screened against a functional kinase to determine the effect of the compound on the kinase activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the kinase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the kinase protein and a molecule that normally interacts with the kinase protein, e.g. a substrate or a component of the signal pathway that the kinase protein normally interacts (for example, another kinase). Such assays typically include the steps of combining the kinase protein with a candidate compound under conditions that allow the kinase protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the kinase protein and the target, such as any of the associated effects of signal

transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82–84 (1991); Houghten et al., Nature 354:84–86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767–778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')$_2$, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant kinases or appropriate fragments containing mutations that affect kinase function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) kinase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate kinase activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the kinase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the kinase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the kinase can be assayed. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

Binding and/or activating compounds can also be screened by using chimeric kinase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate then that which is recognized by the native kinase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the kinase is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the kinase (e.g. binding part-

ners and/or ligands). Thus, a compound is exposed to a kinase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble kinase polypeptide is also added to the mixture. If the test compound interacts with the soluble kinase polypeptide, it decreases the amount of complex formed or activity from the kinase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the kinase. Thus, the soluble polypeptide that competes with the target kinase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the kinase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ^{35}S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of kinase-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a kinase-binding protein and a candidate compound are incubated in the kinase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the kinase protein target molecule, or which are reactive with kinase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the kinases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of kinase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating cells or tissues that express the kinase. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. These methods of treatment include the steps of administering a modulator of

kinase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the kinase proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) *Cell* 72:223–232; Madura et al. (1993) *J. Biol. Chem.* 268:12046–12054; Bartel et al. (1993) *Biotechniques* 14:920–924; Iwabuchi et al. (1993) *Oncogene* 8:1693/1696; and Brent WO94110300), to identify other proteins, which bind to or interact with the kinase and are involved in kinase activity. Such kinase-binding proteins are also likely to be involved in the propagation of signals by the kinase proteins or kinase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such kinase-binding proteins are likely to be kinase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a kinase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a kinase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the kinase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a kinase-modulating agent, an antisense kinase nucleic acid molecule, a kinase-specific antibody, or a kinase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The kinase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The method involves contacting a biological sample with a compound capable of interacting with the kinase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A bio-

logical sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered kinase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10–11):983–985 (1996)), and Linder, M. W. (*Clin. Chem.* 43(2):254–266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the kinase protein in which one or more of the kinase functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are

more or less active in substrate binding, and kinase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Accordingly, methods for treatment include the use of the kinase protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')$_2$, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the kinase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or kinase/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody

to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I, ^{131}I, ^{35}S or ^{3}H.

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Further, such antibodies can be used to detect protein in situ, in vitro, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the kinase peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nuleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a kinase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the kinase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by

recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of

a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the kinase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (antisense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the kinase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in FIG. 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60–70%, 70–80%, 80–90%, and more typically at least about 90–95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60–70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1–6.3.6. One example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 50–65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. As illustrated in FIG. 3, SNPs were identified at 42 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in kinase protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA includes Southern hybridizations and in situ hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a kinase protein, such as by measuring a level of a kinase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a kinase gene has been mutated. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by

virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate kinase nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the kinase gene, particularly biological and pathological processes that are mediated by the kinase in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The method typically includes assaying the ability of the compound to modulate the expression of the kinase nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired kinase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the kinase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for kinase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the kinase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of kinase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of kinase mRNA in the presence of the candidate compound is compared to the level of expression of kinase mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate kinase nucleic acid expression in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for kinase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the kinase nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the kinase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in kinase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in kinase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the kinase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the kinase gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a kinase protein.

Individuals carrying mutations in the kinase gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., Science 241:1077–1080 (1988); and Nakazawa et al., PNAS 91:360–364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., Nucleic Acids Res. 23:675–682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal

genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a kinase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant kinase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., *Adv. Chromatogr.* 36:127–162 (1996); and Griffin et al., *Appl. Biochem. Biotechnol.* 38:147–159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers etal., *Science* 230:1242 (1985)); Cotton et al., *PNAS* 85:4397 (1988); Saleeba et al., *Meth. Enzymol.* 21 7:286–295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., *PNAS* 86:2766 (1989); Cotton et al., *Mutat. Res.* 285:125–144 (1993); and Hayashi et al., *Genet. Anal. Tech. Appl.* 9:73–79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the kinase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control kinase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of kinase protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into kinase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of kinase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired kinase nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the kinase protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in kinase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired kinase protein to treat the individual.

The invention also encompasses kits for detecting the presence of a kinase nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting kinase nucleic acid in a biological sample; means for determining the amount of kinase nucleic acid in the sample; and means for comparing the amount of kinase nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect kinase protein nRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; *Nat. Biotech.* 14: 1675–1680) and Schena, M. et al. (1996; *Proc. Natl. Acad. Sci.* 93: 10614–10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6–60 nucleotides in length, more preferably 15–30 nucleotides in length, and most preferably about 20–25 nucleotides in length. For a certain type of microarray or detection kit, it may be

preferable to use oligonucleotides that are only 7–20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the kinase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the kinase gene of the present invention. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., *Techniques in Immunocytochemistry*, Academic Press, Orlando, Fla. Vol. 1 (1 982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified kinase gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host Cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extra-chromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia

viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, Streptomyces, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as Drosophila, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., *Gene* 67:31–40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., *Gene* 69:301–315 (1988)) and pET 11 d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185:60–89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 119–128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada et al., *Nucleic Acids Res*. 20:2111–2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, et al., *EMBO J*. 6:229–234 (1987)), pMFa (Kurjan et al., *Cell* 30:933–943(1982)), pJRY88 (Schultz et al., *Gene* 54:113–123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., *Mol. Cell Biol.* 3:2156–2165 (1983)) and the pVL series (Lucklow et al., *Virology* 170:31–39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman et al., *EMBO J.* 6:187–195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual.* 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual.* 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the

recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as kinases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with kinases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of Vectors and Host Cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a kinase protein or peptide that can be further purified to produce desired amounts of kinase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the kinase protein or kinase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native kinase protein is useful for assaying compounds that stimulate or inhibit kinase protein function.

Host cells are also useful for identifying kinase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant kinase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native kinase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for

studying the function of a kinase protein and identifying and evaluating modulators of kinase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the kinase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence (s) can be operably linked to the transgene to direct expression of the kinase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al, U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. *PNAS* 89:6232–6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman et al. *Science* 251:1351–1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recom-

binase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. *Nature* 385:810–813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G_o phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect substrate binding, kinase protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo kinase protein function, including substrate interaction, the effect of specific mutant kinase proteins on kinase protein function and substrate interaction, and the effect of chimeric kinase proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more kinase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1
<211> LENGTH: 2320
<212> TYPE: DNA
<213> ORGANISM: Human

<400> SEQUENCE: 1

```
cccagggcgc cgtaggcggt gcatcccgtt cgcgcctggg gctgtggtct tcccgcgcct      60

gaggcggcgg cggcaggagc tgaggggagt tgtagggaac tgaggggagc tgctgtgtcc     120

cccgcctcct cctccccatt tccgcgctcc cgggaccatg tccgcgctgg cgggtgaaga     180

tgtctggagg tgtccaggct gtggggacca cattgctcca agccagatat ggtacaggac     240
```

-continued

```
tgtcaacgaa acctggcacg gctcttgctt ccggtgaaag tgatgcgcag cctggaccac    300

cccaatgtgc tcaagttcat tggtgtgctg tacaaggata agaagctgaa cctgctgaca    360

gagtacattg aggggggcac actgaaggac tttctgcgca gtatggatcc gttcccctgg    420

cagcagaagg tcaggtttgc caaaggaatc gcctccggaa tggacaagac tgtggtggtg    480

gcagactttg ggctgtcacg gctcatagtg aagagagga aaagggcccc catggagaag    540

gccaccacca agaaacgcac cttgcgcaag aacgaccgca agaagcgcta cacggtggtg    600

ggaaaccct actggatggc ccctgagatg ctgaacggaa agagctatga tgagacggtg    660

gatatcttct cctttgggat cgttctctgt gagatcattg gcaggtgta tgcagatcct    720

gactgccttc cccgaacact ggactttggc ctcaacgtga agcttttctg ggagaagttt    780

gttcccacag attgtcccc ggccttcttc ccgctggccg ccatctgctg cagactggag    840

cctgagagca gaccagcatt ctcgaaattg gaggactcct ttgaggccct ctccctgtac    900

ctgggggagc tgggcatccc gctgcctgca gagctggagg agttggacca cactgtgagc    960

atgcagtacg gcctgacccg ggactcacct ccctagcccc ggcccagccc cctgcagggg    1020

ggtgttctac agccagcatt gcccctctgt gccccattcc tgctgtgagc agggccgtcc    1080

gggcttcctg tggattggcg gaatgtttag aagcagaaca aaccattcct attacctccc    1140

caggaggcaa gtgggcgcag caccagggaa atgtatctcc acaggttctg gggcctagtt    1200

actgtctgta aatccaatac ttgcctgaaa gctgtgaaga agaaaaaaac ccctggcctt    1260

tgggccagga ggaatctgtt actcgaatcc acccaggaac tccctggcag tggattgtgg    1320

gaggctcttg cttacactaa tcagcgtgac ctggacctgc tgggcaggat cccagggtga    1380

acctgcctgt gaactctgaa gtcactagtc cagctgggtg caggaggact tcaagtgtgt    1440

ggacgaaaga aagactgatg gctcaaaggg tgtgaaaaag tcagtgatgc tcccccttc    1500

tactccagat cctgtccttc ctggagcaag gttgagggag taggttttga agagtccct    1560

aatatgtggt ggaacaggcc aggagttaga gaaagggctg gcttctgttt acctgctcac    1620

tggctctagc cagcccaggg accacatcaa tgtgagagga agcctccacc tcatgttttc    1680

aaacttaata ctggagactg gctgagaact tacggacaac atcctttctg tctgaaacaa    1740

acagtcacaa gcacaggaag aggctggggg actagaaaga ggccctgccc tctagaaagc    1800

tcagatcttg gcttctgtta ctcatactcg ggtgggctcc ttagtcagat gcctaaaaca    1860

ttttgcctaa agctcgatgg gttctggagg acagtgtggc ttgtcacagg cctagagtct    1920

gagggagggg agtgggagtc tcagcaatct cttggtcttg gcttcatggc aaccactgct    1980

caccctcaa catgcctggt ttaggcagca gcttgggctg ggaagaggtg gtggcagagt    2040

ctcaaagctg agatgctgag agagatagct ccctgagctg ggccatctga cttctacctc    2100

ccatgtttgc tctcccaact cattagctcc tgggcagcat cctcctgagc cacatgtgca    2160

ggtactggaa aacctccatc ttggctccca gagctctagg aactcttcat cacaactaga    2220

tttgcctctt ctaagtgtct atgagcttgc accatattta ataaattggg aatgggtttg    2280

gggtattaaa aaaaaaaaa aaaaaaaaaa aaaaaaaaa                            2320
```

<210> SEQ ID NO 2
<211> LENGTH: 255
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 2

Met Val Gln Asp Cys Gln Arg Asn Leu Ala Arg Leu Leu Leu Pro Val

-continued

```
  1                 5                    10                       15

Lys Val Met Arg Ser Leu Asp His Pro Asn Val Leu Lys Phe Ile Gly
            20                    25                    30

Val Leu Tyr Lys Asp Lys Lys Leu Asn Leu Leu Thr Glu Tyr Ile Glu
            35                    40                    45

Gly Gly Thr Leu Lys Asp Phe Leu Arg Ser Met Asp Pro Phe Pro Trp
    50                    55                    60

Gln Gln Lys Val Arg Phe Ala Lys Gly Ile Ala Ser Gly Met Asp Lys
65                    70                    75                    80

Thr Val Val Val Ala Asp Phe Gly Leu Ser Arg Leu Ile Val Glu Glu
                85                    90                    95

Arg Lys Arg Ala Pro Met Glu Lys Ala Thr Thr Lys Lys Arg Thr Leu
            100                   105                   110

Arg Lys Asn Asp Arg Lys Lys Arg Tyr Thr Val Val Gly Asn Pro Tyr
            115                   120                   125

Trp Met Ala Pro Glu Met Leu Asn Gly Lys Ser Tyr Asp Glu Thr Val
    130                   135                   140

Asp Ile Phe Ser Phe Gly Ile Val Leu Cys Glu Ile Ile Gly Gln Val
145                   150                   155                   160

Tyr Ala Asp Pro Asp Cys Leu Pro Arg Thr Leu Asp Phe Gly Leu Asn
            165                   170                   175

Val Lys Leu Phe Trp Glu Lys Phe Val Pro Thr Asp Cys Pro Pro Ala
            180                   185                   190

Phe Phe Pro Leu Ala Ala Ile Cys Cys Arg Leu Glu Pro Glu Ser Arg
            195                   200                   205

Pro Ala Phe Ser Lys Leu Glu Asp Ser Phe Glu Ala Leu Ser Leu Tyr
    210                   215                   220

Leu Gly Glu Leu Gly Ile Pro Leu Pro Ala Glu Leu Glu Glu Leu Asp
225                   230                   235                   240

His Thr Val Ser Met Gln Tyr Gly Leu Thr Arg Asp Ser Pro Pro
                245                   250                   255
```

<210> SEQ ID NO 3
<211> LENGTH: 59065
<212> TYPE: DNA
<213> ORGANISM: Human

<400> SEQUENCE: 3

```
tcatccttgc gcaggggcca tgctaacctt ctgtgtctca gtccaatttt aatgtatgtg      60

ctgctgaagc gagagtacca gaggtttttt tgatggcagt gacttgaact tatttaaaag     120

ataaggagga gccagtgagg gagagggtg ctgtaaagat aactaaaagt gcacttcttc      180

taagaagtaa gatggaatgg gatccagaac aggggtgtca taccgagtag cccagccttt     240

gttccgtgga cactggggag tctaacccag agctgagata gcttgcagtg tggatgagcc     300

agctgagtac agcagatagg gaaaagaagc caaaaatctg aagtagggct ggggtgaagg     360

acagggaagg gctagagaga catttggaaa gtgaaaccag gtggatatga gaggagagag     420

tagagggtct tgatttcggg tctttcatgc ttaacccaaa gcaggtacta aagtatgtgt     480

tgattgaatg tctttggggtt tctcaagact ggagaaagca gggcaagctc tggagggtat     540

ggcaataaca agttatcttg aatatcctca tggtggaaag tcctgatcct gtttgaattt     600

tggaaataga aatcattcag agccaagaga ttgaattgtt gagtaagtgg gtggtcaggt     660

tacagactta attttggggtt aaaaagtaaa aacaagaaac aaggtgtggc tctaaaataa     720
```

-continued

tgagatgtgc	tgggggtggg	gcatggcagc	tcataaactg	accctgaaag ctcttacatg	780
taagagttcc	aaaaatattt	ccaaaacttg	gaagattcat	ttggatgttt gtgttcatta	840
aaatctctca	ctaattcatt	gtcttgtcca	ctgtccgtaa	cccaacctgg gattggtttg	900
agtgagtctc	tcagactttc	tgccttggag	tttgtgagag	agatggcata ctctgtgacc	960
actgtcaccc	taaaaccaaa	aaggcccctc	ttgacaagga	gtctgaggat tttagaccca	1020
ggaagaatga	gtgatgggca	tatatatatc	ctattactga	ggcatgagaa gagtggaatg	1080
ggtgggttga	ggtggtgttt	taaggcctct	tgccagcttg	tttaactctt ctctggggaa	1140
cgaggggggac	aactgtgtac	attggctgct	ccagaatgat	gttgagcaat cttgaagtgc	1200
caggagctgt	gctttgtcta	ttcatggccc	ctgtgcctgt	gaaacagggt tcggtgactg	1260
tcactgtgcc	tgtggcagtc	tgtagttacc	cagagagaac	aaagctgcat acacagagcg	1320
cacaagggag	tcttgtaaca	accttgtcct	gctttctagg	gctgagtcag gtaccacagc	1380
ttgatctcag	ctgtcctctt	tatttcaaga	agttgacatc	tgagccatac caggagtatt	1440
gtattttgtt	tgaggcctct	ctttttggag	gaacatggac	cgactctgtg cttttgtcta	1500
tgctggtctc	tgagctcaca	caacccttca	ccctcctttc	tcagccagtg ataggtaagt	1560
cttccctatc	ttgcaaggct	cagctcaagt	gtcagcttcc	tctacaaaga ctttcctggt	1620
tcccctcatt	ggagtgaaca	agagttgaca	tggtagaatg	gaaagagcag aagctttaga	1680
atgagccaga	cctgagtatg	aatgctagat	ccaccactta	gctagtcaac cctgcccct	1740
gcctcaagtt	ttaattttcc	tatccattaa	gtgaatataa	taatacctgt gtcacaggat	1800
tattttgaga	attaaatgag	attaggtcta	tgaaagcacc	tagcagagtt cttggcatat	1860
aggaggcatt	cattaaatat	ttgttcttcc	cctttttatac	ccattacttt tcttttttctg	1920
aactaaaata	atacttggtt	ctatctctga	aataacatcc	aagtgaaaaa tcaacaacat	1980
gaaagagcag	ttcttttcca	gtggatttgc	ttcttaagga	gcagagatta tgtaatctaa	2040
cagcctccaa	catacaaaga	gctttgtatc	tagaacaggg	gtccccagcc cctggaccgc	2100
caactggtac	gggtctgtag	cctgttagga	accaggctgc	acagcaggag gtgagcggcg	2160
ggccagtgag	cattgctgcc	tgagctctgc	ctcctgtcag	atcagtggtg gcattagatt	2220
ctcataggag	tgtgaaccct	attgtgaact	gcacatgcaa	gggatctggg ttgcatgctc	2280
cttatgagaa	tctcactaat	ggctgatgat	ctgagttgga	acagtttgat accaaaacca	2340
tcccccccgcc	ccccaacccc	cagcctaggg	tccgtggaaa	aattggcccc tggtgccaaa	2400
aaggttgagg	actgctgatc	tagaggacca	atttattcaa	tgttggttga gtaaatgagc	2460
tcttggatta	ggtgatggaa	aaatctgaaa	aaacagggct	tttgaggaat aggaaaaggc	2520
agtaacatgt	ttaacccaga	gagaagtttc	tggctgttgg	ctgggaatag tcataggaag	2580
ggctgacact	gaaaagaagg	agattgtgtt	cgtttcttct	tctcagagct ataagcaaag	2640
gctgaaagtt	ctagaaaaag	gcaagttttg	tttcagtaga	aaaaaggata atcagaacca	2700
ttttttagaaa	atggaatgag	actacttttg	aggccatgag	ttccttgtcc ctggagagat	2760
gagcagaggt	tggacaagtg	cttaccagag	atcttgtgga	ggcagaaact gtgcatctag	2820
cagagcattg	gcctaaccct	ttcaaatgag	atgctgttaa	ctcagtctta ttctacatgg	2880
taggaatcct	gtccctttgc	ctcctgctac	tttgggcctc	tcaacctctt ggttttgtgt	2940
gcaggtgaag	atgtctggag	gtgtccaggc	tgtggggacc	acattgctcc aagccagata	3000
tggtacagga	ctgtcaacga	aacctggcac	ggctcttgct	tccggtaggt gggcctatcc	3060
tcccatcttt	accagtgtac	tatgggccaa	gcactatttc	atgttctgat ggaaaacaca	3120

-continued

```
gaaacaagct tctgagttga gaatttcaat cttagggtgg ggaaaggaat gtaccaagga    3180

agagctcatg accaaacctc aagtgtggcc cccctgaacc caggttaaat tggaagagcc    3240

ataaatgggc cagctggagg cagggtgggg ggatgagagg agcccttcc agggttgtcc     3300

catatccctc actttatggg tgaggaaact gaggcccagg aagagtgact ttcctgtggc    3360

tgcactacag attatgcagg tacttcaaga gttgtttgta ttcttatttt attttatttt    3420

attttatttt attttatttt attttatgag agggattctt gctgttgccc aggctggagt    3480

gcagtggtgc aatctcggct cactgcaatc tctgcctgct gggttcaagt gattttctg     3540

ccttagcttc ctgagtagct gagatgacag gcacctgcca ccatgcgcag ctaattttg     3600

tattttagtg gagacggggg tttcaacatg ttggtcaggc tggtcttgaa ctcctgacct    3660

caaatgatgc acccacctcg acctcccaaa gtgctggaat tacaggcgtg aaccactgtg    3720

cccagccaag agttgttttt agtgtggttg gcagagccag ctcttccttc accacaggat    3780

gcctccctag gttcctactt tttgttacta gctttttatta tagctatatt attattatta   3840

ttattattat tattattatt attattgaga cagagtctcg ctctgtcgcc caggctggtg   3900

tacagtggtg cgatcccggg ctcactgcaa cctctgcctc ccgagttcaa gcagttctcc    3960

tgcctcagcc ccccgagtag gtgggactac aggcgcctgc caccacaccc ggctaatttt    4020

tgtattttta gtagagacgg ggtttcacct tgttgaccag gctggtctg agctcctgac     4080

ctcaggtaag tgctagaatc acaggcgtga accactgcgc ccagccaaga gttgttttta    4140

gtgtggttgg cagagccagc tcttcctcac cacaggttgc ctccctaggt tcctactttt    4200

tgttactagc tttattatag ctacattatt attattattg ttattattat tgagacagag   4260

tctcgctctg tcgcccaggc tggtgtacag tgatgtgatc ttggctcact gcaacctctg    4320

ccccccgagt tcaagcaatt ctcctgcttc agccccccta gtaggtggga ctccaggcac    4380

ctgccaccac gcccagctaa tttttgtatt tttagtagag gcggggtttc accttgttgg    4440

ccaggctggt ctcaaactcc tgacctcagg tgatccgcct gcctcggcct cccaaaatgt    4500

tgggattaca ggcatgagcc accgcgccct gcctatagct acattatttt tgtaggcagc    4560

tcagtttctt aaaaattata cagacttcaa atcagatttg ttcctgctgt ctgaggctca    4620

gtttcttcat ctggaaaatg gatggtaata atcttgttga gattgaatga aataatatat    4680

gcagtgtatc cagtacatgg tagacacca gtgaatggtt attccttcct cccatcggat     4740

tggaattctc aagggtggga acttgtcttt atattcttca caacgtaaaa tagttgaaat    4800

ttgttggtgg aaagaagagc agtccactcc agaggctgga tgggcatgcc tggcccccaa    4860

ggtctgaagt ggtagggctg tgcctatatc ctgagaatga gatagactag gcaggcacct    4920

tgtgctgtag attccagctc ctgcacatag ctcttgttgt aaaacatccc tgtgcttata    4980

ccaagtaatt gagttgacct ttaaacactt gcctcttccc tgggaaccat atagggatt     5040

ggcctggaga cgtctggcct ctggaagagt tggaaagcag ccatcattat tatcctttcc    5100

tttcagctat aactcagagc tctcaagtct tttctgtgga tcttattgcc ttggttcttg    5160

cccctttac tcccagggaa gttgattctg tcttttctgt tccatttagt atgacaggag     5220

cagagaatgt cagagctgta agggacctta tagttaaagc ctttggctgg tcctttcatt    5280

ttatagctgg gactaataag taacgtcaaa acccaatgag ttcacagatt gggtctcgcc    5340

ttggcatgta acccatatgt tcatattctt gctgtttcc tatgtgtatg aatattttct     5400

atccaaaata agcaggacag ggtagagcaa gttaatcttt ggaatttctg gattctctta    5460
```

-continued

```
gagctaaaaa acttcagaac tagaagaaac cacccactat atggtataac ccattcatat   5520

cacagatgag gcctgaaacc aaaaagactt gctcaggcca tggatgacaa gagctggccc   5580

tagcactgaa ctcttgggtc atttgtaggt ctagtcagat gctagcttgt tagctctgtg   5640

cgtgcgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgagat agagacagaa agataaacata   5700

tgtacacaaa tacataaaga ggaagtagac acgttagcat ggtagataag agtacaggca   5760

ggccaggcgt ggtggctcac gcctgtaatc ccagcacttt gggaggccaa ggcaggtgga   5820

tcacctgagg tcaggaattc gagaccagcc tgaccaacat ggtgaaaccc catctctact   5880

aaatacagaa aaaaattagc ttggcatggt ggcacatgcc tgtaatccca gctacttggg   5940

aagctgaagc aggagaatcg cttgaatccg ggaagcagaa gttgcagtga ccgagattg    6000

tgccattaca gtctagcctg ggcaacaaga gggaaactcc atcgcaaaaa aacaaccacc   6060

accaagagta caggctatgg aatgagacta tggttttaaa tcctggcttt gcaatttatt   6120

aactagcctt aagtgacttc cctgagcttc aggcaccaat ctgtaaaatg aggataagaa`  6180

tattactcat gccacatggt tgttagggag gattaaatgt gataacctat ataaagtggc   6240

tagcatagca tctgacatat agaaaactct taatagggcc ggacgtggtg gcttatgcct   6300

gtaatcctag cactctggga ggccgaggca gaaggatcgc ttgagcccat gagcccagga   6360

gtttgagacc agcctggcca acatggcaaa actccacctc tacaaaaaat acaaaaatat   6420

tagccaggcg tgatggcaca cacctgtagt cccagctact tgggaagctg aggagcgatg   6480

attacctgag cccagggata tcaaggctgt agtgagctgt gatcatgcca ctgtactcca   6540

tccagctggg ggacagagtg aaacccctgt ctcaaaacaa aacaaatgaa aaaaaaaacc   6600

cttaataatc agtaactgtc actttatatt atgttgtgag tgtgtgtcta tatacaccta   6660

tatgtataca tttctcttat tacacattca ttggtgatct gatgtggagc cccagggatt   6720

aagggcaact ttgaactacc ctgacacaat caagccaaat atcattcccg tggaggaagt   6780

agagtatcta ggttctgtct cctagttgca gctttacctt gaggacagag actctaatcc   6840

agctgtgctg aaggagcaca tctcctgact tctgagcttt cccctggtaa attcaaactg   6900

gatgtcacgg cgccctcaga tagagcctgg taatttgccc tggggagagt gactgtcttt   6960

tggatctaat ttgacttttg ccccagttgg aggaaaatct tcagggctag gaaggattgt   7020

atttgtctga ccccagagat aacctgggtt ttgaggaaca tggggcatca acctgaatgg   7080

tcttgtaaga tctctcccac gccagcttgc cagtgtttct ctgatgaatt tagagtacct   7140

gagtagtgca ggcctgctgg gaggaggact ctccctctgt gctactcaga gaaattcatt   7200

cttcaaggcc cccttccagc cttgctctta cccagctggg ctacagttac aataaaggaa   7260

atgacttttc ttctcccctt cccccagtac ctttgttttc ctagtcacag ggtggggctg   7320

gatattgaat ggagaaattg ctggggtcca tcctaaactc ctccctcat ctctccctta    7380

cattaccca ttcttctgtc tgcagccaca tccataatcc tgcctctgtt agccttccga    7440

cagaccctca ggtgcccagg acaacaggaa gctacttaaa gctggaacct cagactgtgc   7500

aatggaggcc agtgacaaaa ctgaaagtag ctctgtcagt aattgtgctg gtgcgattag   7560

gcagctggcc agaatctttt ggatctcctg acatatggc tgactagtcc tcccaagcct    7620

tcccaacagg cctctttttt ttcctttttt tcttttcttt tttttcttttc tttctttctt   7680

tctttttttt tttttttttag gctagtgaag tgaaattgtg ggagtggaaa aggaacaaag   7740

aaatcggtaa ctggtagtga tcaattactt gtaaacacta ttgtacttgg accagcccag   7800

taggcctttt ttaaaactct gagttacctc tctttccttt ccttgagcag tgccattaat   7860
```

-continued

```
tctgtatctg gggcaatcct ttctgatgtt ctctggacct ggctctctct ccttaggaga     7920

ggccaggaga gtagccagag agcatgtcat ttgtagctga ggttaaagtg tggagctatc     7980

aatggtgacc tggcctcttg gcatgttagc aagccagagg accttgacaa cttttttgat     8040

gattgtccgt tcaccctgat caaaggtgtt tggcttagga ggagggaaga aaagctaccc     8100

ctattagtct tgatggcccc agcgtgggtc tctattgctt gacctggttc ctagcagcat     8160

tatcagaagg aaaatccacc gctcttaagg ctcctgggaa ctttcaggac ttcctttctc     8220

aggattgcaa acataagact atttgagctt tcacttttga aaagcggtta ctaataccta     8280

tactctggga aagggctaat gcagatagaa gactgtggtc actgcatcag gcaacagacc     8340

atttccgcta aatttagtga ctccaggaag gccagtgaag aaataacaca cgtagcaacc     8400

agagactgtg ttgtaatatg ttggctgaca gcagggtact ttctgtgatg ctgaaagcca     8460

cattcatttt ctctcccctc atccccatct aagcaagcct ggtagaatca taattacagt     8520

aataggtacc acttattgag tactctgtgc cagacaccct cctgagcata cgacatgcat     8580

agcacattta atccttacaa tgacttaata aaatgtagta ctagtcttac ctacttcgag     8640

aatagggaaa tggaggttac ttgtttaaag tcacagagct aataggtagc atagctgaga     8700

tttgaactca ggcattctta ctccttgcct gcaagagtct cttggcattc ttgaatgcaa     8760

gcatatttct taacctcact gaggctcagt ttcctcttat ataatatggg gtaaagagcc     8820

ctcaccctgc ctgccacaca ctggtagtgt cagataacat tgaagggtgt tagtttaaag     8880

gcttcatgga ctctataatg tcaacaaaag tgctgttaac tttcttctgg gtctcaggct     8940

cctgatgtag agtcagtgga gcaaccctgc catctgctgt tatgctgttg atgttgctgc     9000

cacacttact aacctaaacc tttgattctg gctgtggcct tctccagaag gtgtttactc     9060

atttgtccag tttatctttt aggaaacagc cagcccgtag atcattaagg ctggctattg     9120

gacagggggc tggggcctgc ctgacagagg aaggaagggc agacatctgg ttcttcctct     9180

gcccctacaa gagactccag cctgaccaca gagtggtact cctaggatgt agcagcagca     9240

tatgagcttg aatgtgcctt aatcctgctc tttactttga gaagagagaa ctaaggaccc     9300

acagatgttt cacagcttct ataggaggca gaggtagaaa aatggagaga gatgaggcca     9360

gagatagata actgatatta attaaacgtt gtattaagaa cctcacttag attatctgat     9420

tcaatcttca taataaccct gcaaccccca ccttttttg agaacagggt cttgctctgt     9480

tgtccaggct acagtgcact ggtacaatca tagttcactg cagtgtcaac ctcctgagct     9540

caagcaatcc tcccacctca gccttgcaag cagcttggac tacaggcgtg ccaccacacc     9600

ttgccatttt ttttttatttt aagtagaaac aaggtcttat taatactatg ttgcccaggc     9660

tggtcttgaa ctccagcgat cctcctgccc cagcctccca aagtgcttgg gattacggaa     9720

gtaagccact gtgcctggcc agtgcaaccc ccattttata ctaaaacagg aaggcccaga     9780

aaggtttgga gtaacttgtc cagggtcaca cagatgatat ttgaactcag gtctccctgg     9840

ctcccaagag agtctgcttt ccactaggac tcccaggaga aaaaaaaaa aaaaaacagt     9900

agacttggag acagaaaatc tgatttgagt cttagttgag ctaggctaac tgtgtaactg     9960

tgggcaagtt ccttagcccc tgtgagcctc agtttcttat ctgtaaaatg tcataaaaga     10020

aatccatctc atggagtagt tgtgatgatc aaggactctg aaaacattag aatggtttaa     10080

tgtgaaggat tagcagcagc acatggcaac attgtgcatc ttatattaac tatccaaata     10140

tatcaagcgt catttgctat atataaaagt catcaaatta ggcactgtgg gggatacgga     10200
```

-continued

```
gttggcatac tagcctggcc tcttaattaa ttcattaatt agcttattta tttttgagat   10260

aggtcttgct ctattgccca ggctggagtg cagtggcatg atgatagctt actatagcct   10320

caatctccca ggcttaaaca atcctcctga gtagctggga ctacaggcac acactaccat   10380

gcccagctaa tttttttta attttttgta gagacagggt cttgctctgt tgcccaggct   10440

ggtctcaaac tcctgggctc gagatcctcc cacctgggcc tcacaaagtg ttgggattac   10500

aggtatgagc cacggcacct ggcctggtct cttaactggt tccctaagac agctggaaat   10560

agagaatgtc atggagcatt cctaaccatg ggctccagcc tggctttcat tctgtttctc   10620

ccctgaaaca acattccttt agtaatattc cgaataacag cttcatcagt ctgtctaccg   10680

accactcttc aggcttcatc ttatatgacc tcccaaactg cactaagggt tgtattagag   10740

aaaagtggat aaagttcgga gtcaggctgc ttgagcttaa atgccagctt cacttaccag   10800

ccacctgacc atgagtcagc tgcttaacca ttctttgcca cagtttcctt gtctatgaaa   10860

agggaaatgg ctcccacctc aaaaagttgt taacattaaa ttcaatcatg tattcaaagt   10920

cctgagcaga atgtctggcc atgactggga cttaacagat gttagcattt attattagta   10980

tctgtcagtc ttgaaatgtt ctcttccctt ggctttcatg acattccaca ctctcctggt   11040

tttctcttac ctctctggta atacctgttt gcttatcctt ctttgtccag ctctgggatg   11100

ttaccattcc ttcaggcgtg ctgtttctc cttaggcagt cttacacaca ctcatgactt   11160

ccttccattg tcctccacac actgatgacc ctaaaatcag tatctccagc ctaaaccttt   11220

ccactgagtt ctagacccat atgttgtact atcaacctgg cttgtccatt tgaatgtctt   11280

ccaggcactt cagactctct tctctagact ttgctggact ttcactcttc ccctaaaac   11340

tggctcctct tccactgaaa catgtatgtc attgagaggc accaccatcc acccagtgcc   11400

taagccagaa acctaggaat ccttgatacc tgttctctct catcctgcat atccaagcct   11460

atcagtttta tctctaaatt atattttggt aggtttactt ctttcctttt ctcccaccac   11520

caccctgctc caagctacca tcatctcacc tggatgtctg caatagcctc atctcccaca   11580

gccactctgc acccctaat ctgttctcta tagagcagtt ggaaggagtg atttttgttg   11640

tttgttttgt tttgtttag acagagtctc actctgttcc ccaaggctgg agtgcagtgg   11700

cacaatttcg gctcactgca acttctgcct cccgggttta agcaattctc ctgcctcagc   11760

ctcccaagta gctgggatta aggcaccggc ccccataccc agctaatttt tatattttta   11820

gtagagatgg ggttttgcca tgttggccaa gctagtctcg aactcctgac ctcaagtgat   11880

ccacctgcct cggcctccca aagtgctggg attacaggtg tgagccactg cacctggctg   11940

gaaggagtga tcttaaaaaa aaaaaaaca aaaaaaact tgactgtgtc actctgtgtt   12000

gtctctccta ccttgtatac ttccacaact tcccagtgtt cttggataaa gaccaaaatc   12060

cttaacttgg ccaggcgcgg tggctcacac ctatcatctc agcactttgg gaggccgagg   12120

caggcagatc atgaagtcaa gagattgaga ccatcctggc caacatggtg aaaccccatc   12180

tctactaaaa atacaaaaat tagctggtcg tggtggcgtg tgcctgtagt cccagctact   12240

tgggaggctg aggcaggaga atcacttgaa cctgggaggc agaggttgca gtgagcccag   12300

atcacgccac tgcactccag cctggtgaca gagtaagact ccatctcaaa aaaaaaaaa   12360

aaaaaaaaa ttccttaatt tggcctacag tagagccctc cgtaatgtgg cctctctcca   12420

catctccaca acctcctgct ccctgcactt cagcctcacc tctcttctgg acaggccctc   12480

cttctgacaa gggctttgtt cattctgctc cctctgccta gaatgccccc ttactctgtt   12540

cacttaactc ctgcttatcg tttagatctt tacctggatg gctcagagaa atatagaagt   12600
```

-continued

```
aattcctcac cctgaaaaat aggttaggtc cctgttttat gttttcatag acctttcctt   12660

tgaggctttt tttaaaaaag tagttttaat ctcacattta ttcatgtgat catctcctta   12720

atgatatctt aagacctcta atagaacaat ttggtcatgg actgtggggt ttttgcccct   12780

cattgtgtca gcactgagca tattgttggc ataggaggga tatttgttga atgaattgct   12840

agaggtggcc aagagatatg atgtaagtca ggcttttccc tgcccttccc cttccccttc   12900

cccacatcct tcctatagca gccaccgtgg ctgcagttac tgtaaatggc aagacggaat   12960

cagttccgga cattgggttg ttttagaaaa ttgcctgcaa gtgtcagggt gataagttaa   13020

agctttgtct tttgccctca gaggagctat cccatagtga gtagaagcca gagaagctga   13080

ccccaggagt ccttctttcc agcagcaggt cttgagctgc acttctctgt agctacaatc   13140

caggcaggaa caagccctag gtacctccgg agaggagggc aagagaggaa gaatgagttc   13200

agctactcta gccaccaaac tgattatgaa ttgccctgaa atctgaaaaa tttcaattcc   13260

aatcgtaagt ttgttttgtt tcattttgtt ttcttaaatt gtatatttga aagatggcat   13320

taactaaaga tatatattca atatagagtg gaaaaaatgg aatacttgca tagtatcttt   13380

tacttatagg tgatttatga tggggagtgg ggtggatagg ttggcagttc ccccaagaag   13440

ttggaaatga agtttgtcct ctgtgagttg aactaattag atccacaagt aatgaaagca   13500

gtattgtgtt gtagttaaga gcacactcta gaaccagatt gcttagtttc aaatcctggt   13560

tctgcctttt attatctgtg tactttgggc aagttacttg ccctttgtgt gcttcatttt   13620

tctcatctag aaaatggaga ggccaggcgt agtggctcat gcctataatc ccagcacttt   13680

gggaggccga ggcgggcaga tcacctgagg tgagaagttc aagaccagcc tggccaacat   13740

ggtgaaaccc tgtctctaca aaaatacaaa aattagccag gcatgatggc gggtgcctgt   13800

aatcccagct acccaggagc ctgaggcggg agaaacactt gaacctggaa ggcagaggtt   13860

gtagtgagcc aggattgcac cactgcactc cagcctgggt gacaagagct agactcagtc   13920

taaaaaaaaa aaaaaaaaac aaactggaga tacaggctgg gtgcagggct tacacttata   13980

atatcagcac tttgggaggc ctaggcggga ggattgcttg aactcaggag tttcaagatc   14040

agtctgggta acagagcaag acctcatccc cacaaaaaat caaaaattta gccaggcatg   14100

gtggctcatg cctgtggtcc cagctactca ggaggctgag gcgagaggat tgcttgagcc   14160

caggaggttg aggctgcagt gaaccatgac tgcaccacta catgccagcc tggatgacag   14220

agcaagaccc tatctcaaaa aaaaaaaaa aaagaaacga gccaggcgcg tttgctcacg   14280

ccagtaatcc cagcactttg ggaggccaag gcaggtggat cacttgaggt caggagatcg   14340

agactagcct ggccaacatg gtgaaacccc atctcaactg aaaatacaaa aattagccag   14400

gcatggtggc atgctcctgt agtcccagct actcacttgg aggctgaggc acgagaatcg   14460

cttgaaccca ggaggcggag gttgcagtgg gccaacatca tgtcactgca ctccagcctg   14520

ggagacagag cgagactctg tctcaataaa taaataaaca taaaataaaa taaaataaaa   14580

taaaataaaa taaaaaaata tggaggccag caggcacggt ggctcacgca tgtaatccca   14640

gcactttggg aggccgaggg ggcggatca caaggtcagg agatcgagac catcctggct   14700

aacacagtga aaccgcgtct ctactaaaaa tacacaaaat tagccaggca tggtggcagg   14760

cacctgtagt ccctgctact caggaggctg aggcaggaga atggcgtgaa cccgggaggc   14820

ggagcttgca gtgagctgag atcgcgccac tgcagtccag cctgggcgac agagcaagac   14880

tctgtctcaa aaaaaaaaaa aaaaatggag gttgggcgcg gtggctcgcg cctgtaatcc   14940
```

53 54

-continued

```
cagcactttg ggaggtcgag gcgggcggat cacctgaggt caggagttcc agaccagcct  15000

ggccaacatg gtgaaacctt gtctctacta aaattacaaa aattagccag gcacgatggc  15060

aggcacctgt aatcccagct acttaggaga ctaaggcagg agaatagctt gaacctggga  15120

gatggaggtt gcagtgtgct gagatcgcgc cactgccctc cagtagagtg agattccgtc  15180

tcaaaaaaaa aaaaaagaa gaaatggaga tacaaactta ctacctacct ccttacaacc  15240

taccctcaca gtattactgt gaataaaagt gtgtgtagca ctgggaacac tattcacaga  15300

gcactcatga atgtttgttc tttgttatta gttactagag aggcaaatgt ctgccagggc  15360

tgaataatat gtgtgaattg gtgattgtcg cacatatcta aagaagtagt tattttttc  15420

aattaaaact tagtttaaaa accaatataa ggccgagcgc agtggctcac acctgtaatc  15480

ccagcacttt gggaggccga ggtgggcaga tcatttgagg tcaggagttc gagactagcc  15540

tggccaacat ggtgaaaccc tgtctctgct aaaaaaaaaa aaaaagtaca aaaattagcc  15600

aggcatgatg gcaggtccct gtaatcccag ctacttggga ggccgaggca ggagaattgc  15660

ttgaacccag gaggtggagg ttgtagtgag ccgagtttgt gccactgcac ttcagcctgg  15720

gtgacagagg gagacactgt ctcaaaaaaa aaaaaaaaa accaaaacca atataataaa  15780

taagtggcca gcaatgaaac agaaagtgaa aagttagtga agcaaaacta gtactgtatt  15840

cagataaaga tgctgaatct agatttggtc accagaatag ggtcctttgt ggcaacctgg  15900

gctagtttgg ctgactcacc actgccagga tgaaatttct ttcagtggct actcatttcc  15960

ctttatttta agtccatgct cacagagcaa ccttctgatg cctaattcag cttcctggga  16020

tacttaataa caggaagggt ctggaagtag tacctgtata ggggatatga gtgttctgat  16080

tttaatagtc aattcataag tgtacagagg gtttgataaa tggttaggtc agaaccatca  16140

cagaatgtct acacctcttt ggacattagg aaggtcaaaa acctgaaagg ccaaaagcta  16200

ggcctagatt agggtcattc accaagaaaa catcagcctt gaagagttct ctgggtggtc  16260

caccagtcaa ccttcctttg atcacacctc cttcctcgtt gcttctttaa gcattgacct  16320

gtaatgggta tggaattttt tgctcaccta actccttcct tttacagagg aagaagttga  16380

agcccagaga gatttaatgg cttgcctaag atcacacgca gattttctgt taaccagggt  16440

gatttttcag gtgttccctg ccagacgagg gctttttttcc ttgaattgcc tagagatttc  16500

ttgagatatc cgaagcattt ttcccagtgc agcctggaga aggatgtccc tgtcaacaca  16560

gcatttgtta ctcaatgtta gacattcaat tttctaatta gtatcatgga gcaacagtgg  16620

atgattatct ataaggggtt gcaattccat gcttatgtgc ttacagccca tatagacaaa  16680

tatcagctgt taaaatgaca aggcagtaga gatgtggccc caggacaaag gcatactctg  16740

ctgttagtga acactagttg gccagcaaat ttcacatggg catatacacg gccaactgta  16800

gactttaggc atttataccc attcagagag ccaaactggc aactaaagat cagcattctc  16860

tttggcattt cagctttgcg ttctgttaaa aatcactgct tgcttaaata cctctgatag  16920

ctcttcactg cctgtaggca actctttagc ctagcagact tggtctttag tgctctgccc  16980

ctactctctt ccaccattct ggcctcctgt ctaattgctg cccatatgtg ccatgcacta  17040

gagcttacag acctgctcag cgttatatga gcataccata ctctttatgc ctcagtgcat  17100

ttgcacatgt tgttccttca ggcagaatg cctgttactg cctggcaatc agcctattag  17160

agtctgccaa taccatccca tcttctgtgg aggagcccc cgccaaatcc acccatacct  17220

ctccccacca atcagagact tcttctctct ttgttattct cttcgttatt ctcttcatac  17280

ctcagttata tccatttcag tatttgttta cacatctagc atcactctta gagtgtgaaa  17340
```

-continued

```
attgctgggt atgttgagtt cttgtatctg attttttctag atttcctgcc cacattctta  19740

ctgtctggat atcaggaaag agtttatcaa atgcctgtgg aaatccaaga taaggtctca  19800

tgatgagtaa cccagtgaaa acatgaagtc aagtctaact agtcactact atttcactac  19860

tgctgactcc tgatgatcag ctcctttct aagtgcttac tgtccactta ttccatcatc  19920

tgcctagaat ttatgtgaag gaatcaaagc aaaaggatca taaggcttcc tttttccagt  19980

atgttttcc tccttttga aaactgggcc agttagctat ctccattttt atttcatgaa  20040

tacatcccca gcgcctggta tatagtagat atggaacatt acactttgga gatattgcac  20100

ccattctcca gtttctccaa agttactaac aatggttcca tcactgtgcc aacatatttt  20160

ctttttcaa tatattggga aataattctc ccagtctgaa aatctgaaca catttcatgt  20220

gacttggtat cctcatatgt cttgggcttc caattctcca ttcctagttt caagttcatg  20280

aactgtaaaa caaaggatta gactaaatct ctaaagttct atccagatgc caaattcttt  20340

tctctttcca tgatacctaa gatagatgcc aaatattgtc ttttacctgg tgtttgtgaa  20400

catgacatca cattacagga gtagcagata ctaaactctc actctgtaaa acactgactg  20460

agttccatga gccagatact gaagtgagct tgttcacata tgttctcatt taatgctcat  20520

aaccctgtga agctgggaat tgctgggaca ttttatttat ttatttattg agacggagtc  20580

tggctctgtc acctaggctg gtgtgcaatg gcatgatctt ggctcaccgc aacctccgcc  20640

tcccgggttc aagcgattct cttgcctcag cctccgcagt agctgggatt acggggcaca  20700

caccaccaca tccagctaat tttgtatttt tagcagagat ggagtttctc catgttggcc  20760

aggttggtca cgaacacttg acctcaagtg atctgcctgc ctcagcctcc caaagtgctg  20820

ggattacagg catgagccac catgcctgcc cgggacccctt gtttagaag gatgactgct  20880

gctataatgt agaaagtgat ttggaagagg ggaggagtgg ggcacgaaag atggttagta  20940

gatggggtg gtaatgctta cctttcagta tttggaggct tcggagtcct caaaaattct  21000

cttccttgat tggagtcctc ccagccaata gagggcttca cacaaacagt ttcttgggtt  21060

ttgaattgtt tgaccagagc tttcttccga caaaaggttg gggtgattca ttcacttacc  21120

acaccttgcc tgaacattca cttggggctg ccggttatga aggctattgt tctccagcct  21180

gtcacagacg ctttgaagac ctgtgcctca gctggttcta aggagtcagt ttgttcagct  21240

ccgtgccagg tttccaactt atgaaatgtg ctggagatta acacctctcc tgccatttta  21300

tccctactat aattgccagt caaaggattc ctgcagttgc ctctggcagc cataactgat  21360

gaatgttctg ccagctgctc tgaggaccta gaagagcagt tttctatcca ggaccagttt  21420

ccaagggtgg gagggtgaaa tatatcctcc agtgtgacat ttcatctccc agtgatgggt  21480

ggcttgggcc ctttgaagtt ggctctgagg aaccacacac ttgggtctga gcagccagca  21540

gcttatcaca tctggtgatc aatccttcaa aggttcctcc tgaagtctga attttttggag  21600

gtcaaatgga ttccacctgg gagggcttc tgcttcaact caggacatgg ggagaaggct  21660

gttcctcttc caggggagg cagttttcat ggcattgaga tgtcctctca cttattcccc  21720

acccacccac caagtccttt gtaagaggag taggggaga ggagagcgcc tgcagcctcc  21780

tgctcacatt cctagacacc gactcactga gcccgtcgcc gctggaacag cagagctgtg  21840

tgaaatgtca agaggagtta tgctcatagg ctccctggcc tcagtctctt tgtggcttgc  21900

atattcttcc attagtactg tgttcatcac atggaaatca gagggtacaa ttaaaagata  21960

atttgctagt cccagactta atttggggcc cccttcttgc ctgattgaat tacaggggaa  22020

cataatagat ttttggtgag aaatagttgt ctgtgtggct gggagaaaga ttgctcccag  22080
```

```
ctctccagct gggcagccct ttcagtatcc cgtatgttat ttccccactt ccagcccacc   22140

tcacctcctc tgtggccctt gtgtgtcccc tcggctagga tcctgacctc ctgctcaaga   22200

gtttaaactc aacttgagac ccaaggaaaa tagagagccc tctgcaacct cataggggtg   22260

aaaaatgttg atgctgggag ctatttagag acctaaccaa ggcccagaca gagagagtga   22320

cttgctaaag gccacatagc tagcccacag tagttgtaac aatagtctta atgatattaa   22380

tggctaacat ttatcaacct ttaatgtgtc ccagactttg tgccaagggc ttacatgcag   22440

tgcattgtcg cattcaaacc cagacagtct ggctctgggc ccaggctgag ctttggtata   22500

gcatggtaga acgttgtcta taatgtctag tctgggttca aatcctggct tcacttctca   22560

catttacagc tgagtgacct caggcaagtg atttaacctc cctgtacctc agttgcttta   22620

tctgtaaaga gaaaaatcac agcactgtgg aatagtgggg gttaaaattc attcatacaa   22680

gtagtgctgc aagcaatgtt taatacaggg tgagcacctg ttcagtgctt ccttcttctg   22740

gctgcctctg gggctagagt gtggtgtctt cgtggtatag atagatagat atggctgagc   22800

tctgcacaaa caccaagagc tgttcttcac tattagaggt agtaaacaga gtggttgagc   22860

tctgtggttc tagaacagag gccggcaagc tatggcccat tgcctatttt aatacggcct   22920

gtgattgatt gatttttttt ttctttttga cagagtttt cactcttgtt gcccaggctg   22980

gaatgcaatg gcacgaactc agctcaccgc aacctctgcc tcctgggttc aagcgattct   23040

cctgtctcag cctctcgagt agctgggatt acaggcatgt gccaccacgc ctggctaatt   23100

tttgtatttt tagtagagac agggtttctc catgttggtc aggctagtct cgaacttcca   23160

acctcaggtg atctgcccgc ctcagccttc caaagtgctg ggattacagg cgtgagccac   23220

catgactggc ctgattgact gatttttta gtagagatag ggtcttggtt tgttacccag   23280

gctggtctca aacttctggc ttcaagcagt cctcctcct tggcctctcg aatgctggga   23340

ttataggcat gagccactat gcctggccta tatgacctgt gatttttaat ggttagggga   23400

aaaaaagcaa aagaatgctt tgtgacatgt ggaaattaca tgaaactcaa atatcagtgt   23460

cccagcctgg gcaacaaagt gagaccctgt ctctacaaaa aataaaaaaa aataagccag   23520

ggccgggcgc agtggctcac acctataatc tcagcacttt gggaggccga ggcaagtgga   23580

tcacctgagg tcaggagttc aagaccagcc tgaccaatat ggtgaaaccc tgtctgtact   23640

aaaaacacaa aaattagccg agcatggtgg catgcgcctg tagtcccagc tacttgggag   23700

gctgagacaa gagaattgct tgaacctggg aggcggaggt tgcagtgagc caagatcgcg   23760

acactacact gcagcctggg caacagagcg agactccgac acacgcacgc acgcacacac   23820

acacacacac acacacacac acgctgggta tggtggccag cacgtgtggt cccaggatgc   23880

actggaggct taggtaggag gatcacttga gcttaggtgg ttgagactac aatgaaccat   23940

gtttatacca ctgcacttta gccagggcaa cagtgtgaga ctgaatctca aaagaaaaaa   24000

aaaaaaaga aaaaatctt tccataagta aatatctgtt ggaacatagc catgtccctt   24060

agtttatgtt ttatatatgg ctgcttttgc cctataatga cacaattgag tggccacgac   24120

agtctgtatg gcctgcagag cctaagatat ttgctctctg gccctttaca gaaaaagtgc   24180

cttgacctgt gctctagagc catatgtacc aggtttgaaa ctcagcctca cagctgggtg   24240

tgatggcacg catctgtagt cccagctact ctggaggctg aggtgagagg atcacttgag   24300

tccagaaggt cgaggtcaag attgtagtga gccatgatgg catcaccgca ctccagcctg   24360

agtgacagag agagaccctg actcaaaaaa aaaaaacaa aaaaaaaaa caccctcacc   24420
```

-continued

```
acttatcagc tatttgtctt gagaatagtg acataacccc tcagaaccta tttcctaatc   24480

tgttaaatga ggctgatgac gtttcctcct tttactggca atttaaacat gatggataat   24540

aaatgctaag cacttaacac agggcctaga agatattaac tgctcaataa atggtagctt   24600

cttaacagta ttcaaaccca tgtgctctta tcacatgcat tgttgtccct gtgtccagtt   24660

ggtggaatgg gaaaaggctc ccttgtaacc ccatctacca tctttatcag actttcctgc   24720

catggttcac agtaagagat agaagctgca cggtgacttc tggctcttta caatggtgag   24780

cggtgtgtgc ctggtaaggg agagctgatg tcactgcccc aaatccagta gtgagatctg   24840

agtgttctgg tttcctccag cagccttgct ttttccttta caatcctgca ggcagggaga   24900

caagggcttt ctacatggta ggctctggtt tggtcatcgt cacaactggg ggctgttcag   24960

gtgggctccc attccagata cctaggctta tcaatccctt ttggcacccc aggccttttt   25020

ctccctcatg ccccattttt cagtttgaaa agcatggtta tcacaggaca agtagaagaa   25080

gctccactgt ccactgaggc caatggatgg tgttctgcat gtgaacactc agtgaatagt   25140

gagtgaatga gagtaacctg ggctccatcc tatttgcaga gagctttgga aaagattttt   25200

ctccttaaag agccagaatg aagcctggta gtgggagagc tccagctcta gagtcacatg   25260

agcctacatt taaattccag ccctgccact gactcccttt ttgaccttga gtgagttacc   25320

taatctctct gtacctcact tttcttgtct gtagagtggg aataattcct gtctcagaga   25380

aataaaagag tgcatatagt gtttgccaca tggagacaca tcaggtgtag gttaatactc   25440

tgggccttgt ttccttattt gcaacacagc cctgccctgg agtggaagtg gcacctccca   25500

ttggtcagct cttgaggctg tccccaggac aggcagaggg agggaatgaa tgggagccct   25560

agtgccagga cagaacagat ggcagctcag agctaggatg gctctctgga cctgtctctc   25620

ctaccagagg tcccccgtc tggtgtggct cttcctggac ctggcatcct ctgctttttt   25680

ttttttttcca cctccaagca gaattactgt cctgtaggca gctcctctgc ttgaggacat   25740

ctggggccag atatgttcac actctatcct gccttgccct tccctgagct caggatggac   25800

gctcaattgg tcccagttat tgtctgcagc gcctgcctgc agcctcgatc cagcccagct   25860

ccacccttg cctgcaaggt ctgtttccta acagctgctc caaccacaca cctcggttct   25920

gcgggagccc ctcctcttcc tccctccctc cctcattcag gggtgggact gaagaagaag   25980

gctaacttga cagcagcgct tctttcttag ctagtcaccg gcccctgctc aagaatgcca   26040

gtgtgtgtgt agcctccaca gagaggtcgt tttctcggag tccagagggg ccgcctgagc   26100

ttctgagaac tagggaggag ccatcccagc catgagcccc tgtgggaatc tgctgggggc   26160

caagtggcct ggagtcctca ggctcccgca gctgctccgg agggagaggt gagctcaggg   26220

cagcctgcct gcagccagag gtgccgggag ccccgggcct gtcatggtgg ccatctacag   26280

ccggcctgag gcagtcacag acggatttgc agctgagcct gtctatctgg tgtgggaaga   26340

agatggggag ttacttgtca gtcccggctt acttcacctc cagagacctg tttcggtgag   26400

ttggtctccg agttccctc tccatctctc ctggccctg gtcctgagag gagggtggtc   26460

tccctaaatc tccttctcac ttagtccttt accatcggtt ctgccgggca gaagccagcg   26520

gaggttatac ccaaggagaa tcggccttgt gaggtacccc cattatgtcc tggaagtggt   26580

gaggggaggg atatacccag aaggaacttc ttagggagct ccagctcccc ttctatccca   26640

gacaaacctg aaggagcctc caaaagatgc cactgacctg cccattgtag atgttactgc   26700

ttccgggggg aatagcccaa atagagtgct gtttccagct ctcacatgtc ttacctgcgg   26760

gccatgctgc ctgcccagga atttgtccca acaagcagga tgggcaggtt ttgccaaact   26820
```

-continued

```
gtggaaactg gcaagtcctg ggtgtgggta gcctggtaca cagtaggcac cttataaacg   26880

tttgttctct taatggcagg cacatttgcc tctggccttg aagggcttct gagctcccag   26940

gtgaatgtag ttgctgggga aagacctggg cgagtgcttc taagactgga gcaatgggct   27000

ttagagtgtt cctgagctgc tgggccagcc cccacacctc ctcagtccct aggcctaagt   27060

acctccacga gcctctctct gtggggcttc tcagagggag atgtggaaac tctacctcta   27120

acctggcttt ctttgctcat tgccccactc cacctcccat agaaactccc caggggqttt   27180

ctggccctct gggtcccttc tgaatggagc cattccaggc tagggtgggg tttgttttca   27240

ttctttggga gcagcctgtt gttccaaaaa ggctgcctcc ccctcaccag tggtcctggt   27300

cgacttttcc cttctggctt ctctaagcta ggtccagtgc ccagatcttg ctgccgggat   27360

actagtcagg tggccaggcc ctgggcagaa aagcagtgta ccatgtggtt ttgtggaatg   27420

accggaccct ggtagattgc tgggaagtgt ctggacaggg ggaaggggga agggaactgg   27480

tcctcaatgc tgactctacc aagcgccctg ctagacactt tatcctttaa tctctcaaca   27540

gcctaaagag attatatatc cccattttac agatgaggca accagtttca acagagttaa   27600

catatggagc ctcactgggc agcttttttct gtcttcctga ctttctctca tccttcaggg   27660

ggctgcaggt ttgtttttctt ctcctagtgg agaggaaatt ctcaggtttg ttttcctctc   27720

ctagcagaga gtaaaaaaag ggatagtttg cctgacttgt tgaaggtgtg gctgagattg   27780

ttttctaaag agccaatgga aattgatctt gagtttagga gaaagctttt acatgtggaa   27840

ttaagatgcc aagtgttgaa gtagccacat ttcaggtcct cattaatttc tcttaatcct   27900

gggaaggcag cttaggagaa gggttgttcc tttaggagcc aggaactata cccctttac   27960

ccttggagag gcagggaagc cagggaggac acaacttctc aggaagagga gaagctagag   28020

cagatagtga actctcaacc tgaacctttta agggccagac cactaatgcc acccaagtcc   28080

acctgccgtt tgtcttgttc tgtcccaggc tttctggaga acctgatctt cttgcccta   28140

cccccaagct ccgtttgccc agctagagtc tggggggtac tgactgactt tcgtagacat   28200

tcttcccttc cccaaataag aggccacatt cctgaagtca cttctgaaga gatagctgcc   28260

acacagggct ctttccccccc agggagggac cacccagacc ctctgctctc ccaggtatcc   28320

gttaccacat cactacctgg tcagaaagct gtttctgcca ttagcccctc cctcttttat   28380

tataggatat cctcaagggc tcctctttgg gcctcagttt catccttggc agaaagtaga   28440

agctagactt cttgggctcc tgaacagggt ccttgctgga ttctgtgaaa caaattaagt   28500

tcttgacccct aggcctctgg gggagtacaa agtctatggg agttctgggg ctgtggttgc   28560

aaggaaagtg acgcaaccag attccatggg gacatgatca ggcgtgacat gtgagggagg   28620

aagagggagc aagggaatga agaatacaac ttctgtgtcc catacacccc tgcctgacag   28680

gccatacata ctcagcagag aatgcactgt ctttcctacc acactagcgt gaggagtgag   28740

ctgcaattac cactgtgctt ccaagtaaga aaataacctca aattggaatt tacaaaagag   28800

gtaaattagg gagtggcttt tgtcggacat ctttaaagca tttttctttt tatagaattt   28860

cacttaatgt ccaatactga tttaatgagc ttgggtttac acattatctc ttgaagaaaa   28920

caaatgaacc tttgtgttcc aaagcaatcc atgtttaaag ggaaaaaatt atgcataact   28980

ctgcccagct tcacagtaac ctttggcagg tgccttaggt cctctgggac tcttttcctt   29040

atctgaaaaa tgaaggactt ggatcaggtg aatggttccc agctctgcaa cttatgtggc   29100

tcctcagagg cacacaagct ctttttccatt atttgccaaa taatggaggc cctgtctttta   29160
```

-continued

```
actgcagtac aactacacaa aatacttgaa actacagtct tcctggtttt tggttggaac   29220

tgaatcagtg cactctagca acacttattt cttgctgttc gtaggcttca ttatgtgttt   29280

ggttaatttt ttaaaacaac aataacatat tccataataa ttacagctta attggcagac   29340

tgtttcagtc tataggatct gcaggaagga ggagtaataa agggattttt gactgagctc   29400

ttatggaaca gagtctctct aggcccctgt catatctgcc cttctgggcc ctggggaaaa   29460

gttggcatcc ccagttgtgg tgctctccag gtgccctcag gctgtggtgg agggagcttc   29520

ccattctctc cttcagccca ctcaattcag aggctagggg ctgaaagaag cttctctaca   29580

actggctgtt cactgggagg ttaagggatg accatccagc caggccttcc tcaggacatg   29640

ggagggctta tgctttaaca tgtgtaaatc cactgcaata atgactggtt cttttacccc   29700

ataaggttga gaatttacct gtaaacattt ttgtctgaag aatttggatg taagtgaggg   29760

ctgggcctct atcttatctc acttggcttc tctcagcaca gcaccttgcc tgcttgttct   29820

tacacatcct agatgcacag taactatttc ctaattatta gaaatctatt agaatcaatt   29880

gatttcagct gggcttggtg gctccttcct gtaatcccag cactttggga ggctaaggct   29940

ggaggatcac ctgagtccag gagtttaaga ccagcctggg caacataggg agaccctgtc   30000

tctacaaaaa ataaaaaatt agccaggcat ggtggtgtgc acctgtagtc ccagctactc   30060

aggaggctga ggcaggagga tctcttgagc ctgggaggtc agactacagt gagcaatgat   30120

tgtgccactg cactccagcc tgggtgacag agtaagactc tgtctcttaa aaaaaaaaa   30180

aaaaagttg atttctattt ggatagataa ataattcatt ttaggacctt tctttttcac   30240

ttacagaaat ctgtttcatt ctgggctgag aagcaggtcc atattgctag gcataggaga   30300

aaaaggggtc tgtctgcatt tgcccttggt ggtctcaaat tggggaggga aagaaatgaa   30360

cacttactgg ctaccttctg tgagccaggc atcatgcaag acatctgtac ataatttaat   30420

tctcataacc ccataagata ttattagcaa tgtacaagtg aggaaactga ggctcagagt   30480

catgaagtaa ctggccttgg gtgacacaga tggtaaatgg cagagaagga atatggatcc   30540

aggtcttgaa agagaaaatc tcaactgatt atcttttta aaaaactcat atgttctctg   30600

ctgactcaaa aggtctctgt gtggatctgg gttgacccac tgaactgacc atcagggttc   30660

catgcacttt gtatctgccc aagccctcag aaccctcag taatgttttg gaagatgagt   30720

tttggaggtt gtccttaggc atagcctcag cgtatgtagg cctctaggtg atctcccta   30780

acctgaggat ttcagctcaa ttcactctgg ctcctcagga cagtgggatg actggttcag   30840

acctcagctt taccacctcc cagctgggta ctcttctacc tacagccagg gcagattttg   30900

actttcactt gaaacttcca aaaattgaaa ggtagaaaaa cagccttggc tttgggaaga   30960

acgtatgatg tccatggcct ctaagcatct gaggtgggac atgttcgagt agcaccttac   31020

agttccaaag tgtgttctgg gttctttgtt taaaagaaca gagactgctg gggaattgaa   31080

cactgtgaag tatatgaagg aggagaattg tgctatttaa cattcagtac ttgggctaaa   31140

ggagaagcat cacgaagtgt taacactcaa agggtcttga gctgtcaggg ctccagcttc   31200

cttattttca caggtgagaa tcctgaggct cagctgttga gatgtgctgt ctcactccgg   31260

tgacatagta cagtggatgt ggctttgcag ccaagcacac atagcttcac attccagctc   31320

catcaattat gtattgggca gctttgcaga atgatttgac tttaactctg cttttcagtc   31380

ttctgtaaaa cagggataat cctgctaccg tagggttgtc aggattagag ataatataaa   31440

taaggtacct catataggac ctggattatg gctggcattc aataaatagt agctgttaat   31500

tgatagctaa gctagaactc tgaagtctac catggcaact tcttaagtgg tctgagaacc   31560
```

-continued

```
aggacctcca aggagagtgt tacaggctga gaggaggata tacttaggtt gtctttaggg   36360

aatcagaaaa ggagactctg aataggctg gcagagagag gggctacctc ctatacctgc     36420

tctggacaaa cgactttaag catagtgaca gatttgccaa ccctgtattg gaagaactga   36480

tcttttttag tggggatgat tacttctggg gatttcttct cataactgag accaaaacag   36540

ttttgtgcag tctcagaaat gacaggaggt accaatctga cacttccttt ggaagctcta   36600

gggcagagag tgaaagagtg gattttgacg ggggccttgc ttggaggtca ttcacccacc   36660

cctgtcctca ctccagcaac agtgataact cacttccttc ctccctttgt acacccttct   36720

ccccacctgc tcacaggtgg ctggggagtt caagtaccac ccagagtgct ttgcctgtat   36780

gagctgcaag gtgatcattg aggatgggga tgcatatgca ctggtgcagc atgccaccct   36840

ctactggtaa gatagtggtc ctttgtctat cctctcccat ataagagtgg ctggcgggga   36900

gggacagtgg cagggtgagt tgggcagaag gagtgttagg gtagtcagag cattggattc   36960

ttaccacagc agtgctctta accagctctt taacttgtaa gcagaatgat ttacacatgt   37020

ctctaccctt tttccttacc aaccttgaaa atgtcttcac tctgccctgc aatcctccca   37080

gtgggaggca ctcttcaagg acgatcccag aacattaaag tcaaagaccc cttagagctc   37140

accctgtcca accaccttgg ttgataaaag aagtcagcct ggggcccatg gaatagaata   37200

gtacaagggc aaggttctca ttgtgagtca aaggtagagt gaagagaacc cagaccatct   37260

caccccaacc caggccagtg ttttccaaa tataccactt gctgcagatc tagctcagca   37320

ccccagtcc cagcccaccc tgagaaccca ggctcctcat tctgagcagc cagctagaat   37380

catgacaaag agggtggtag tgagactatg ggtactgttg cttaaagcca catggtgcag   37440

tggttgctgg ggggcttctg tgtgggactc tagcatctta ttccccctg tgccctctcc   37500

ccagtgggaa gtgccacaat gaggtggtgc tggcacccat gtttgagaga ctctccacag   37560

agtctgttca ggagcagctg ccctactctg tcacgctcat ctccatgccg gccaccactg   37620

aaggcaggcg gggcttctcc gtgtccgtgg agagtgcctg ctccaactac gccaccactg   37680

tgcaagtgaa agagtaagta ttttgagaac ccttcagcag gggttcttga gcagagtctg   37740

taaatgggcc tcagagggct tagacctcca aagtctcatg cagaactccc tttattctca   37800

tctcatatct ttctcctgga ccccactatg ctgtaaccgt acctgggcct tggcacttac   37860

tgttctctct gcccaggcta cttcctaccc gatacttaag gcaagaatca ctcacctttc   37920

aggtgtcagg tttcaggtca tgtttgctct ttgaaatcat ctggcttgat tatgtgtatt   37980

agttgtttat cttctatccc ctccactaga atgtaaattc cagaagaaac ttgctgtctt   38040

attcagtgct gcatgcccag ggcttggaag agtacctggc atatagtagg agttgattga   38100

ttattatttt gtcagtcgag agaatgaatg gagaaaatgt ggtccatggc ccaaaagaag   38160

ttaagaccct atcctagatt caggccagac accagatgga gaaagagtct gtgtctatct   38220

aataccagta atgtcgtacc tctggccgct taccatgtaa atattgattg tgtatctacc   38280

atgtgttgga cactaggcta gtgcttgcac agcaggtgaa agatactaga gtttgggaag   38340

tcaggaggag ctaaggtctg ttctacaacc ttattagatg aagaggagag ggaattgtgt   38400

tcagggcaga gggagaagca tttctccaaa agtaggagtc ttaatcatgt ctgatgtagg   38460

ttgagtgtgg ccagaaaagg ggctgttaag tatagagggc ctggattatg aaaatccagc   38520

agatccattg agagtttaag cagcaaggtg ttgtgaccaa gttaacattt tagaaggatc   38580

actggtatgg aggttggatt ggagagggga aagcctaaag gtatagagac tagttaggaa   38640
```

-continued

```
agataaaggt ggctgtctca ccaattatgt aaggattaaa tgtggaaaag gacataaagt   41100

tgtatagtgc tgccataggg acagtgttca gtaaacgtga cacattctta gtatcactaa   41160

gaatcaggtt cttggccagg caccgtggct catgcctgta atcccaacac tctgggaggc   41220

ctaggtcgga ggatggcttg aaacacaggag tttgagacca gcctgagcaa catagtgaga   41280

cactgtctct acaaaaaaaa aataataata ataattgttt ttaattagat gggcagggca   41340

ctgtggctca cacctgtaat cccagcactt tgggaggcca aggccggagg attgcttgag   41400

gccaggagtt caggagcagc ctgggccaca ttcctgtctc tacaaagaat aaaaaagtta   41460

actgggcatg gtggcacatg cctgtaatcc cagctactca agaggctgag gaggaggatt   41520

gcctgagccc aggagttcaa gactgcagtg agccttgatc acaccactgt actacagctt   41580

gggcaacaga gtgagacctt gtctccaaaa aaaaaagttt gttttttttt atccactctc   41640

ctcaccaaac aaactgagta agttagagcc ctctcagctg gcatgtgttg gaaacagtgc   41700

cctctcatta aagtgctgcc ctcactccca ttgcctcttg gccttggtca gtatgatgaa   41760

attagtggga ggcagggcaa cagagggcag ggaagagcta gaaatccatg gcctggaaaa   41820

gggaagattt gggagtggcc aggtatctgt agagccacca tgcagaggag gggggcagct   41880

agccttgtgt gctctggtgg gcatggtcag caggaggcag agcaaaagga caagggtaag   41940

taaacctgta ggtcgggaca agccaagagc catccagcgt cagtcctctc tgggtagccc   42000

aagtaaagca ggagcatacc ccagagagaa agttcgcagg gctgttcacc tgcagtgctg   42060

tggacttcaa ccttcttgtt ccttcttcag taagtgaaaa taacagtcat tgaccatgac   42120

tattatcgac cgcttttgaa aatgtaaaca tagtgacttt attgctgtaa aaatcatacg   42180

tgtttatcat cttaaaattc aggaaacatg gacaggtaca aagatgtgca aaatatcatc   42240

caaaatccca tttgctggcc aggcacggtg gctcacgcct gtaatcccag cacattggga   42300

ggccgaggcg ggcaaatcac ttgaggtcag gagtttgaga ccagcctggc caacatggtg   42360

aaaccctatc tctactaaaa atacaataat taggctgggc gcagtggctc acgcctataa   42420

tcccagcact ttgggaggcc gaggtgggcg aatcacaagg tcaggagttt gagactagcc   42480

tggccaatat ggtgaaaccc catctctact aaaaatacaa aaattagggc cgggtgtggt   42540

ggctcacgcc tgtaatccca gcacttaggg aggccgagac agatggatcg cgagatcagg   42600

agttcgagac caacctagcc aacatggtga acccccatct ctactaaaaa aatacaaaaa   42660

ttattcggtt gtggtggcac acgcctgtaa tcccagctac ttgggaggct gaggcaggag   42720

aatctcttga acctgggagg cagaggttgc agtgagtgga gatcccgccg ttgcactcca   42780

gcctgggcga cagagtgaga ctccatcaaa aaaaaaaaa aaaaaaaaa aaattagccg   42840

ggcgtggtgg cgtgcaccta tactcccagc tacttgggag gctgaggcag gagaatcgct   42900

tgaacctgga aggcggaggt cgcagtgagc cgagatcgtg ccattgcact tcagcctggg   42960

cgacagagcg agactctgtc tcaaaaataa taataataac aataactagc cgggcctggt   43020

ggcacatgcc tgtagtccca gttactcagg aggcggaggc atgagactca ggtgaactag   43080

ggagacagag gttgcagtga gccaagatca caccactgca ctccagcctg gttgacagag   43140

cgagactctg tctcaaaaaa aaaaaaatcc catttgctca tttttttggat actagtataa   43200

ctatcactct aaaccagtta gtacttaaat caagcagata tgggagatgg tgaattacca   43260

tctacagtgt tgtcatatat gtcacatact gagcattatc agctagtaga atctagttaa   43320

ttgttctatg tgtgatgtat gcagagttcc cattttgaat gtgtttttac tatgcttaaa   43380
```

-continued

```
taaatgactg atgtcagcaa ccccaaaatg atacatctga tgtaagagcc cctgttcccc   43440

aataataaca tctaaactat agacattgga atgaacaggt gccctaagt ttcctccctc    43500

cagggtttct tggccggtct ctgaggacta cacatcccta ctcccgtctt tcctcatctt   43560

caggcgcagt aacagtatct ccaagtcccc tggccccagc tccccaaagg agccctgct    43620

gttcagccgt gacatcagcc gctcagaatc ccttcgttgt tccagcagct attcacagca   43680

gatcttccgg ccctgtgacc taatccatgg ggaggtcctg gggaagggct tctttgggca   43740

ggctatcaag gtgagcgcag gcaacaattg ctttgctctt ctgcccccag tccctctgtc   43800

actgtctttc ggggatttct catcacttgg ccccacccca caccatgcag gatgccaggc   43860

ctccttcctg gctttgggtg ttggtgtgag aggtatcctt caccccacc caggccacct    43920

aaggtcaatg ttgctgttac agtgagcttg tggacctgga gatccaggtt gggttgagct   43980

gtgcctgtgg ccctcctgcc tccagtcagt gggtgtttgt taggtgcctg cagacctcag   44040

taccgggcat gctacaagga gcacacaggg gaatggctcc tgcctccctg gtgaacagtc    44100

tcagggacta acctctctct ttctctcctc ctcctcctct tctgctgaga actgggaggg   44160

ggggtcaggt aagacgtgtg tctcagcttg ggggcagcag ggctggagag ctcacccccg   44220

atccacccag ctccctggtg catgtctttg gcactgacct tcctgccccc agacttctgt    44280

tcactcagga gactcacttc tatgccaaat gaccagagcc cctgcttggc ttggcagcat    44340

cccctcctgc cttcttcccc acttcccttt tctgggttct tgcctgtcct ctgtgcatgc   44400

ccagctctcc aggaaagagg gtttgcttcc gtgtgagtcc catgttgctc cacgctgcat    44460

cttccacaca tgaactctgt cattctgacc cggctcagtg tgccctccaa gggatgggat   44520

ggccagctgc atagattttc tcaaacagtt ctccagaact tcctctggtc tcagcaccat   44580

taacagtcac cctccctgta ggtgacacac aaagccacgg gcaaagtgat ggtcatgaaa   44640

gagttaattc gatgtgatga ggagacccag aaaacttttc tgactgaggt aagaagatgg   44700

aggggccccg ggaggttggt gtcaccattg gaagagagaa gaccttacaa ataatggctt    44760

caagagaaaa tacagtttgg aattactgtc ttaaagacta agcagaaaag agccctagag   44820

gaatatccca ctccctctaa attacagcgt aattatttgt tcaatgaaca cttactaaaa   44880

gcaacacaaa cagggtacaa gggatgcagt aacaaaagat acagggttca gaagagctct   44940

caggttatga ggatgatgga catgaaaaca ctccaattta gtacaactca atgttataat   45000

cctcacctga acgccctgct aagggagcct ggaggggagc tccctgagca ctcacactcc   45060

ttgggcattt acagttttca ctaccctcc caagttactt catggagtaa cttaagttgg    45120

ggacacctgt ggtctgggta ttgccctcca agccacttgg ccactcccac cccagttctc   45180

ccaatgcagt tccaagggta aggcctatga agccatctcc atctatatgg tggtggtctt   45240

ccctcatcct gatcttagtg ccctgtcata tcacaagata ggaggtagga gatacaggtg   45300

gtaacacttg tcaagctgat tccttggagg gaagaggtaa ggaagacagt gagaagttaa   45360

ccaccagctt tccttggctt ccccacccc caggtgaaag tgatgcgcag cctggaccac    45420

cccaatgtgc tcaagttcat tggtgtgctg tacaaggata agaagctgaa cctgctgaca   45480

gagtacattg aggggggcac actgaaggac tttctgcgca gtatggtgag cacaccaccc   45540

catagtctcc aggagccttg gtgggttgtc agacacctat gctatcacta ccctaggagc   45600

ttaaagggca gaggggccct gctttgcctc caaaggacca tgctgggtgg gactgagcat   45660

acatagggag gcttcactgg gagaccacat tgacccatgg ggcctggacc acgagtggga   45720

cagggctcaa cagcctctga aaatcattcc ccattctgca ggatccgttc ccctggcagc   45780
```

-continued

```
agaaggtcag gtttgccaaa ggaatcgcct ccggaatggt gagtcccacc aacaaacctg    45840

ccagcagggc gagagtaggg agaggtgtga gaattgtggg cttcactgga aggtagagac    45900

cccttcctat gcaacttgtg tgggctgggt cagcagctat tcattgagtt tgtctgtgtc    45960

actgaaactg accccagcca actgttctca gttcacagcc ctgtttтcaa agaattacac    46020

atctctaaag gcaaacaggg cacggacaag gcaaactgga gaggcaaact gtagcctgag    46080

atggcctggg cttgccatca caggtattca ggtgctgagg gcccttagac caactagagc    46140

acctcactgc ctaggaaatc aatgaagggg aaatgagttc tagcggagcc ctgaaggatc    46200

agaattggat aaagttctta ttggcagaga ggcaccagga ttgaagtgac aggagcaaag    46260

acctgggagg aaagaggaga aaatcatcta tttcacctgg aaacaaatga ttccaagcat    46320

agaaataata acagctgaca agtactgagt gccctctata tgctaggcac tgggctgagg    46380

gattaacatg catgtgcatg tttattcctc atgacaacct tggtttccag ataagctgga    46440

ctggaaaggg acagagctgg gatcctgggc taatcagtct ggtcgccaag cctgagactt    46500

tagccactgc ccttcacatg ggggtccatg aaaatagtag tagtctggaa cagtttgggg    46560

gtacatcaag gtcgctgtgt tttaagctat ggagtctgga ctataggaga caaatgtaaa    46620

agagtttttt ggttgactgg ctttttggtt tttttgtttg tttgtttgtt tgtttgtttg    46680

tttgtttgtt ttttcctgtt tctggggctt gaatcaggaa ggaggttttt ttgttgttgt    46740

tgttttgaga aaggatattg ctctgttgcc cagactggag tgcagtggca cgatcatggc    46800

tcactacagc ttcgacctcc tgggctcaag caatcctcct gccttagcct cccaagtagc    46860

tggactacag gtgtgtacca ccacacctaa ttttttgaat ttttttttct tttttttttt    46920

tttttttttt ggtagagaca ggttctcact ttgttgccca ggcctgaatc tcaaactcct    46980

gggctcaagc attcctcctg cctcgccctc ccaaagtgtt gggattacag ttgtgagcca    47040

ccatgcccgg caggaaaaga ttttttaagca agaaagctta agagctgtgg ttttttccaaa    47100

atgagtctgg gctggcacag tggctcatgc ctgtaatccc agcacttttt tgggaggccg    47160

aggtgagtgg atcacttgag gtcaggagtt tgagaccagc ctggccaact ggtgaaaccc    47220

ctgtttctac taaagaaaaa aatgcaaaaa ttagctgggc gtggtggtgc acgcctgtag    47280

tcccagctac tcaggaggcc gaggcaggag aatagcttga acctgggagg cagaagttgc    47340

agtgagccaa gatcacacca ctgcattcca gcctgggtga cagagtgaga cttcatctca    47400

aaaaaaaaaa aaaagagaga ctgatatggt tagtacattg gggtggaatg cggagggtcc    47460

agggaatgga gccctgcata gggggctaat gaaacatttc agatttctga attaaggtag    47520

tggctgtggg gacaggagcc tgggaggcag ggtggagtca gaatggagag actggttggc    47580

aatgagggaa caggaggagg aggaggagga gttacgagtg gcttgaggtg tcacttacca    47640

gacatttggg ggatggggga tagccgtgat tgttgagcaa ctggtttggg aagagctagc    47700

attgatccct gctgttctgt gctagcagaa cctatcagca tcttctgggc aggaaactgg    47760

ctccatgaga ctggcttagg gagaggctgc tagtcaccta atctgcagag aaggggcagc    47820

tggagctgtg ggacagaaga ggcatccatg tagctggtgg gggtgtctca gcttgtgaag    47880

aggagatggc tttgagcagg gctgacactg aaaaggctgg aagaaaaaaa cagacacaca    47940

agagtctcag gatcaggtag cataggaaag ttgtggacag tctttgagga gcactccctc    48000

aggcaggcag gcaggcaggt catgagctat agcgattcag gaagagctcc ctgggtgtgt    48060

gagcagctcc aggagcctaa gggatgaaag tagtattgca gggggctgga gagcaaggag    48120
```

-continued

```
tggctccttc tacatttgca agggaaggag aaaggaagtt gctcctgaga gtggtaagag  48180

tcagtggtgg aggcctggag aggagacata acaaacaaat ttgttgacaa acattttggt  48240

aggaaggggg agagcttaaa gtttagacag tggggaaggt ggagtcttag aggaggtgaa  48300

tgtctgaaag acagagctag ctggagcaag aagtcacttc tctgttgcag gcaggaagga  48360

tccaaagtgg ctcaagccag agattgggag agtggggagg agggagcagc ctggatctaa  48420

gtaaaatggg tagaggtgga gggggtgctg caacggccag ggttttctga agttggggac  48480

attaggagag agctgtgagg gctttggcca gccactgtgc tagtgattgg tgaaccaaag  48540

gatgggcagg agatggcagc agggaagcag aggaagtcca ggcttcctgt tggtattggg  48600

acaagggaga ggccatagga ggccctggcc ctgttgtcca ggttgggttc tgaagctggg  48660

tgggcatggc ctggtaggag agcatctatg gcgcccaatt ccagattcag ggtctagttg  48720

atttgctggc cctgtagcct cagctcatgc ttctgttcca ggcctatttg cactctatgt  48780

gcatcatcca ccgggatctg aactcgcaca actgcctcat caagttggta tgtcccactg  48840

ctctgggcct ggcctccagg gtcctatcct tcctggcttc cttgtcacaa aggaggctga  48900

cttgtcccct ctggctagag ggcagaggtg ttgcctagga gctcctatct ttcccttcct  48960

gcttcttcca atgcccttct ctgtcctctg ggagctccga gacacacaca gacataattt  49020

caccttctct cattagcaac ctttgaaata atttgattag aagggacttc agaagtttgt  49080

tgactatatg tagaaaaccc tgtcatttta cctgcttttg ccccatagta gtcttgtaaa  49140

acagttcatt gctgacccca ttttacagtg gtggcacctg aagcctcagc ctgaggccac  49200

cgagctagta aatttacagg gaccagtttg agaccagcat tcctcccact gcccctcagc  49260

tgtggtggtt acaatgttgt ttgtcttact gacttgctat ctggcttcct gggtgtctac  49320

cggctggccc tggctctgcc ctctagaccc acaccacgca atcttcattc ctttcccaca  49380

tgactgccct gtagctattc aaagagcttg tctcccccaa gtctccccat ctactgcctc  49440

caccttgcct ttttctgtct tatcctggtt ctagccactg cctgaaatca ttttaggaat  49500

aagacaggac agggaaaaac aaaagcaacc ccctgtccca cctctgagtt ccactctcca  49560

agtccctgag cctcacctcc agggctccag tggctctgcc atgaacccac tgtgggctgg  49620

gagtctgctg tgcacagata ccagaccctc agaaacacaa atgccaagtg tgtctgtttt  49680

tttgttttgt tttgtttttgt tttttagatg gagtctcatt ctgtttccca ggctggagtg  49740

cagtggtgca atcttggctt actgcagcct ctacctcccg ggttctagtg attgttctgc  49800

ttcagcctcc cagtagctag gactacaggc gtgtgccacc acgcccagct aatttttttt  49860

tttttttttt tgtatttta gtagagacag ggttttgcca tgttggccag gctggtcttg  49920

aactcctgac ctcaggtgat tcacccgcct tggcctccca aagttctggg attacaggtg  49980

gaagccaccg tgcctggcct gagtgtgtct atttgataga gctttctgct ctgattctcc  50040

cttgctatac acctttttctc cccttctcag tggcttctct tgcctatgct tcctccccag  50100

ggccaggttt gagaacatcc ccatgaagtc ctgacctgtc ttttatccta ccaggacaag  50160

actgtggtgg tggcagactt tgggctgtca cggctcatag tggaagagag gaaaagggcc  50220

cccatggaga aggccaccac caagaaacgc accttgcgca agaacgaccg caagaagcgc  50280

tacacggtgg tgggaaaccc ctactggatg gcccctgaga tgctgaacgg tgagtcctga  50340

agccctggag gggacacccg cagagggagg acagatgctg cccttgcatc agagccctgg  50400

gaattccagg ggaggcctgt gaagcgtagg accggatacc cagagctgag gatattttc  50460

ccttgccagg tggggcctca cgatttagct cctgagctca gggggctggg aactgatcag  50520
```

-continued

```
tgtcccatca tgggggataa ggtgagttct gactgtggca tttgtgcctc aggggatcgct  50580

aagagctcag gctattgtcc cagctttagc cttctctctc catggtgaga actgaagtgt  50640

ggtgccctct ggtggataat gctcaaacca accagagatg ctggttggga ttcttgaaat  50700

cagggttgtg aggcctcaga aatggtctga atacaatcca ttttggagtc tgaggcccag  50760

agaagttcag tgaattgcct aggagcatac agctgcctaa tggcagaggc tagatgaacc  50820

ctagtctggt tcttttccac tttaacgtgc agtttcatcc taggcagtgt tatgttataa  50880

gggctctcca aggcagttca cctacggctg aggaaggact attttcaggt ggtgtctgcg  50940

caggacagcc tgtggggtgt ccctacagaa cctgttctag ccctagttct tagctgtggc  51000

ttagattgac cctagaccca gtgcagagca ggtaagggat gtaaacttaa cagtgtgctc  51060

tcctgtgttc cccaaggaaa gagctatgat gagacggtgg atatcttctc ctttgggatc  51120

gttctctgtg aggtgagctc tggcaccaag gccatgcccg aggcagcagg cctagcagct  51180

ctgccttccc tcggaactgg ggcatctcct cctagggatg actagcttga ctaaaatcaa  51240

catgggtgta gggtttttatg gtttataacg catctgcaca tctttgccac gttcgtgttt  51300

cattggtctt aagagaagga ctggcagggt tttttttgttt tagatggagc ctcacttcgt  51360

tgcccaggct ggagtgcagt ggcacaatct gggctcactg caacctctgc cttctgggtt  51420

caagtgattc tcctgcctca gcctcccaag tagctgggac taccggcaca caccaccatg  51480

cccggctaat ttttgtattt ttagtagaga cagggtttca ccatgttggc caggctggtc  51540

ttgaactccg gacctcaggt gatccgcctg cctcagcctc taaaagtgct ggaattaata  51600

ggcgtgagct acctcgcccg gccaggtttt tttttttttt ttttttagttg aggaaactga  51660

ggcttggaag agggcagtgg cttgcacatg gtcgataagg ggcagatgag actcagaatt  51720

ccagaaggaa gggcaagaga ctgttcatgt ggctgtctag ctagctcttg ggccaaatgt  51780

agcccttctc agttcccttc aagtagaagt agccactcta ggaagtgtca gccctgtgcc  51840

aggtaccacg tggacagagt gaggaatctt ggaaagattc ctacctttag gagtttagtc  51900

aggtgacagc atatctcagc gactcaaaca cacacacatt caaagccttc tgtaattcct  51960

acaaagttgt gaggggtaga ggagaggaga gacaagggat ggttaggata atgaaggaat  52020

gttttgtttt tgtttttgtt tttgagatgg agtttcactc tgtcacccag gctggagtgc  52080

agaggtgcaa tcttggctca ctgcagcctc cgcctcccag gttcaagcaa tcctcctgcc  52140

tcagcctccc aagtagctgg gactacaggt gtgcgccacc acgcctggct aatttttgta  52200

ttttcagtag agacagggtt tcgccatatt ggccaggctg gtctcaaatg cctgacctca  52260

ggtgatacac ccgcttcagc ctcccaaagt gctgagatta caggcatgag ctaccgtgcc  52320

tggccatgaa ggaagatttg ttttaaaaaa ttgtttctt taatattaat tgaacacctc  52380

tgttcagagc actgggctgg tgccagaggg tttcagacat gaatcagatc cagcacctca  52440

tagagcctta atctggcaca cacacacagc cacaaggaga cacagacaag gcagggtagg  52500

atgagtggaa gctaggagca gatgctgatt tggaacactt ggcttctgca gtgaagcccc  52560

ttcttagtcc tcttcagtaa cccagctctc agtggataca ggtctggatt agtaagattt  52620

ggagagatga ttgggattg gggagagctc tctaacctat tttaccacct cctcttctgc  52680

cattcttcct gtccacatcc ccagcatccc tttcccttgc caagtatctg tggcctctgt  52740

agtcctttgt aaacagctgt cttcttaccc tacagatcat tgggcaggtg tatgcagatc  52800

ctgactgcct tccccgaaca ctggactttg gcctcaacgt gaagctttc tgggagaagt  52860
```

-continued

```
ttgttcccac agattgtccc ccggccttct tcccgctggc cgccatctgc tgcagactgg   52920

agcctgagag caggttggta tcctgccttt ttctcccagc tcacagggtc ctgggacgtt   52980

tgcctctgtc taaggccacc cctgagccct ctgcaagcac agggtgaga gaagccttga    53040

ggtcaagaat gtggctgtca acccctgagc catctgacaa cacatatgta caggttggag   53100

aagagagagg taaagacata gcagcaagta atctggatag gacacagaaa cacagccatt    53160

aaaagaaagt ttaaaagaag gaaattcacc caaaccattt gaatacagta agtgtattca    53220

tctttcgata ttcccctgtc catatctaca catatacttt ttttttatagt aaatagttct   53280

gtattttgcc ctgcatttcc cttgtgttta ctatccagtc ttcctgttta tcattttgt     53340

cgacaacatg aaattctatt gagagactgt ctgaacatat tgtaatgtag atgttcaggt    53400

ttttccagtt tctctttaca ataggtattt aactacagtg agcagtttta tgcatttagc    53460

taatttctcc tttgaggaag tattttcaaa attacctttt ttcttctcag gtaataattt    53520

cattattacc aaagttaccc taggtctttt caagtgtgtg gttaaaaaac gagaatctgg    53580

ctgggcgcga tggctcacac ctgtaatccc agcactttgg gaggctgagg ctggtggatc    53640

acctgaggtc tggagttcga gaccagcctg gccaacatgg tgaaacccca tctctactaa   53700

aaatacaaaa cttagccagg catggtggca ggtgcctgta acccagcta cttgggaggc     53760

tgaggcagga gaattgcttg aacccagggg cggaggttgc agtgagccga tatcacgcca    53820

ttgcactcca gcctcggcaa caagagtgaa actctgtctc aaaaatgggg ttcttttcct    53880

gccatcaaaa atcatgtttc tttttaaaaac aagttcaaac attaccaaag tttatagcac    53940

aggaaatacg tcttctgtaa tctcccttaa ccaatatatc cctcaacatt ctcctcaccc     54000

ccaactccac cctcccagga taaccagttg ggacataatc tttatttaaa aatggtttcc    54060

ggatagagaa agcgcttcgg cggcggcagc cccggcggcg gccgcagggg acaaagggcg    54120

ggcggatcgg cggggagggg gcggggcgcg accaggccag gcccgggggc tccgcatgct    54180

gcagctgcct ctcgggcgcc cccgccgccg ccctcgccgc ggagccggcg agctaacctg    54240

agccagccgg cgggcgtcac ggaggcggcg gcacaaggag gggccccacg cgcgcacgtg    54300

gccccggagg ccgccgtggc ggacagcggc accgcggggg gcgcggcgtt ggcggccccg    54360

gccccggccc ccaggccagg cagtggcggc caaggaccac gcatctactt tcagagcccc    54420

ccccgggggcc gcaggagagg gcccgggctg ggcggatgat gagggcccag tgaggcgcca    54480

agggaaggtc accatcaagt atgaccccaa ggagctacgg aagcacctca acctagagga    54540

gtggatcctg gagcagctca cgcgcctcta cgactgccag gaagaggaga tctcagaact     54600

agagattgac gtggatgagc tcctggacat ggagagtgac gatgcctggg cttccagggt    54660

caaggagctg ctggttgact gttacaaacc cacagaggcc ttcatctctg gcctgctgga    54720

caagatccgg gccatgcaga agctgagcac accccagaag aagtgagggt ccccgaccca    54780

ggcgaacggt ggctcccata ggacaatcgc tacccccga cctcgtagca acagcaatac      54840

cggggaccc tgcggccagg cctggttcca tgagcagggc tcctcgtgcc cctggcccag      54900

gggtctcttc ccctgccccc tcagttttcc acttttggat tttttattg ttattaaact     54960

gatgggactt tgtgtttta tattgactct gcggcacggg ccctttaata aagcgaggta     55020

gggtacgcct ttggtgcagc tcaaaaaaaa aaaaaaaat gatttccagc ggtccacatt    55080

agagttgaaa ttttctggtg ggagaatcta taccttgttc ctttataggc caaggaccgc    55140

agtccttcag taacaccagt gtaaaagctt gaggagaaat tgtgaagcta cacagtattt    55200

gttttctaat acctcttgtc attctaaata tctttaattt attaaaaaat atatatatac    55260
```

-continued

```
agtattgaat gcctactgtg tgctaggtac agttctaaac acttgggtta cagcagcgaa    55320

caaaataaag gtgcttaccc tcatagaaca tagattctag catggtatct actgtatcat    55380

acagtagata caataagtaa actatattga atattagaat gtggcagatg ctatggaaaa    55440

agagtcaaga caagtaaaga cgattgttca gggtaccagt tgcaatttta aatatggtcg    55500

tcagagcagg cctcactgag gtgacatgac atttaagcat aaacatggag gaggaggagt    55560

aagcctgagc tgtcttaggc ttccggggca gccaagccat ttccgtggca ctaggagcct    55620

ggtgtttccg attccacctt tgataactgc attttctcta agatatggga gggaagtttt    55680

tctcctattg tttttaagta ttaactccag ctagtccagc cttgttatag tgttacctaa    55740

tctttatagc aaatatatga ggtaccggta acattatgcc catttctcac agaggcacta    55800

ctaggtgaag gagtttgcct gacgttatac aaccaggaag tagctgagcc tagatccctt    55860

ccacccaccc catggccctg ctcatgttcc acctgcctct aatttacctc ttttccttct    55920

agaccagcat tctcgaaatt ggaggactcc tttgaggccc tctccctgta cctgggggag    55980

ctgggcatcc cgctgcctgc agagctggag gagttggacc acactgtgag catgcagtac    56040

ggcctgaccc gggactcacc tccctagccc tggcccagcc ccctgcaggg gggtgttcta    56100

cagccagcat tgcccctctg tgccccattc ctgctgtgag cagggccgtc cgggcttcct    56160

gtggattggc ggaatgttta gaagcagaac aagccattcc tattacctcc ccaggaggca    56220

agtgggcgca gcaccaggga aatgtatctc cacaggttct ggggcctagt tactgtctgt    56280

aaatccaata cttgcctgaa agctgtgaag aagaaaaaaa cccctggcct ttgggccagg    56340

aggaatctgt tactcgaatc cacccaggaa ctccctggca gtggattgtg ggaggctctt    56400

gcttacacta atcagcgtga cctggacctg ctgggcagga tcccagggtg aacctgcctg    56460

tgaactctga agtcactagt ccagctgggt gcaggaggac ttcaagtgtg tggacgaaag    56520

aaagactgat ggctcaaagg gtgtgaaaaa gtcagtgatg ctcccccttt ctactccaga    56580

tcctgtcctt cctggagcaa ggttgaggga gtaggttttg aagagtccct taatatgtgg    56640

tggaacaggc caggagttag agaaagggct ggcttctgtt tacctgctca ctggctctag    56700

ccagcccagg gaccacatca atgtgagagg aagcctccac ctcatgtttt caaacttaat    56760

actggagact ggctgagaac ttacggacaa catcctttct gtctgaaaca aacagtcaca    56820

agcacaggaa gaggctgggg gactagaaag aggccctgcc ctctagaaag ctcagatctt    56880

ggcttctgtt actcatactc gggtgggctc cttagtcaga tgcctaaaac attttgccta    56940

aagctcgatg ggttctggag gacagtgtgg cttgtcacag gcctagagtc tgagggaggg    57000

gagtgggagt ctcagcaatc tcttggtctt ggcttcatgg caaccactgc tcacccttca    57060

acatgcctgg tttaggcagc agcttgggct gggaagaggt ggtggcagag tctcaaagct    57120

gagatgctga gagagatagc tccctgagct gggccatctg acttctacct cccatgtttg    57180

ctctcccaac tcattagctc ctgggcagca tcctcctgag ccacatgtgc aggtactgga    57240

aaacctccat cttggctccc agagctctag gaactcttca tcacaactag atttgcctct    57300

tctaagtgtc tatgagcttg caccatattt aataaattgg gaatgggttt ggggtattaa    57360

tgcaatgtgt ggtggttgta ttggagcagg gggaattgat aaaggagagt ggttgctgtt    57420

aatattatct tatctattgg gtggtatgtg aaatattgta catagacctg atgagttgtg    57480

ggaccagatg tcatctctgg tcagagttta cttgctatat agactgtact tatgtgtgaa    57540

gtttgcaagc ttgctttagg gctgagccct ggactcccag cagcagcaca gttcagcatt    57600
```

-continued

```
gtgtggctgg ttgtttcctg gctgtcccca gcaagtgtag gagtggtggg cctgaactgg   57660

gccattgatc agactaaata aattaagcag ttaacataac tggcaatatg gagagtgaaa   57720

acatgattgg ctcagggaca taaatgtaga gggtctgcta gccaccttct ggcctagccc   57780

acacaaactc cccatagcag agagttttca tgcacccaag tctaaaaccc tcaagcagac   57840

acccatctgc tctagagaat atgtacatcc cacctgaggc agccccttcc ttgcagcagg   57900

tgtgactgac tatgaccttt tcctggcctg gctctcacat gccagctgag tcattcctta   57960

ggagccctac cctttcatcc tctctatatg aatacttcca tagcctgggt atcctggctt   58020

gctttcctca gtgctgggtg ccacctttgc aatgggaaga aatgaatgca agtcaccca   58080

ccccttgtgt ttccttacaa gtgcttgaga ggagaagacc agtttcttct tgcttctgca   58140

tgtgggggat gtcgtagaag agtgaccatt gggaaggaca atgctatctg gttagtgggg   58200

ccttgggcac aatataaatc tgtaaaccca aaggtgtttt ctcccaggca ctctcaaagc   58260

ttgaagaatc caacttaagg acagaatatg gttcccgaaa aaaactgatg atctggagta   58320

cgcattgctg gcagaaccac agagcaatgg ctgggcatgg gcagaggtca tctgggtgtt   58380

cctgaggctg ataacctgtg gctgaaatcc cttgctaaaa gtccaggaga cactcctgtt   58440

ggtatctttt cttctggagt catagtagtc accttgcagg gaacttcctc agcccagggc   58500

tgctgcaggc agcccagtga cccttcctcc tctgcagtta ttcccccttt ggctgctgca   58560

gcaccacccc cgtcacccac cacccaaccc ctgccgcact ccagcctta acaagggctg    58620

tctagatatt cattttaact acctccacct tggaaacaat tgctgaaggg gagaggattt   58680

gcaatgacca accaccttgt tgggacgcct gcacacctgt ctttcctgct tcaacctgaa   58740

agattcctga tgatgataat ctggacacag aagccgggca cggtggctct agcctgtaat   58800

ctcagcactt tgggaggcct cagcaggtgg atcacctgag atcaagagtt tgagaacagc   58860

ctgaccaaca tggtgaaacc ccgtctctac taaaaataca aaaattagcc aggtgtggtg   58920

gcacatacct gtaatcccag ctactctgga ggctgaggca ggagaatcgc ttgaacccac   58980

aaggcagagg ttgcagtgag gcgagatcat gccattgcac tccagcctgt gcaacaagag   59040

ccaaactcca tctcaaaaaa aaaaa                                          59065
```

<210> SEQ ID NO 4
<211> LENGTH: 265
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 4

```
Leu Thr Glu Val Lys Val Met Arg Ser Leu Asp His Pro Asn Val Leu
1               5                   10                  15

Lys Phe Ile Gly Val Leu Tyr Lys Asp Lys Lys Leu Asn Leu Leu Thr
            20                  25                  30

Glu Tyr Ile Glu Gly Gly Thr Leu Lys Asp Phe Leu Arg Ser Met Asp
        35                  40                  45

Pro Phe Pro Trp Gln Gln Lys Val Arg Phe Ala Lys Gly Ile Ala Ser
    50                  55                  60

Gly Met Ala Tyr Leu His Ser Met Cys Ile Ile His Arg Asp Leu Asn
65                  70                  75                  80

Ser His Asn Cys Leu Ile Lys Leu Asp Lys Thr Val Val Val Ala Asp
                85                  90                  95

Phe Gly Leu Ser Arg Leu Ile Val Glu Glu Arg Lys Arg Ala Pro Met
            100                 105                 110
```

-continued

```
Glu Lys Ala Thr Thr Lys Lys Arg Thr Leu Arg Lys Asn Asp Arg Lys
        115             120             125

Lys Arg Tyr Thr Val Val Gly Asn Pro Tyr Trp Met Ala Pro Glu Met
    130             135             140

Leu Asn Gly Lys Ser Tyr Asp Glu Thr Val Asp Ile Phe Ser Phe Gly
145             150             155             160

Ile Val Leu Cys Glu Ile Ile Gly Gln Val Tyr Ala Asp Pro Asp Cys
            165             170             175

Leu Pro Arg Thr Leu Asp Phe Gly Leu Asn Val Lys Leu Phe Trp Glu
            180             185             190

Lys Phe Val Pro Thr Asp Cys Pro Pro Ala Phe Phe Pro Leu Ala Ala
            195             200             205

Ile Cys Cys Arg Leu Glu Pro Glu Ser Arg Pro Ala Phe Ser Lys Leu
    210             215             220

Glu Asp Ser Phe Glu Ala Leu Ser Leu Tyr Leu Gly Glu Leu Gly Ile
225             230             235             240

Pro Leu Pro Ala Glu Leu Glu Glu Leu Asp His Thr Val Ser Met Gln
            245             250             255

Tyr Gly Leu Thr Arg Asp Ser Pro Pro
            260             265
```

That which is claimed is:

1. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
   (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
   (b) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:1;
   (c) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:3; and
   (d) a nucleotide sequence that is completely complementary to a nucleotide sequence of (a)–(c).

2. A nucleic acid vector comprising a nucleic acid molecule of claim 1.

3. A host cell containing the vector of claim 2.

4. A process for producing a polypeptide comprising culturing the host cell of claim 3 under conditions sufficient for the production of said polypeptide, and recovering the peptide from the host cell culture.

5. An isolated polynucleotide consisting of a nucleotide sequence set forth in SEQ ID NO:1.

6. An isolated polynucleotide consisting of a nucleotide sequence set forth in SEQ ID NO:3.

7. A vector according to claim 2, wherein said vector is selected from the group consisting of a plasmid, virus, and bacteriophage.

8. A vector according to claim 2, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that the protein of SEQ ID NO:2 may be expressed by a cell transformed with said vector.

9. A vector according to claim 8, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.

* * * * *